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Summary
Gestational diabetes mellitus (GDM) can affect up to 1 in 5 of pregnancies and is
associated with adverse pregnancy outcomes including pre-eclampsia, neonatal
hypoglycaemia, large for gestational age, increased adiposity and birth trauma. Good
glycaemic control is the key to reduce these outcomes. Diet and lifestyle modification
followed by insulin as necessary is the conventional type of management. Metformin
is increasingly used in pregancy but with limited evidence, its role in GDM has not
been well-established.
A systematic review including both randomized and non-randomized controlled
studies have been conducted to evaluate the contemporary evidence of metformin in
GDM. It is suggested that metformin in GDM could be a useful alternative to insulin
and is regarded as the best oral anti-hyperglycaemic agent in GDM management
currently. However, almost half of metformin-treated GDM patients required
supplementary insulin to achieve target glucose levels (metformin failure). Women
with higher metabolic risk factors are likely to develop metformin failure.
A clinical cohort of metformin-treated GDM is used to develop the predictive model
to identify GDM women who are at risk of metformin failure. It has been found that
women identified by new IADPSG and NICE 2015 fasting criteria are highly likely to
develop metformin failure. It has also been established a number of algorithm based
on various baseline characters of GDM women which will help primary healthcare
physicians choose the best medication for GDM management.
One of the possible side-effects of metformin includes lowering of serum vitamin B12
levels whereas serum vitamin B12 deficiency during pregnancy which is associated
with increased insulin resistance. It is reported that in low vitamin B12 state,
xxi
offspring’s insulin resistance is found to be higher among women with high folate low
B12 state. Hence, in order to fully appreciate the role of vitamin B12 deficiency in
metformin failure, it is first necessary to understand the effects of folate in low vitamin
B12 condition on pregnancy outcomes in GDM. It has also been found that in normal
vitamin B12 GDM women, serum folate levels are negatively associated with plasma
glucose levels but not low B12 state. This underlines the fact that in order for folate to
have its role, it is important to have normal vitamin B12 levels.
Despite increasing use of metformin, it is not yet routine to check vitamin B12 levels
before it is given. It is important to understand whether vitamin B12 has a role in
metformin action. Thus, the mechanism by which vitamin B12 deficiency might
interfere with metformin action was studied. In vitamin B12 deficient hepatocytes,
metformin stimulation of AMPK was reduced which was followed by reduced
downstream signalling in lipid metabolism. This effects were reversed by vitamin B12
supplementation. Thus, it is concluded that vitamin B12 deficiency could interfere
with metformin action and before metformin is given, every GDM woman should be
checked for serum vitamin B12 levels and should be supplemented if deficient.
Overall, vitamin B12 could play a critical role in GDM management and it is important
for every GDM woman to have normal vitamin B12 levels.
1CHAPTER 1
INTRODUCTION
21.1 Gestational Diabetes Mellitus (GDM)
In the late 1950s, the term “Gestational Diabetes Mellitus” was first developed by O’
Sullivan and his colleagues as “glucose intolerance of any degree which is first
recognized during pregnancy” by using 100 gram oral glucose tolerance test (OGTT)
(Kitzmiller et al, 2010). Although the definition does not change over time, different
diagnostic cut-off values have been adapted in many countries using their local or
national data. It should also be noted that because of lack of specificity in definition,
the population might be mixed with undiagnosed type 2 diabetes (Alberti et al 1998;
Metzger et al 2007). Basically, GDM is partly caused by placental hormonal
disturbance resulting in impaired insulin sensitivity and deranged pancreatic beta cell
function (Yogev et al 2008).
1.1.1 Epidemiology
1.1.1.1 Risk factors
It is understood that women with certain characteristics are at risk of impaired glucose
tolerance during pregnancy. These characters include advanced maternal age, higher
BMI, previous history of GDM, previous history of macrosomic baby, family history
of type 2 diabetes and being a high-risk ethnic descent (Zhang 2010; NICE 2015;
Galtier 2010). Like in type 2 diabetes, obesity plays a key role, modification of which
could benefit the most on the overall prevalence. It is also well-recognized that pre-
pregnancy obesity is invariably and directly related to high risk of GDM(Chu et al
2007). The risk factors associated with high risk of GDM were described in table 1.1.
3Table 1.1 Risk factors of GDM (Galtier 2010)
Modifiable risk factor Non-modifiable risk factor
 Physical activity
 Diet
 Cigarette smoking
 Obesity
 Socioeconomic factors
 Age
 Ethnicity
 Previous history of GDM
 Family history of Type 2 diabetes
 Maternal birth weight
 Polycystic ovary syndrome
 Obstetric history ( history of macrosomia,
intrauterine foetal death, multiparity)
 Gestational weight gain
 Multiple pregnancies
1.1.1.2 GDM and Ethnicity
The relationship between ethnicity and severity of insulin resistance during pregnancy
seems to be independent of age and pre-pregnancy body weight (Yue et al 1996). Data
on prevalences of GDM among different ethnic groups mostly come from metropolitan
US-based studies. These studies invariably reported that the non-Hispanic European
are at the lowest risk in studies which have diversity in population conducted at any
time period(Lawrence 2010; Hunsberger et al 2010; Ferrara 2007; Savitz et al 2008).
Savitz et al also reported that women from South Central Asia (Bangladesh, Indian,
Pakistan) are at the remarkably highest risk of GDM among their population studied
(Savitz et al 2008). Likewise, one UK-based study revealed that Indian women are at
the highest risk (4.4%) followed by Southeast Asian (3.5%) and Black (1.5%) whereas
White constituted only 0.4% of GDM population (Dornhorst et al 1992). GDM risk of
being Black or African American is still controversial that some studies are found to
4be the same (Ferrara 2007) while others are slightly higher than the non-Hispanic
White (Savitz 2008; Dornhourst et al 1992). In addition, being a migrant or ancestry
of migrants is another factor associated with high risk of GDM (Savitz et al 2008).
1.1.1.3 Prevalence of GDM
According to 2014 International Diabetes Federation (IDF) report, the prevalence
varies from 10% to 25%, depending on ethnicity, diagnostic criteria, population being
studied and diagnostic criteria being applied [15]. In UK where diabetes affect 2-5%
of all pregnancies, almost fourth-fifths of adverse diabetes-related pregnancy
outcomes could be attributable to gestational diabetes (IDF 2014). Despite global high
prevalence and increasing trend of GDM worldwide, until now, internationally-agreed
diagnostic glucose cut-off values for GDM have not yet been determined (Agarwal
2010; Simmons et al 2010; Cutchie et al 2006). Moreover, the methods of GDM
screening also differ in that some countries use risk factor-based screening whereas
others use 50 gram oral glucose challenge test (Agarwal 2010; Simmons et al 2010;
Cutchie et al 2006). Generally the diagnostic values of impaired glucose level vary
from 5.3 to 7 mmol/L of fasting plasma glucose (FPG) and 7.8 to 9.2 mmol/L of 2-
hour postprandial (2hr PP) blood sugar using 75 (or) 100 grams OGTT [6, 16, 19-22]
whereas in some countries, the contemporary criteria, recommended by World Health
Organization (WHO) (Alberti et al 1998) & other international diabetes panels
(Metzger 2007; IDF 2014) have been adopted. In 2010, International Association of
Diabetes and Pregnancy Study Groups (IADPSG) have proposed the universal
diagnostic criteria for GDM which have been developed from the pregnancy outcomes
of Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study (Hadar et al 2013).
5According to IADPSG criteria, GDM is diagnosed if fasting glucose ≥ 5.1 mmol/L or 
1 hour post prandial glucose ≥ 10.0 mmol/L or 2 hour post prandial glucose ≥8.5 
mmol/L by using 75 gram OGTT test at 24-28 weeks gestation. If this criteria is
adopted, the prevalence of GDM will be tripled (Gopalakrishnan et al 2015). The
prevalences of GDM in 15 different countries by IADPSG criteria was described in
Figure 1.1(Sacks et al 2012). Recently, the National Institute for Health and Care
Excellence (NICE) has changed their GDM criteria which are fasting glucose ≥ 5.6 
mmol/L or 2hour post prandial glucose ≥ 7.8 mmol/L by using 75 gram OGTT 
test(NICE NG-63 2015). The prevalence of GDM detected by this criteria is similar to
that by IADPSG criteria (Meek et al 2015). Overall, it should be noted that there will
be burgeoning number of GDM in very near future.
Figure 1.1 Prevalences of GDM by IADPSG criteria in 15 different countries (Data
taken from Sacks DA et al. Diabetes care 2012; 35(3):526-528 and the figure taken
from internet, shared by Khue NT in www.slideshare.net)
61.1.2 Consequences of GDM
It is understood that maternal hyperglycaemia, whether mild or severe, may impose a
serious threat to both mothers and their babies. Moreover, a recent multicentre
observational study has proved that there is continuous linear relationship between
maternal hyperglycaemia and adverse pregnancy outcomes which is even below the
diagnostic or target glucose levels used by different diabetes in pregnancy
organizations (HAPO group 2008). Nevertheless, there is a great deal of evidence that
the higher the maternal blood sugar level, the higher the risks of complication due to
GDM (HAPO group 2008; Rowan et al 2010).
Figure 1.2 Pederson Hypothesis on consequences of hyperglycaemia during pregnancy
(Figure taken from internet, shared by Khue NT in www.slideshare.net)
7One of the major issues with GDM is the glycaemic impact on size of babies (HAPO
group 2008). Macrosomia predisposes both mothers and newborns to other serious
adverse perinatal outcomes. The term neonatal macrosomia usually refers to birth
weight more than 4000g. Alternatively, it is defined as birth weight ≥ 90 percentiles 
for gestational age, also termed large for gestational age (LGA) (NICE NG-63 2015).
By passing across the placenta, high blood sugar levels in mothers stimulate the fatal
pancreatic beta cells to secrete more insulin. As insulin is an anabolic hormone, this
will subsequently increase neonatal growth resulting in neonatal macrosomia and other
associated risks (Pederson hypothesis) (Figure 1.2) (Singh et al 2008). This
hyperglycaemic stimulation of foetal pancreatic insulin secretion can be compounded
by gut-derived glucagon like peptide-1 (GLP-1), explained by Lois Jovanovic
(Jovanovic 2007). These studies highlighted that when maternal hyperglycaemia was
more than fatal renal threshold (<110 mg/dl), the overloaded glucose would be
excreted into the amniotic fluid and >20 weeks gestation, the time when he could
swallow, the glucose rich amniotic fluid would then enter the fatal gut and
subsequently, would increase the gut-stimulated incretin secretion. He also mentioned
that fatal β cell could be stimulated for hours despite being maternal hyperglycaemia 
for <1h/day (Jovanovic 2007). This vicious cycle together with transplacental glucose
load results in an overfed, fat foetus. The foetal macrosomia together with subsequent
increased incidence of shoulder dystocia and birth trauma is a major indication for
instrumental delivery and caesarean section which impose a risk to mothers (Singh et
al 2008; Wong et al 2011). At the same time, small for gestational age (SGA) is
another important outcome related to pregnancy pertaining to GDM. It is usually
defined as foetal birth weight less than 10 percentiles for gestational age (NICE NG-
63 2015). SGA in GDM could be probably explained by placental vasculopathy
8attributable to hyperglycaemia together with hyperlipidaemia (Dabelea 2010).
Recently, it was found that maternal weight gain can have impact on both LGA and
SGA in gestational diabetes (Barnes et al 2013).
Another major issue of GDM is neonatal hypoglycaemia which is attributable to the
postnatal persistence of glucose-provoked foetal hyperinsulinaemia (Langer 2008). It
is clinically defined as foetal glucose level < 2mmol/l or need for glucose injection
(NICE NG-63 2015). Maternal glucose level at birth is the most influential factor of
this outcome. The risk of neonatal hypoglycaemia among babies born to GDM is
10.38(95%CI 6.15 to 16.56) (Langer 2008). The lack of timely appropriate
management of neonatal hypoglycaemia can lead to brain damage. However, data on
risk of gestational diabetes on cognitive skills of offspring have not yet been well-
documented (Veena et al 2010).
The other well-established risks of gestational diabetes are neonatal respiratory
distress due to hyperinsulinaemia, neonatal jaundice probably explained by increased
chance of birth trauma or increased red cell turnover because of foetal asphyxia,
prematurity with underlying impending preeclampsia or foetal jeopardy, operative or
assisted delivery (instrumentally assisted delivery or caesarean section), perinatal
mortality, polyhydramnios, antepartum (infection related complications) and risk of
macrosomia related postpartum complications, hypertensive complications of
pregnancy and iatrogenic maternal hypoglycaemia (NICE NG-63 2015; Langer 2008).
Moreover, there are well-documented data of impact of maternal hyperglycaemia
during pregnancy on offspring in long run. Firstly, it is suggested that untreated
gestational diabetes could affect the intellectual abilities and mental development of
the offspring (Langer 2007). This was found to have a relationship with raised level of
9poor glycaemic measures (ketone bodies) in maternal serum in late pregnancy or
history of spontaneous hypoglycaemia in neonatal period. Additionally, gestational
diabetes associated adverse lipid profile could also impair the intelligence scales.
Secondly, it is evident that babies born to GDM mothers have significant higher
metabolic risk markers and higher chance of development of metabolic syndrome than
those born to normal glucose tolerance, particularly those with large for gestational
age (Boney 2005) and there is a clear link between exposure to increased insulin in
intrauterine life to impaired insulin sensitivity in their adult life(Tam 2010).
Overall, GDM can have adverse effects on both immediate and long-term outcomes
of pregnancy. The risks are imposed in GDM by hyperglycaemia and
hyperinsulinaemia, its associated obesity and inflammatory cytokines. There is strong
evidence that optimal and stable glycaemic control can reduce these risks(Landon
2009).
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1.1.3 Pathogenesis of GDM
Gestational diabetes is universally accepted as a state of insulin insensitivity where
there is impaired β-cell function to overcome abnormally high insulin resistance  
(Singh et al 2008). In fact, pregnancy itself is an insulin resistant state, resulting from
diabetogenic placental factors. During pregnancy, impaired glucose tolerance can
normally be compensated by enhanced beta-cell function. Hence, normally, it is not
very common for pregnant mothers to develop GDM (Yogev et al 2008) Even though
GDM has been widely believed as having moderate degree of similar pathophysiology
as type 2 diabetes mellitus, in almost a-tenth of GDM, islet cell autoantibodies are
found to be implicated (Retnakaran 2010). A brief description on inflammatory
cytokines and signalling molecules implicated in GDM is described in Figure 1.3.
Figure 1.3 Inflammatory cytokines and insulin resistance in gestational diabetes (Data
taken from Sholelson et al 2006, Qatanani et al 2007, Savage et al 2007; Figure taken
from Omu AE. Gestational Diabetes - Causes, Diagnosis and Treatment 2014.
Available at http://dx.doi.org/10.5772/56634)
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Insulin resistance in GDM due to disturbance of placental factors could be at either
insulin secretary or insulin performance stage: receptor level, post-receptor level or
both (YOgev 2008). To our knowledge, the placental factors implicated in insulin
resistance involve hormones – cortisol, human placental lactogen (hPL), human
placental growth hormone and oestrogen & progesterone, inflammatory proteins – C-
reactive protein (CRP), Tumour necrotic factor-alpha (TNF-α) and adipokines – 
adiponectin, leptin (Retnakaran 2010; McCurdy et al 2010; Omu 2014). Of these, high
CRP and low adiponectin have been well-established as independent and significant
risk factors of incident GDM (Retnakaran 2010) while placental hormones like cortisol
and hPL are attributable to impaired pancreatic insulin secretion, inflammatory
cytokines such as TNF-α interfere with post-receptor mechanisms, particularly at IRS 
level (Yogev et al 2008). As a result, the translocation of glucose transporter (GLUT
2) in liver or GLUT 4 in muscle and adipose tissues) to the cell surface is impaired
with ultimate impact of hyperglycaemia (Yogev et al 1008; Retnakaran 2010; Omu
2014; Carrie et al 2010).
At the same time, any disturbance leading to accumulation of fatty acid in the cytosol
can provoke insulin resistance, no matter whether increased free fatty acids may or
may not be detected in the plasma (Ruderman et al 2006). During pregnancy,
cholesterol and polyunsaturated fatty acids are essential for central nervous system
development of foetus. Normal pregnancy adapts this high demand by increased fatty
acid production through hormonal changes and increased placental transfer of essential
fatty acid, highlighted by placental lipid transfer protein expression. Unfortunately,
increased triglyceride production is invariably associated with GDM, even in the lean
mothers, and even worse, GDM impairs vulnerability of peripheral tissues to oxidative
stress imposed by raised fatty acids while increased triglycerides is related to high
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incidence of preeclampsia (Knopp et al 2010). Taking all things into consideration,
insulin resistance during pregnancy could be partly attributable to impact of high levels
of free fatty acid on insulin sensitizing tissues.
1.1.4 Current management of GDM
The aim of management of gestational diabetes is to maintain blood glucose within
safe limits for mother and fetus. The limitation is that there does not seem to be a clear
threshold of glycemic level and risk of adverse pregnancy outcomes (HAPO group
2008). The risk seems to be linear without any clear cut-off point (HAPO group 2008).
There is growing evidence that treating mild maternal hyperglycaemia (FPG <5.3
mmol/L) which is much lower than major international diagnostic blood glucose
recommendation is associated with reduction in the incidence of adverse pregnancy
outcomes (Landon et al 2009; Crowther et al 2006). On the other hand, it is stated that
the risk of small-for-gestational-age infants is likely to be increased at much lower
maternal mean capillary glucose level, specifically < 4.8 mmol/L (Metzger et al 2007).
The currently agreed safe glucose levels vary between FPG of 3.8 to 6.1 mmol/L and
postprandial level (either 1hr/2hr/3hr) of up to 9 mmol/L.
Though there might be conflict in diagnostic cut-off values, similar management
guidelines have been applied to subsequent diagnosed GDM. They are managed first
with medical nutritional therapy which is designed to meet nutritionally balanced diet
for GDM mothers. If the diet therapy is failed to optimize glucose levels, the first
universally agreed intervention is insulin, as insulin does not readily cross the placenta
(Jovanovic et al 2007). It is undeniable that insulin is the effective pharmacological
intervention for diabetes of any type and any degree to meet the glycemic control in
pregnancy. However, there is concrete evidence that it has negative impact on
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pregnancy outcomes as well as maternal satisfaction of using the drug (Alwan et al
2009; Rowan et al 2008). Use of insulin is associated with increase in incidence of
maternal hypoglycaemia. It is also possible that the use of insulin in mothers can
increase the risk of neonatal hypoglycaemia (Alwan et al 2009). Moreover, the high
cost of insulin makes it impractical for implementation in resource poor healthcare
system.
The application of IADPSG consensus criteria has been shown to benefit women at
mild glycaemic level with reduction in adverse perinatal outcomes (Lapolla et al
2011). However, there is no randomized controlled trial (RCT) intervention evidence
for treating women with GDM based on IADPSG criteria. It could be predicted that
most countries will bring down their diagnostic criteria to lower glycaemic limit of
GDM in near future. For these newly identified GDM who could presumably have
lower baseline glucose levels than the current guidelines, insulin with hypoglycaemic
risk would no longer be a good choice to address the challenge.
The risks and costs associated with use of insulin encourage searching for alternative
available oral hypoglycaemic agents (OHA) in type 2 diabetes management. Up-to-
date, glibenclamide (glyburide) and metformin have been appeared mostly as second-
line (Alberti et al 1998; Metzger et al 2007; Cutchie et al 2006; CDACPGE committee
2003; ADA 2004; IDF 2009) and rarely as first-line therapy(NICE NG-63 2015; SIGN
2010). Glyburide is second-generation sulfonylurea drug which works by increasing
insulin secretion and improving insulin sensitivity. It is understood to be as effective
as insulin in the reduction of adverse neonatal outcomes in gestational diabetes
mothers (Moretti et al 2008).
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1.2 Metformin
Metformin is an ideal, first-line oral anti-hyperglycaemic agent widely used in Type 2
diabetes mellitus since 1957. Beyond its blood glucose lowering effects, it has other
potential clinical roles in the prevention of progression to type 2 diabetes from pre-
diabetes (impaired fasting glucose and impaired glucose tolerance)(Lilly et al 2009),
improving fertility rates in women with polycystic ovary syndrome (PCOS), treating
patients with liver steatosis and recent advances in prevention of carcinoma (Scarpello
et al 2008).
1.2.1 Metformin in Pregnancy
Metformin is increasingly used during pregnancy recently in women with PCOS and
those with GDM. However, the role of metformin during pregnancy is still not much
significant owing to the concern that metformin does cross placenta and the drug level
in the foetal compartment is as high as that in mother(Charles et al 2006). Even though
the controversy continues, metformin has been frequently used in the pharmacological
management of polycystic ovary syndrome. The increased conception rate in these
relatively infertile women with metformin could underline the beneficial role of
metformin in pregnancy. Although systematic review of randomized studies done by
Lord et al have reported that metformin could reduce the risks of insulin resistance
and have benefit on blood pressure and serum lipid levels in pregnancy (Lord et al
2003), one multicentre randomized trial did not find any association(Vanky et al
2010). At the same time, there are a few reports of metformin-associated increased
perinatal risks. Hellmuth et al found greater numbers of stillbirth in metformin group
whereas Coetzee and his group noticed high rate of neonatal jaundice in intrauterine
metformin-exposed babies(Hellmuth et al 2000; Coetzee et al 1979). On the other
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hand, Jean-Luc Ardilouze mentioned that congenital anomalies might not be an issue
with the use of metformin in GDM saying that GDM is usually diagnosed in second
trimester when embryogenesis and organogenesis of fetus have been completed
(Ardilouze et al 2010). A meta-analysis of metformin in first trimester supported this
hypothesis that metformin is not associated with major congenital anomalies with even
better protection of some risks (Gilbert et al 2006). Recently, Tertti and his college
reported that despite the comparable concentration of metformin in placental blood to
maternal blood, there was no adverse pregnancy outcomes (Tertti et al 2014).
Moreover, while NICE, SIGN, Canadian and Global Federation guidelines have
included metformin as glucose lowering agents in GDM (NICE NG-63 2015; SIGN
2010; CDACPGE committee 2003; ADA 2004; IDF 2014), others yet to do so(Seshlah
et al 2009). In Canadian guidelines, glibenclamide has been favoured over metformin,
stating that metformin has higher failure rate, i.e., the proportion of GDM who have
been achieved glycemic control with metformin alone therapy is less than that with
glibenclamide alone therapy (CDACPGE committee 2003). Although metformin is
included in a few guidelines of GDM management, the specific dosage
recommendation has not yet been determined. In current GDM treatment, metformin
is given initially as 500 mg or 250 mg together with meal once or twice daily,
increasing the dose until optimal glycemic profiles have been achieved or maximum
dose of 2500/2000mg/day, whichever comes first. This dosage guideline is taken from
non-insulin dependent diabetes management (BNF 2015).
During the period of this PhD being undertaken, a number of meta-analyses in GDM
has been published and it is found to be a beneficial drug for GDM (Balsells et al 2015;
Kitwitee et al 2015; Su et al 2014; Gui et al 2013; Lautatzis et al 2013). In NICE 2015
GDM guidelines, metformin is also upgraded to give as first-line in GDM with
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maternal consent (NICE NG-63 2015). So far, the evidences of metformin on
pregnancy outcomes are still limited and as a promising drug with placental transfer,
it is worthwhile to monitor metformin efficacy and safety on pregnancy outcomes,
both in short and long run.
On the other hand, it has been reported that there is increased risk of prematurity (<37
weeks) with metformin therapy with the odds of 1.60 (95% confidence
interval(CI):1.02-2.52) (Rowan et al 2008). The cause of this is not known. It could
be possibly related to 1) gastrointestinal side-effects of metformin which mimic labour
pain leading to delivery or 2) longer duration of suboptimal glycaemic control during
escalation of metformin, thereby, promoting pre-eclampsia or similar adverse
pregnancy outcomes necessitating immediate labour or 3) alteration of calcium
metabolism in the gut, resulting in disturbance in uterine contractility (Bauman et al
2000). The finding reported by one small study, where metformin was ceased in
metformin failure mothers and changed to insulin treatment rather than continuation
with top-up insulin therapy until delivery, was that there was no difference in
gestational age at delivery(Corbould et al 2013). This finding was controversial as
this study included only 25 metformin users and did not report glycemic control after
treatment. Nevertheless, if GDM were controlled more stringently and carefully after
the diagnosis, the overall outcomes should be improved because all of poor outcomes
in GDM are mostly due to poor glycemic control (HAPO group 2008).
Almost half of diet-failed GDM women who start with metformin therapy required
supplementary insulin (referred as metformin failure in this thesis)( Rowan et al 2008;
Ijas et al 2011, Goh 2t al 2011). Regarding metformin monotherapy in type 2 diabetes,
2-years evaluation of metformin done by Brown et al found that 42% of metformin-
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treated type 2 diabetes needed additional glucose lowering alternatives within 5 years
after successful glycemic control with metformin (Brown et al 2010). They also
described that patients who develop diabetes at younger age, longer duration of
diabetes or higher HbA1c could predict the higher risk of secondary metformin failure.
It is stated that the failure rate could be as low as 12.2% if metformin is started within
3 months of diagnosis of diabetes. The data on the indicators of metformin failure in
GDM are limited. Some studies have found that metformin-treated women with GDM
who needed insulin have higher BMI and are possibly more insulin resistant (higher
fasting & postprandial glucose and fructosamine at diagnosis) (Ijas et al 2011; Tertti
et al 2013; Spaulonci et al 2013). One small study reported that GDM with fasting
glucose at OGTT ≤5.2 mmol/l can achieve optimal glycaemic levels with metformin 
alone [71]. Moreover, it could be assumed that being European ethnicity have lower
risk of metformin failure than Hispanic or South Asians (Rowan et al 2008; Goh et al
2011; Moore et al 2010). Given the slower onset of action, if metformin is initiated
early in pregnancy, there may be lesser failure rate. Thus, if the treatment strategy of
metformin is developed based on the maternal characters at the time of diagnosis, it
can ensure consistent proper glycaemic control by addition of appropriate insulin to
those with high chance of treatment failure. The significance of GDM women with
high failure rate remains an area to be explored. It is also stated that the cost analysis
of metformin in GDM has shown that metformin is not as costly as insulin, the
additional cost associated with metformin failure is likely to be much higher (Lai et al
2008). So far, there are few studies that described the association of maternal
characters and metformin response in GDM.
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1.2.2 Recognized risks of metformin
The adverse effects of metformin in type 2 diabetes are well-recorded. In current
clinical practice, metformin is notorious for gastrointestinal side-effects - anorexia,
nausea, vomiting, abdominal discomfort and diarrhoea, which usually occurs at the
start of the treatment, but most patients can tolerate with dose reduction [80]. The
discontinuation rate is also not common with only 5% of patients giving up treatment
(Bailey et al. 2007a). It is stated that lactic acidosis, the most serious adverse effect of
biguanide group, is rarely seen with metformin. For safety, metformin is not
recommended to those with severe systemic hypoxia like uncompensated cardiac &
respiratory failure, recent myocardial infarction, renal and hepatic dysfunction (Bailey
et al 2007b).
1.2.3 Mechanism of action of metformin
The mechanisms of blood glucose lowering action of metformin differ by organ types.
It is reported that metformin reduces hepatic glucose output, insulin sensitizing effects
in muscle and adipose tissue and preservation of pancreatic beta cell function(Bailey
et al 2007c). Recently, there is also evidence that metformin stimulates GLP-1
secretion in animal studies (Yasuda et al 2002) and inhibits DPP IV (dipeptidyl
peptidase IV: a degradation enzyme for GLP-1) activity in type 2 diabetes
patients(Lindsay et al 2005). Despite strong efficacy of blood glucose lowering effects,
it has very few effects on blood glucose levels in normoglycaemic patients and thus it
has very few hypoglycaemic risks. It has beneficial effects on blood lipid levels, i.e.,
reduction in triglyceride and Low Density Lipoprotein (LDL) cholesterol as well as
improvement of High Density Lipoprotein (HDL) cholesterol(Schulters et al 2003;
Campbell et al 2007). Furthermore, as a weight neutral anti-diabetic agent, it also
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benefits on body weight control which could be observed as early as 6 weeks(Wulffele
et al 2004). In addition, it is also effective in reducing cardiovascular risks reported by
in UK prospective diabetes group study (UKPDS)(UKPDS group 1998).
Figure 1.4 Mechanism of metformin action (Figure taken from Pernicova et al. Nature
Reviews Endocrinology 2014; 10,143-156)
1.2.3.1 Molecular mechanisms of action of metformin
The molecular mechanisms by which metformin lowers blood glucose level have not
been well understood. Current understanding of metformin action at cellular model
was illustrated in figure 1.4. The up-to-date data have shown that metformin primarily
works by inhibiting at complex I of respiratory chain, thereby increasing energy
demand (i.e. increasing the ratio of adenosine monophosphate (AMP) by adenosine
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triphosphate(ATP))(Owen et al 2000; Pernicova et al 2014). The resultant increase in
AMP: ATP ratio activates the energy sensor AMPK (adenosine monophosphate-
activated protein kinase) enzyme which is a master energy regulator of the cell.
Tumour suppressor serine/threonine kinase 11(STK11/LKB1) is suggested to be the
upstream of AMPK by transmission of signal from mitochondrial inhibition(Pernicova
et al 2014; Xie et al 2008). It helps balance the energy within the cell that metformin-
induced energy depletion is counterbalanced by increasing energy breakdown
pathways while reducing energy utilizing pathways, thereby, improving the overall
metabolic function of the cell (Zhou et al 2001). In liver, AMPK activation favours
fatty acid degradation, together with blockage of its synthesis and thus, helps improve
insulin sensitivity and reduction of hepatic glucose output (Zhou et al 2001). AMPK
activation is also important for its cardioprotective effects by promoting nitric oxide
synthesis and decreasing the production reactive oxygen species in vascular
endothelial cells (Scarpello et al 2008). At the same time, AMPK enhances peripheral
glucose uptakes by potentiating insulin sensitizing effects on translocation of GLUT-
4 receptor to cell surface in skeletal muscle and adipose tissue (Lee et al 2011) as well
as it improves glucose metabolism in enterocytes by enhancing abundance of glucose
transporters SGLT-1 and GLUT 2 (Sakar et al 2010). Alternatively, a decrease in
AMPK activity can lead to impaired insulin sensitivity by allowing lipid deposition in
skeletal muscle, adipose tissue and pancreatic β cells (Ruderman et al 2006). In
addition to that, AMPK involves in the synthesis of mitochondria by promoting the
regulation of transcriptional co activator PGC 1α (Ruderman et al 2006; Pernicova et
al 2014). Hence, impaired AMPK function may reduce its metabolic efficacy by
reducing the number of mitochondria. The pharmacokinetics of metformin also plays
important roles in metformin action. Metformin is actively carried across the
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membrane by its organic cation transporters (OCTs) which thereby determine the
availability of metformin at the site of action (Rena et al 2013). There are various
members of OCTs in the body; for active absorption across enterocyte membrane
(plasma membrane monoamine transporter [PMAT] and OCT3) and into hepatocyte
(OCT1) as well as for active secretion into bile (multidrug and toxic compound
extrusion-1 [MATE1]) and into renal tubules (OCT2 and MATE2) (Rena et al 2013).
The lack of OCT1 in animal model showed significant reduction in metformin efficacy
and hence, it highlights the liver as primary site of metformin action (Rena et al 2013).
In Liver, metformin exerts its anti-hyperglycaemic effects by decreasing hepatic
glucose output (HGP) at fasting (Zhou et al 2001). It is stated that this effect occurs
through AMPK-dependent and AMPK-independent mechanisms (Renal et al 2013).
Metformin-induced LKB1-AMPK axis inhibits gluconeogenesis by decreased
transcription/expression of gluconeogenesis genes such as phosphoenolpyruvate
carboxykinase (PEPCK) and glucose-6-phosphatase (G6P) (Zhou et al 2001). At the
same time, among metformin given to LKB1 and AMPK knockout mice, HGP
inhibition was found to be related to depletion of hepatic energy charge (ATP), and
suppression of gluconeogenesis which occurs through transcription-independent
mechanism(Rena et al 2013). The mechanism is suggested by Miller et al that
metformin can diminish the effects of its counter-regulatory hormone, glucagon, on
adenylate cyclase, thereby, depletion of cyclic AMP (cAMP) and concomitant
activation of cAMP-dependent protein kinase (Protein kinase A/PKA) (Miller et al
2013).
Moreover, AMPK activation by metformin in liver also reduces hepatic lipid
accumulation (Zang et al 2004). Once activated, AMPK phosphorylates and inhibits
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the activity of Acetyl CoA Carboxylase (ACC) and thereby activating fatty acid
oxidation resulting in reduction of intracellular lipid content (Zang et al 2006) . ACC
is a bidirectional and rate-limiting enzyme in lipid biosynthesis and is also cross-link
between lipid oxidation and synthesis (Nguyen et al 2008). During fed state, the non-
phosphorylated active ACC form converts acetyl CoA to malonyl CoA, a precursor
for elongation in fatty acid synthesis. There is evidence that AMPK influences fatty
acid metabolism where low AMPK activity favours pathways towards assembly of
fatty acyl CoA in the cytosol whereas phosphorylated AMPK favours lipid oxidation
by decreasing malonyl CoA biosynthesis which limits mitochondrial fatty acid entry
(Ruderman et al 2006; Zhou et al 2001). Once phosphorylated, it activates fatty acid
oxidation by inhibiting ACC while increasing the activity of malonyl CoA
decarboxylase which converts malonyl CoA to succinyl CoA, an essential substrate
for Krebs citric acid cycle (KCAC). Zhou et al have found that metformin-induced
AMPK activation also suppresses the mRNA expression of transcription factors
important for triglyceride and cholesterol biosynthesis (known as sterol regulatory
element binding factors/SREBFs)(Zhou et al 2001). Moreover, it also decreases the
expression of the major enzymes in lipid synthesis such as ACC and Fatty acid
synthase (FAS) in triglyceride biosynthesis and 3-hydroxy-3-methylglutaryl-CoA
reductase (HMGCR) in cholesterol biosynthesis (Zhou et al 2001; Lee et al 2012). As
a result, metformin reduces hepatic lipid accumulation by increasing fatty acid
degradation, together with blockage of its synthesis (Zang et al 2004).
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1.2.4 Metformin and reduced vitamin B12 levels
It has been extensively studied that long-term metformin use in type2 diabetes is
associated with significant reduction in vitamin B12 level (Ting et al 2006; Liu et al
2006; Sorich et al 2008; Carpentier et al 1975; de Jager et al 2010) although there are
some observational studies which have found no association (Radfar et al 2011;
Hermann et al 2001). In 1971, Tomkin and his co-workers demonstrated that 30% of
type 2 diabetes patients on metformin for more than 2 years were at risk of reduction
in vitamin B12 levels, and stopping of metformin could return the B12 level to normal
within 1 month (Tomkin et al 1971). The metformin-induced lowering of vitamin B12
levels could be due to alteration in calcium level in the gut, gut bacterial flora or
abnormal fat absorption (Bauman et al 2000).
The prevalence of metformin induced vitamin B12 reduction varies from 14-30%
(Hermann et al 2001). In fact, vitamin B12 deficiency (<150pmol/l) is significantly
associated with duration (> 3years) (Ting et al 2006) and current dose of metformin
use (Ting et al 2006; Sorich et al 2008). One randomized trial over 52 months with
metformin performed by Jager et al reported that metformin-related vitamin B12
reduction is progressive over time (de Jager et al 2010). Ting et al have also reported
that an increase in 1gram/day dose of metformin significantly rises the risk of vitamin
B12 deficiency by more than 2 times and that of vitamin B12 insufficiency (150-220
pmol/l) by almost 4 times (Ting et al 2006). Sorich et al have reported “a significant
negative correlation” between current metformin dose and vitamin B12 level (r= -0.27,
p=0.02)(Sorich et al 2008). Furthermore, the randomized controlled trial of Jager et al
have reported the number needed to be treated for both Vitamin B12 deficiency and
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insufficiency being 13.8 per 4.3 years (95% CI 43.5 to 8.3) and 8.9 per 4.3 years (95%
CI 21.7 to 5.6)respectively(de Jager et al 2010).
The use of metformin for less than 6 months has been found in two randomized studies.
Sahin et al studied the effect of metformin on Vitamin B12 level in type 2 diabetes
over 6 weeks period where 850 mg bd per day of metformin was offered to newly
diagnosed type 2 diabetes patients (Sahin et al 2007). Although the study showed
clinically significant change in Vitamin B12 level (mean difference -20.2 (-5.3 to -
45.7) pmol/l, it failed to prove statistical significance (p=0.119)(Sahin et al 2007).
Another randomized study of high dose metformin (mean dose 2163 mg/day) over 16
weeks done by Wulffele et al demonstrated significant reduction in Vitamin B12
level[mean change -14(-4.2 to -24 pmol/l) (p<0.0001)](Wulffele et al 2003). Although
studies have almost invariably reported metformin-induced fall in vitamin B12 level,
clinical reports of vitamin B12 deficient neurological and haematological disorders are
rare.
In addition to dose and duration of metformin, there are also other risk factors related
to metformin-induced Vitamin B12 deficiency. Ting et al reported that being
vegetarian increases the odds of metformin-induced Vitamin B12 deficiency and
insufficiency although the reported confidence interval is wide (OR 16.2(95% CI 1.69,
154)) (Ting et al 2006). Moreover, it is found that 10-yr increment in age is
significantly associated with both B12 deficiency and insufficiency with the odds of
1.36 (96% 1.08-1.69) and 1.6 (1.24 to 2.04) respectively. The effect of H2 receptor
blockers, proton pump inhibitors and antibiotics on the reduction of B12 level is still
controversial(Ting et al 2006; Sorich et al 2008; Tomkin et al 1971). In fact, the
prevalence of vitamin B12 deficiency related to reduced dietary intake in type 2
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diabetes population who are not exposed to metformin is as high as almost 50% and
half of these patients could be corrected with oral vitamin B12 over 3 months (Jawa et
al 2010).
At the same time, the use of metformin in type 2 diabetes is also associated with rise
in plasma total homocysteine (tHcy) level and fall in folate level although the evidence
has not yet been confirmed (Sahin et al 2007; Wulffele et al 2003; Pongchaidecha et
al 2004). Jager et al found that metformin related folate reduction is dependent of body
mass index and smoking status(de Jager et al 2010). The change in tHcy in metformin-
treated type 2 diabetes is both vitamin B12 and folate dependent (Wulffele et al 2003).
Kilicdag and colleagues have also found that metformin-induced rise in tHcy level
could be counteracted by B group vitamins (vitamin B1, B6 and B12) and folic acid
(Kilicdag et al 2005). Recently, Rowan and her group have also reported that short-
term use of metformin in GDM women is associated with reduction in serum vitamin
B12 levels. In summary, metformin is understood to be progressive decrease in
vitamin B12 whereas its effects on folate and homocysteine are still left to be justified.
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1.3 Micronutrients in Pregnancy
1.3.1 Vitamin B12
Vitamin B12 (Cobalamin) is water-soluble essential vitamin and it was recognized in
the late 1940s (Depeint et al 2006). It contains cobalt ring and is synthesized only by
bacteria or microorganisms. It presents in three forms in the diet as adenosylcobalamin
(coenzyme B12), hydroxycobalamin and methylcobalamin. All three forms are found
in meat and fish, especially liver, while dairy products have mostly hydroxycobalamin.
Strict vegeterians are required to take it as a regular supplement. It is commercially
available as cyanocobalamin which is then coverted to hydroxycobalamin and
methylcobalamin. The daily requirement is very trivial (1-2ug/day) for a normal adult
and increased to 2.6 ug/day during pregnancy. It can be stored in the liver adequately
for 6 years and thus, deficiencies are rare.
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1.3.1.1 Digestion, Absorption and Transport of Vitamin B12
An overview on vitamin B12 transport is illustrated in Figure 1.5. Firstly, cobalamin
(Cbl) digestion begins in the stomach where pepsin helps releasing it from dietary
protein in the acidic environment(Depeint et al 2006; Andres et al 2004). It then binds
to salivary R binder which transports it to the small intestine. There, pancreatic
enzymes digest the binder and it is then transferred to stomach-derived intrinsic factor
(IF), forming IF/Cbl complex. With the help of specific IF receptor or cubilin, the
complex then enters into the enterocyte by endocytosis. After that, it is dissociated in
the lysosomes and the free Cbl is bound to newly synthesized transcobalamin II (TC
II) which carries it to the portal system. In the liver, the TCII/Cbl complex enters by
endocytosis by TCII specific receptor action and then it is freed again by proteolytic
digestion in the lysosomes and endosomes. Cobalamin released to the cytosol is readily
converted to methylcobalamin by methionine synthase reductase. The mechanism how
vitamin B12 is transported to the mitochondria is still unknown. In the mitochondria,
Cbl is reduced by reductase and is then transformed by adenosyl transferase and ATP
to adenosylcobalamin which subsequently binds to methylmalonyl-CoA mutase
(MMCoAM) as a coenzyme. Methylcobalamin, bound to transcobalamin I (TC I) or
haptocorrin, are also released into the plasma and delivers to other peripheral tissues
via asialoglycoprotein receptors. In the blood, 60-80% of Cbl are found in the form of
methylcobalamin and 20% in adenosylcobalamin whereas 70% of Cbl in the liver
represents adenosylcobalamin with 5% methylcobalamin(Bender 2003). Any
physiological or pathological abnormalities in the function of gastrointestinal tract or
plasma transport system can lead to diseases due to vitamin B12 deficiency. E.g.
pernicious anaemia in the elderly due to impaired absorption and inborn error of
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cobalamin metabolism due to defect in mitochondrial cobalamin binding protein(Ball
2004b).
Figure 1.5 Overview of vitamin B12 digestion, absorption and transport (Figure
taken from www.b12g.org/book/export/html/1291)
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1.3.2 Folic acid
In the late 1930s, folic acid was discovered as vitamin necessary to reduce anaemia
during pregnancy. It is not synthesized in the body. Folates are available in the diet as
2 forms: dietary folates – from green leafy vegetables, eggs and legumes and fortified
folates. Deficiency can result from poor nutritional intakes or malabsorption or high
metabolic demands in conditions like pregnancy or anti-folate chemotherapy (e.g.
methotrexate) (Ball 2004a).
Table 1.2. Daily requirement of folates in different age groups (adapted from Bailey
et al 1999)
Group Recommended Daily
Allowance (µg/day)
Children and adolescents
1-3
4-8
9-13
14-18
Adults
≥19 
Pregnant women
All ages
Lactating women
All ages
150
200
300
400
400
600
500
The daily requirement of folates in different age groups is shown in Table 1.2. These
estimates are required to maintain normal red blood cell (RBC) folate levels. RBC
folates are indicators of liver and other tissue storage of folates(Bailey et al 1999).
Folates in the body function as a one-carbon (1C) carrier, required for methylation
reactions which are important for deoxyribonucleic acid (DNA) synthesis and repair
and gene expression. During pregnancy, adequate folate intake is vital for normal
growth and development of fetus throughout gestation. Folate deficiency in pregnancy
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can result in megaloblastic anaemia, neural tube defects and low birth weight infants
(Depeint et al 2006).
1.3.2.1 Digestion, absorption and transport of folates
Folates in the diet are usually bound to polyglutamate proteins which need to be
converted by proteases to monoglutamate forms before absorption in the proximal
jejunum (Depeint et al 2006). Then, monoglutamates are transported to liver by H+ co-
transporter in the liver and folate receptor in other cells and mitochondria (Ball 2004a).
Once in cytosol and mitochondria, they are elongated so that they can retain inside the
cell.
1.3.3 Understanding cellular functions of Vitamin B12 and Folates
General overview of interaction of vitamin B12 and folates as a methylation reaction
was given in Figure 1.5.
In the cytosol,
Vitamin B12 and folate play indispensible roles in one-carbon transfer pathway, which
is important for DNA methylation and repair. Folate in the form of tetrahydrofolate
(THF) plays as a carrier of 1C group from methy donars like serine inside the cell
whereas vitamin B12 as methylcobalamine plays a cofactor in methyl group transfer.
The reaction involves conversion of homocysteine to methionine by transfer of methyl
group from methyltetrahydrofolate (MTHF) to the former, catalysed by methionine
synthase (MS)(Kalhan 2009; Sardesai et al 2011). Methionine is subsequently
converted to the active form called s-adenosylmethionine (SAM-e) which then passes
over methyl group to methyl acceptor, required for “DNA methylation and gene
expression” (Saravanan et al 2010). At the same time, demethylated MTHF/5-THF (5-
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tetrahydrofolate) is remethylated back to form 5,10-methyltetrahydrofolate (5,10-
MTHF) by the transfer of methyl group from deoxyuridine monophosphate (dUMP)
and finally 5,10-MTHF is converted by 5,10-MTHFR to 5-MTHF, a readily available
methyl donar for methionine formation. Meanwhile, the demethylated dUMP also is
also transformed to deoxythymidine monophosphate (dTMP) which is important for
nucleic acid formation and DNA repair (Sardesai et al 2011; Saravanan et al 2010;
Nielsen et al 2012). Alternatively, either of functional vitamin deficiency can reduce
methylation potential inside the cell and can impair one-carbon transfer, leading to
hyperhomocysteinaemia, poor cardiovascular risk factor and “DNA hypomethylation
and altered gene expression”, contributing to “foetal programming”(Yajnik et al
2008). It has been reported that there is increased intracellular cholesterol
accumulation in vitamin B12 deficiency due to hypomethylation and increased
expressions of sterol regulatory element binding factor-1 (SREBF1), low density
lipoprotein receptor (LDLR) and other cholesterol biosynthesis enzymes
(Adaikalakoteswari et al 2015).
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Figure 1.6 Model of vitamin B12 deficiency on cellular insulin resistance (taken from
Saravanan P, Yajnik CS. 2010 in The British Journal of Diabetes and Vascular
Disease)
dTMP = Thymidine monophosphate, dUMP = deoxyuridine monophosphate, TS =
thymidylate synthase; MTHF = methyl tetrahydrofolate;MTHFR = methylene
tetrahydrofolatereductase; DHF = dihydrofolate; THF = tetrahydrofolate; MS =
methionine synthase; SAH = S-adenosylhomocysteine, SAM-e = S-adenosyl
methionine; R = methyl acceptor; R- = methylated compound; MM-CoA =
methylmalonyl-CoA mutase; CPT1 = cartinine palmitoyltransferase-1
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In the mitochondria,
Vitamin B12 as adenosylcobalamin
Folates in the mitochondria are important for mitochondrial protein biosynthesis as
well as glycine and serine cycling, both of which are important amino acid for purine
and pyrimidine synthesis (Ball 2004b). At the same time, vitamin B12 plays as a
coenzyme bound to MMCoAM for the synthesis of succinyl-CoA from
methylmalonyl-CoA (MMCoA). MMCoA is converted from the propionyl-CoA
which is a 3-carbon glucogenic fatty acid, end-product metabolites of methionine,
valine, isoleucine or odd-chain fatty acids oxidation. The oxidation of long-chained
fatty acids is initiated in the cytosol and then enters mitochondria as fatty-acyl CoA
with the help of carnitine palmitoyltransferase I (CPT I), which is a rate-limiting step
for fatty acid degradation and usually inhibited by high levels of malonyl-CoA. Once
in mitochondria, they are then degraded to acetyl CoA and propionyl CoA. Propionyl
CoA, is carboxylated to methylmalonylCoA which requires vitamin B12 to convert
to succinyl-CoA (Sardesai et al 2011; Saravanan et al 2010; Nielsen et al 2012).
Succinyl-CoA is an essential substrate for Tricarboxylic acid (TCA) cycle, an energy-
generating cycle. In a state of B12 deficiency, MMCoA is pooled to form
methylmaloic acid (MMA). MMA is structurally similar to malonyl CoA, which
imitates malonyl CoA at CPT I level, thereby, interfering with fatty acyl Co A transfer
and β-oxidation (Zierz et al 1987). Accumulation of fatty acyl CoA in the cytosol is
diverted into extra mitochondrial lipid pathways producing lipid esters (e.g.
diacylglycerol) and releasing metabolic stressors (e.g. reactive oxygen species) which
provoke insulin resistance in liver and peripheral tissues (Ruderman et al 2006).
However, the data of vitamin B12 deficiency on mitochondria is still limited. It is
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stated that vitamin B12 is important for coenzyme Q biosynthesis, which is important
for mitochondrial respiratory function (Ball 2004b). Therefore, it would be of worth
presumption that mitochondria function might be impeded in vitamin B12 deficiency.
In addition to its involvement in insulin resistance, vitamin B12 is also important for
optimal neuronal function in the sense that the aggregated MMCoA substitutes the role
of malonyl CoA in fatty acid synthesis which is essential for generation of nervous
tissue, resulting in impaired adaptability of neuronal function (Saravanan et al 2010).
Moreover, the accumulated MMCoA, which is converting backwards to propionyl
CoA (3-carbon CoA) may favour formation of odd-chain fatty acids, which also
interferes with cell membrane integrity if being incorporate into membrane
phospholipid synthesis (Sardesai 2011) By these means, B12 is indispensible for
stabilization of myelin sheath membrane. There is also evidence that the aggregated
MMCoA substitutes MMA in fatty acid in neuronal membrane and interferes with
neuronal integrity and adaptability (Ball 2004b).
It has already mentioned that in B12 deficiency, homocysteine can be accumulated.
High homocysteine level during pregnancy could probably be an explanation for
insulin resistance in GDM (Guven et al 2006; Seghieri et al 2003). Homocysteine is
“a thiol (SH)-containing amino acid”, one of which pathways includes conversion to
essential amino acid, methionine, by going through methylation reaction with the
acceptance of methyl group from folate with the help of coenzyme vitamin B12(Hague
et al 2003). As mentioned above, methionine acts as a methyl donor, transferring its
methyl group to “methylated acceptors”, that involves in DNA synthesis. High
homocysteine level in pregnancy has been well-established as being responsible for
neural tube defects, pre-eclampsia, and placental vasculopathy with its related early
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pregnancy loss and abruptio placenta. Similar to its association with GDM, high
homocysteine level is also found to be related to insulin resistance in polycystic ovary
syndrome (Schachter et al 2003) and insulin resistance syndrome (Meigs et al 2001).
Any disturbance in metabolism of homocysteine including B-group vitamins and
folate deficiency as well as enzyme defect could result in high homocysteine level.
1.3.4 Transgenerational impact of vitamin B12 deficiency
The possible mechanisms how maternal B12 level relates to the long-term risk of B12-
related metabolic diseases in offspring have been reviewed by Yajnik et al (Yajnik et
al 2008) (Figure 1.6). They have explained that this may occur through either “foetal
programming” or shared dietary pattern between mothers and offspring. If maternal
vitamin B12 is not enough to supply methyl group for cellular differentiation of the
embryo, it may interfere with protein synthesis, resulting in lower lean body mass. At
the same time, disturbance in fatty acid synthesis may lead to unfavourable lipid
distribution in offspring of B12 deficient mothers. Moreover, there is also evidence
that newborn’s B12 and homocysteine level defined by cord blood at birth is strongly
predicted by maternal vitamin B12 level at labour (Guerra-Shinohara et al 2002). After
birth, the newborns tend to share the same dietary pattern with their mothers and
subsequently, they may have low B12 levels. Their low B12 levels will determine their
body composition of adipose tissue. Therefore, like their moms, newborns of B12
deficient mothers are at risk of being fat.
In accordance with their explanations, Yajnik and his co-workers have also reported
that newborns of B12 deficient high homocysteine mothers tend to be at risk of lower
birth weight at birth (Yajnik et la 2005) and at 6 years more insulin resistant than their
B12 sufficient comparators (Yajnik et al 2007). The increased maternal MMA level is
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found to have significant association with central fat deposition and impaired glucose
tolerance of offspring at 6 years of age (Yajnik et al 2007). The highest insulin
resistance in the 6-year-olds was found in those with maternal lowest B12 but highest
folate tertiles (Yajnik et al 2008). This group has also reported that low maternal B12
could have risks on offspring’s’ memory and attention span (Bhate et al 2008). It is
evident that maternal B12 levels may influence not only foetal body composition but
also neuronal function.
1.3.5 Impact of Low Vitamin B12 High Folates conditions
During pregnancy, there is high demand of B12 and folate for methylation reaction
and DNA synthesis. Reduction in neural tube defects by folic acid supplementation
has led to fortification of food in US since 1997. A decade later, it was found that high
folate levels particularly in the state of vitamin B12 deficiency are associated with
increased homocysteine and methylmalonic acid levels and increased incidence of
anaemia and neurological impairment in the elderly (Selhub et al 2007; Ralph et al
2005; MacFarlane et al 2011). High folates are not normally recommended to pregnant
women during pregnancy. However, in some cases like diabetic pregnancy which is
highly associated with neural tube defects and in some countries where dietary folate
deficiency are common, high folates of 5mg are given to pregnant women. So, in
pregnancy folate deficiency is rarely seen. In fact, both folic acid and vitamin B12 are
responsible for optimal development of neural tube (Kirke et al 1993). High
homocysteine level could be implicated in B12 deficient mothers, even in adequate
folate supply (Yajnik et al 2008).
As mentioned above, it is common to see pregnancy with low B12 and high folate
states. During the past few years, there have been reports on impact of low B12 high
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folate states on pregnancy outcomes. The interaction of folate level in B12 deficient
pregnant women is found to have positive relationship with Homeostasis Model
Assessment (HOMA) insulin resistance whereas the significant reverse relation is
observed in non-deficient mothers (Krishnaveni et al 2009). Similarly, it has been
reported that high folates low vitamin B12 states during pregnancy can increase the
risk of infants with small-for-gestational-age (SGA) and low birth weight (LBW)
(Dwarkanath et al 2013; Gadgil et al 2014). Moreover, this imbalance can also
increase the incidence of gestational diabetes mellitus in mothers (Krishnaveni et al
2009). This might be due to the detrimental effect of B12 deficiency implicated high
homocysteine level although the study failed to report homocysteine level. This
association has been found to be obesity-related. However, this cross-sectional study
was not able to establish the causal role of B12 deficiency in GDM. Recently,
Krishnaveni and her group have found higher insulin resistance in the adolescent
offspring born from mothers with higher folate concentrations, but not vitamin
B12(Krishnaveni et al 2014). Thus, it should be noted that although folates are
essential in pregnancy, high folate intakes can have detrimental effects on pregnancy
outcomes, especially in the presence of vitamin B12 deficiency. The question of
whether high folate or low vitamin B12 or combination can have these adverse
outcomes are still controvertial.
1.3.6 Vitamin B12 deficiency and insulin resistance in clinical studies
It is suggested that the considerably higher diabetic risk of GDM in South Asians could
be related to increased adipose tissue composition, compared to their European
counterparts (Barnett et al 2006). A study on comparison of body fat composition in
multi-ethnic UK children has showed that despite lower BMI in South Asians, their
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proportion of adiposity, determined by skin fold thickness and waist circumference, is
found to be significantly higher than the White (Nightingale et al 2011). This excess
fat composition nature of South Asians could be explained by B12 insufficiency
(Yajnik et al 2008). Owing to the lack of B12-abundant food such as meat and milk in
their regular meal, the South Asians are found to have lower B12 level than the
Europeans (Chambers et al 2000).
Similarly, a comparison study of insulin sensitivity among different ethnic groups has
reported that insulin resistance is higher in South Asians and Asians in comparison to
their Caucasian counterparts(Retnakaran et al 2006). In this study, it has also been
found that being South Asian is modestly associated with pre-pregnancy body mass
index (BMI) in contrast to strong relationship between other Asian population and
their pre-pregnancy BMI, suggesting that ethnicity is an independent risk factor
modulating insulin resistance among this population(Retnakaran et al 2006). In
consistency with this finding, level of insulin-sensitizing protein, adiponectin, was
found to be decreased in South Asian population(Retnakaran et al 2004). Similarly,
Moore et al observed greater proportion of metformin-treated GDM necessitating
additional insulin in Hispanic ethnic group (Moore et al 2010; Moore et al 2007). At
the same time, another study has reported that Hispanics have lower B12 than
neighbour matched non-Hispanic White despite being non-vegetarians (Kwan et al
2002). Therefore, it could be concluded that relation between ethnicity and insulin
resistance might probably be, at least in part, mediated through vitamin B12
deficiency.
1.3.7 Vitamin B12 deficiency and Lipid Metabolism
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It has been reported that vitamin B12 deficiency is associated with impaired lipid
metabolism. There are also a number of reports from clinical studies that there is
significant association between vitamin B12 deficiency and dyslipidaemia
(Adaikalakoteswari et al 2014). Recently, an adipocyte cell culture study has found
that vitamin long-term vitamin B12 deficiency increased intracellular cholesterol
biosynthesis by reducing s-adenosylmethionine (AdoMet) to s-adenosylhomocysteine
(AdoHcy) ratio and thereby, modifying the expression levels of SREBF1 and LDLR
by hypomethylation (Adaikalakoteswari et al 2015). They have also reported the
negative correlation between serum vitamin B12 levels and total cholesterol, LDL
cholesterol and cholesterol to HDL ratio in both pregnant and non-pregnant population
(Adaikalakoteswari et al 2015). Similarly, the clinical studies looking at vitamin B12
levels and lipid profiles among patients with history of coronary artery disease and
type 2 diabetes have reported the same observation that vitamin B12 deficiency was
associated with higher triglyceride levels and cholesterol to HDL ratio
(Adaikalakoswari et al 2014). At the same time, Koplay and his group have also
reported that low serum vitamin B12 levels were significantly associated with higher
risk of non-alcoholic fatty liver disease and vitamin B12 deficiency could induce high
grade liver steatosis (Koplay et al 2011). However, there is no molecular study looking
at how vitamin B12 deficiency in the liver can give rise to fatty liver disease. Based
on the evidence from adipocyte study, one of the possible mechanisms could be
through hypo-methylation. A recent study of vitamin B12 supplementation to wistar
rats during pregnancy has suggested that there is increased plasma triglyceride levels
in offspring of vitamin B12 supplemented rats with decreased eicosapentaenoic
acid(EPA) content in the liver (Khaire et al 2015). It is reported that EPA regulates
triglyceride metabolism by regulating key enzyme involved in triglyceride synthesis.
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It is suggested that the pathway could occur through AMPK signalling pathway, which
could be another interesting area to explore the mechanism behind how vitamin B12
deficiency contributes to dyslipidaemia.
To explore the possible mechanisms behind, it is first important to understand the
regulation of lipid metabolism in the body.
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1.4 Lipid metabolism
1.4.1. Transport of Lipids in the body
Lipids are important for normal physiologic function in the body not only by serving
as energy storage and production but also as cell membrane stabilizer as well as
precursors for bile acids and hormones biosynthesis (Nguyen et al 2008). Being
insoluble in the blood, they are packaged into lipoproteins to travel in the circulation
from their site of synthesis or absorption to the sites of utilization. Lipoproteins contain
cholesterol ester and triglyceride in the core which are coated by hydrophilic particles
such as apolipoproteins (apoB, apoC and apoE), phospholipids and free cholesterol
(Kingsbury et al 2003). Apolipoproteins serve a number of functions including
receptor binding and enzyme activation (e.g. lipoprotein lipase (LPL) by apoC-II
which eliminate triglyceride from lipoproteins) and maintaining the structural integrity
of lipoprotein particles. There are two main types of lipoprotein in the blood: HDL
containing apoA1 and non-HDL containing apoB48 or apoB100. Moreover,
depending on sources of lipids, density and lipid components, they can be sub-divided
into 5 different classes: chylomicrons, very low density lipoprotein (VLDL),
intermediate density lipoprotein(IDL), low density lipoprotein(LDL) and high density
lipoprotein (HDL) (Table 1.7). LDL and chylomicrons are main carriers of triglyceride
in the blood whereas LDL is major contributor of plasma cholesterol levels (Adeli et
al 2001; Baltimore et al 1999).
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Table 1.3. Classification of Lipoprotein in Human Plasma (Baltimore MD Manual of
Lipid Disorders: Reducing for Coronary Heart Disease 1999; 2-10.)
There are three major lipid transport pathways within the body, namely the exogenous
pathway, the endogenous pathway and the pathway of reverse cholesterol transport
(Kingsbury et al 2003) (Figure 1.8). The exogenous pathway includes dietary lipids
which are packaged into chylomicrons by coating with apoB48, produced from
intestinal cells, and are carried in the lymphatic circulation to the utilization sites. The
endogenous pathway contains lipoproteins produced within the liver. Liver produces
triglycerides and cholesterols from plasma non-esterified fatty acid (NEFA) pools and
from Acetyl CoA (de novo lipogenesis). Some of them are stored in the liver cytosolic
lipid pools whereas some are then packaged with apoB100 to dissolve in the
circulation and are carried to the peripheral tissues. The reverse cholesterol transport
helps removing cholesterol deposits at the periphery by taking them back in the form
of HDL to the liver for clearance. Thus, any defect of the pathways including enzymes
like lipoprotein lipase (LPL) – responsible for taking up of triglycerides by peripheral
tissue or abnormal apolipoprotein production can result in blood dyslipidaemia(Adeli
et al 2001).
Lipoprotein Major Lipid
component
Main
Apolipoproteins
Lipid Transport
Pathway
Chylomicron TG ApoB-48 Exogenous – from intestine
to liver
VLDL TG ApoB-100 Endogenous – from liver to
peripheral tissues
IDL/LDL CE ApoB-100 Endogenous – from liver to
peripheral tissues
HDL Protein ApoA-I Reverse cholesterol – from
peripheral tissues to liver
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Figure 1.7. Overview of Lipid Transport in the body (Figure taken from internet
available at http://www.clinbiochem.info/studentlipids1.html)
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1.4.2. Role of liver in blood lipid regulation
The liver plays a central role in lipid metabolism. The balance between insulin
sensitivity and fatty acid availability in the cytosol maintains the intrahepatic lipid
composition and, when the influx of lipids are more than the efflux, lipid accumulation
in liver (steatosis) develops(Tessari et al 2009). The sources of lipids in the liver come
from adipose tissue lipolysis contributing to plasma NEFA pools, dietary lipids and de
novo lipogenic particles. Their efflux mechanism includes oxidation and VLDL
secretion.
1.4.2.1.Liposynthesis, de novo lipogenesis and VLDL assembly and secretion
Liver takes up triglycerides in the circulation via hydrolysis by hepatic lipase (HL) and
LPL enzymes whereas LDL cholesterol remnants are endocytosed by specific LDL
receptor (LDLR) on the surface (Nguyen et al 2008). Free fatty acids (FFA) (activated
as fatty acyl CoA) from NEFA pools are esterified with glycerol (activated as alpha-
glycerophosphate [α-GP]) by glycerophosphate acyltransferase (GPAT). GPAT gene 
transcription and activity are stimulated by insulin and nutritional status, while
glucagon inhibits it. The esterification and lipoprotein synthesis are activated by FFA
flux to the liver. Moreover, the internalized LDL cholesterol are hydrolysed in the
lysosomal enzymes for further usage in bile acid production and membrane
phospholipid synthesis.
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Figure 1.8. An illustrative model of hepatic glycolytic and lipid pathways. All the
enzymes in the figure are induced at transcriptional levels by a high-carbohydrate diet
through ChREBP and SREBP transcription factors (the known transcription factors
and their regulated genes are described at the bottom). (Figure taken from Foufelle F
et al. Biochem J 2002 Sep 1; 366(Pt2):377-91)
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De novo lipogenesis
In humans, liver is the major organ for de novo lipogenesis (Kersten 2001). Glucose
enters into hepatocyte by the help of facilitated glucose transporter (GLUT2) which is
a high capacity low affinity glucose transporter. Once in the cell, it is converted to
glucose-6-phosphate (G6P) by glucokinase(GK), which is the rate-limiting enzyme for
further glucose utilization (Figure 1.9). Then, G6P binds to carbohydrate responsive
element binding protein (ChREBP) which regulates genes involved in glycolytic and
lipogenic pathways such as pyruvate kinase(PK), FAS and ACC by binding to glucose
or carbohydrate-response elements(ChoRE) on the promotor region of the target
genes. ChREBP is also an essential link between carbohydrate and lipid metabolism
(Raddatz et al 2011). Sterol regulatory element binding factor/protein-1c
(SREBF1c/SREBP1c) is also another transcriptional factor which regulates
triglyceride synthesis and capacity of storage inside the liver (Horton et al 2002).
SREBP are normally resided in endoplasmic reticulum (ER) and they control fatty acid
metabolism by integration of signals from different pathways (Figure 1.10). They are
stimulated when intracellular lipid levels are low (SREBP1c and SREBP2
preferentially for triglyceride and cholesterol biosynthesis respectively). Low
cholesterol levels are initially sensed by SREBP cleavage-activating protein (SCAP)
which subsequently transports SREBP from ER to Golgi apparatus. The
SERBP/SCAP complex is then cleaved by two proteases, Site-1 protease (S1P) and
Site-2 protease (S2P), releasing NH2-terminal domain of basic helix-loop-helix-
leucine (bHLH-Zip) region from the membrane. The newly synthesized bHLH-Zip
domain translocates to the nucleus where it binds to sterol response elements (SREs)
in the promotor regions of various target lipogenic enzymes including PK, FAS, ACC,
Stearyl-CoA (SCD) and 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR).
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Apart from GK which is only under insulin control, all other genes involved in
glycolytic and lipogenic pathways can be induced by both insulin and glucose
(Raddatz et al 2011). As mentioned above, insulin enhances de novo lipogenesis by
activation of glucokinase and SREBPs. Of these, ACC and HMGCR are rate-limiting
enzymes in triglyceride and cholesterol synthesis respectively (Nguyen et al 2008).
Figure 1.9. An illustration of how SREBPs are released from endoplasmic
reticulum(ER). (Taken from Horton JD. J. Clin Invest. 2002. 109:1125-1131)
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De novo lipogenesis is initiated with acetyl CoA formation from pyruvate by L-
PK(Foufelle et al 2002). Then, under the insulin control, acetyl CoA is carboxylated
to malonyl CoA which further undergoes triglyceride synthesis while it is converted
to Hydroxy-3-Methylglutaryl-CoA (HMG-CoA) by Hydroxy-3-Methylglutaryl-CoA
Synthase (HMGCR), both of which are in independent of FFA (Figure 1.9). ACC is
bidirectional enzyme which regulates FFA partitioning between oxidation and
lipogenesis at the availability of malonyl CoA. Under the insulin control, malonyl CoA
accumulation favours FFA towards esterification and triglyceride production while
inhibiting fatty acid beta-oxidation (β-oxidation) by blocking the activity of 
mitochondrial fatty acyl transporter, carnitine palmitoyltransferase-1 (CPT-1)(Kersten
et al 2001).  By contrast, glucagon enhances β-oxidation and ketogenesis by 
stimulating CPT-1 activity. On the other hand, the overflow of FFA to liver, e.g.
diabetic ketoacidosis, can saturate both pathways denoted by combined
hyperlipidaemia and hyperkitonemia. After esterification, the newly synthesized FFA
molecule are elongated by FAS and the resultant palmitoyl-CoA is desaturated by SCD
to palmitoleyl CoA, both of which are under insulin control(Nguyen et al 2008). At
the same time, HMG-CoA in cholesterol biosynthetic pathway is further reduced by
HMGCR, forming mevalonate. Mevalonate is then eventually converted to cholesterol
by the action of farnesyl diphosphate synthase and squalene synthase. All the enzymes
described above in cholesterol biosynthesis are under SREBP2 control. Interestingly,
the SERBPs stimulation by insulin can be observed in states of marked insulin
resistance and thereby favouring de novo lipogenesis(Foufelle et al 2002; Adiels et al
2008). The other transcription factors involved in de novo lipogenesis includes
peroxisome proliferator-activated receptors-gamma (PPAR-γ) stimulated by SREBP-
1c activation and newly discovered regulatory protein Spot 14 (S14) stimulated by
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high-carbohydrate diet and thyroid hormone. Interestingly, it has been reported that
only a small part of total triglyceride synthesis in liver is affected by de novo
lipogenesis in humans (Postic et al 2008). However, whether this pathway is
profoundly affected in the state of insulin resistance is still an area required for further
exploration.
1.4.2.2.Lipid transport
The newly synthesized lipids are then exported out of liver by binding to ApoB100
(Adeli et al 2001). Increased FFA and TG levels and mitochondrial transfer protein
(MTP) stimulate ApoB biosynthesis whereas insulin inhibit it. MTP initiates lipidation
of nascent apoB molecule and further enhances the assembly of apo-B containing
lipoproteins by catalysing the transfer of lipids from triglyceride rich droplets in
smooth endoplasmic reticulum to nascent Apo-B particle.
1.4.2.3. Lipid oxidation
The oxidation of non-esterified acyl-CoA occurs in mitochondria, peroxisomes and
microsomes in liver (Nguyen et al 2008). Oxidation of very long chain fatty acids
occur in peroxisome and microsomes whereas mitochondria is responsible for
oxidation of short, intermediate and long fatty acids. The lipid oxidation is regulated
in the liver by the balance between fatty acid supply (from lipolysis of adipocytes) and
the rate of lipid oxidation and esterification by microsomes.
Intramitochondrial oxidation of fatty acids with more than 14 carbon requires carnitine
parmitoyl transferase I (CPT-I) enzyme because mitochondrial matrix lack the Acetyl-
CoA synthetase (ACS) enzyme responsible for activation of these fatty acids. CPT-I
is again negatively controlled by mitochondrial malonyl-CoA levels, which is the first
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intermediate of de novo lipogenesis, catalyzed by acetyl coA carboxylase (ACC) under
the control of insulin (Postic et al 2008). When there is intracellular negative energy
balance and low malonyl CoA levels, fatty acyl CoA from plasma non-esterified fatty
acid pools are carried into mitochondria with the help of the transporter, CPT II, for
beta-oxidation. Once in mitochondria, they are converted to malonyl CoA and then to
succinyl CoA, an essential intermediate of krebs citric acid (KCA) energy cycle.
Finally, succinyl CoA enters into the KCA cycle and energy is released. CPT-1 can
also be regulated by methylmalonyl CoA(MM CoA) which is the product of odd chain
fatty acid oxidation and requires vitamin B12 for conversion to succinyl CoA(Nguyen
et al 2008). Thus, in case of vitamin B12 deficiency, MM CoA is accumulated and
inhibits CPT-1 and impairs fatty acid oxidation.
Peroxisomal and microsomal fatty acid oxidation is much similar to mitochondrial
oxidation(Nguyen et al 2008).However, they produces less ATP-energy than
mitochondria because they do not have electron transport chain. Microsomes have
cytochrome P450 CYP4A ω-oxidation system which allows them to hydrolyse very 
long chain fatty acids into much shorter fatty acids which are preferred substrate for
peroxisomal oxidation. Then, the products of peroxisomal oxidation enter into
mitochondria for further oxidation. When there is fatty acid overload, these three
systems work co-ordinately to regulate fatty acid metabolism inside the liver.
1.4.2.4.Hepatic glucose output
Liver also involves in glucose production by glycogenolysis and gluconeogenesis from
non-carbohydrate precursors such as lactate and glycerol(Raddatz et al 2011).
Glucose comes mainly from glycogenolysis within 2-6 hours of meal while
gluconeogenesis mainly contributes to blood glucose levels during prolonged fasting.
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The enzymes controlled gluconeogenesis are phosphoenolpyruvate carboxykinase
(PEPCK), fructose-1,6-biphosphatase(FP2ase) and glucose-6-phosphatase(G6Pase)
which are inhibited by insulin and stimulated by glucagon or glucocorticoids.
1.4.2.5.Insulin signalling
Insulin signalling is initiated by binding of insulin to its cell surface receptor (Kim et
al 2010). The insulin receptor complex then activates tyrosine kinase activity which
phosphorylates subsequent downstream molecule, insulin receptor substrates (IRSs),
such as IRS-1 and IRS-2. The stimulated IRSs lead to the docking of phosphoinositol-
3 kinase (PI-3K) (p85-p110) which further phosphorylates Akt. The phosphorylated
Akt subsequently phosphorylates and inhibits the activity of glycogen synthase kinase
(GSK) which blocks glycogen synthase for glycogen synthesis.
As we have described above, normal liver function is very important for lipid
metabolism as it plays central role in the regulation of blood lipid levels. At the same
time, vitamin B12 deficiency has possibility of contribution to insulin resistance and
blood dyslipidaemia. There are very limited number of studies looking at mechanism
behind vitamin B12 deficiency and abnormal lipid metabolism. It would be of great
value if the possible cellular mechanism of vitamin B12 deficiency is fully established
in the development of vitamin B12 supplementation strategy.
In summary, the role of metformin in GDM is increasing. However, metformin can
reduce vitamin B12 levels, even given for short term period of metformin
administration. Vitamin B12 is an essential micronutrients during pregnancy and it
functions in close relationship with folates. Moreover, there is evidence that vitamin
B12 deficiency can induce insulin resistance and dyslipidaemia. Thus, it was
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hypothesized that if vitamin B12 is deficient in the cell, metformin cannot function at
its full potential.
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1.5 Thesis Aims and methods
The thesis aims to explore factors influencing the efficacy of metformin in the
treatment of GDM and the role of micronutrients, particularly vitamin B12, in
treatment failure. It comprised of a systematic review, clinical and cell culture studies
to evaluate role of metformin in GDM, factors influencing its efficacy and mechanisms
by which vitamin B12 deficiency interferes with metformin study.
Systematic review
 To evaluate efficacy and safety of metformin in the treatment of GDM
Clinical studies
 To identify maternal characters of metformin failure in GDM
 To investigate the association between vitamin B12, folate & homocysteine
with the pregnancy outcomes in GDM
Laboratory study
 To explore the mechanisms by which B12 deficiency interfere with
metformin action in hepatocytes
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Figure 1.10. An overview of PhD thesis
Metformin in Gestational Diabetes Mellitus
(GDM)
Question 1:
What is the efficacy and
safety of metformin in
GDM?
Study 1: Metformin in
GDM: Systematic review
and Meta-analysis
Question 2:
How can the efficacy of
metformin be improved?
Clinical studies
Study 2: Predictors of
metformin failure in GDM
Study 3: Correlation of
serum folates with glucose
levels in relation to vitamin
B12 status
Laboratory study
Study 4: Vitamin B12
deficiency in Lipid
metabolism and Metformin
in Liver
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CHAPTER 2
EVALUATION OF METFORMIN IN GESTATIONAL DIABETES:
SYSTEMATIC REVIEW AND META-ANALYSIS
(STUDY 1)
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2.1 Introduction
GDM is the commonest medical disorder in pregnancy and the prevalence would be
tripled if the new IADPSG guidelines are introduced and can be up to 25%(Duran et
al 2014; Cundy et al 2014). Moreover, the prevalence of GDM women has also been
increased by 64% in the past 2 decades, most possibly due to increasing maternal
obesity and aging mothers at first pregnancy (Duran et al 2014). Thus, it could be well-
expected that the percentages of GDM will be booming up in next couple of years.
Currently, clinical emphasis is on the achievement and maintenance of maternal
glycemic control, which acts as a modifiable principal predictor of adverse outcomes
to mother and fetus (Rowan et al 2010). Importantly, hyperglycemia during pregnancy
is strongly associated with neonatal hypoglycemia and impaired foetal lung maturity
leading to respiratory distress and polycythemia after birth (Langer et al 2008). GDM
also has a negative impact on the risk of metabolic diseases and impaired cognitive
function in later life(Langer et al 2008; Clausen et al 2008; Pirkola et al 2010).
Management of GDM starts with lifestyle modification followed by medical
intervention. Almost half of GDM women need medication which include insulin and
oral hypoglycaemic agents because of poor glycaemic control (Terttie et al 2008; Goh
et al 2011). The role of oral hypoglycaemic agents in GDM is increasing nowadays.
Metformin and glibenclamide are now approved to be offered to GDM women in some
guidelines,but their efficacy and safety are not well-understood yet. Considering the
strong association between GDM and obesity, metformin is a promising drug for GDM
because it can benefit on lowering maternal weight gain than insulin.
Up to date, there are six systematic reviews which have looked at the evidence of
metformin in gestational diabetes compared to insulin and glibenclamide (Balsells et
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al 2015, Kitwitee et al 2015; Su et al 2014; Gui et al 2013; Lautatzis et al 2013; Amin
et al 2015). The most recent one included 8 randomized controlled trials (RCTs) in
their outcome estimate synthesis(Kitwitee et al 2015). Although metformin may
benefit on GDM than either insulin or glibenclamide, the effects are still varied and
there are large heterogeneity among studies. This might be due to differences in
diagnosis of GDM (e.g.75g or 100g OGTT) or variations in intervention strategies.
Moreover, it is reported that metformin use in GDM is associated with higher
incidence of prematurity (Rowan et al 2008). Inclusion of non-randomized controlled
trials (NRCT) will increase the sample size and will also enable subgroup analysis and
sensitivity analysis to generate more specific and precise outcome estimate with wider
inferential value. Furthermore, as these NRCTs have much more clinically pragmatic
design (i.e. inclusion of physician’s judgement on treatment therapy), this might also
help research methodology to be developed in future studies.
At the same time, another concern for metformin in GDM is that up to 50% of women
required additional insulin treatment. Exploration of the factors that can predict GDM
subgroup with high potential of supplementary insulin will allow avoidance dose
titration period with metformin which usually takes around 1 to 3 weeks and help better
glycaemic control from the time of GDM diagnosis until delivery. Thus, it has been
carried out the systematic evaluation of current available evidence of metformin in
GDM to fully appreciate its efficacy, limitation and implacability and to explore the
maternal characters that can predict metformin failure.
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2.2 Methodology
This review was conducted after a review protocol had been developed with general
agreement on the objectives and methodology among 4 reviewers [May Oo Khin
(MOK), Manu Vatish (MV), Simon Gates (SG), Ponnusamy Saravanan (PS)].
2.2.1 Criteria for considering studies for this review
i) Type of studies
All published observational studies or randomized trials comparing metformin with
other blood glucose control alternatives were included. For metformin failure studies,
metformin alone compared with metformin plus insulin (metformin failure group)
were considered to include in this review. Only studies with primary data were
considered, i.e, compilation of cases from hospital data or case note reviews were
excluded because of the concerns over validity of the findings and lack of comparisons.
ii) Type of participants
Pregnant women with any degree of glucose intolerance must be identified by standard
75 (or) 100 grams oral glucose tolerance test (OGTT). Gestational age at diagnosis of
GDM must be after 10 weeks. Studies of women with pre-pregnancy diabetes (type 1
or 2) were excluded. Studies ≥ 80% GDM population in each arm or those with 
separate analysis of GDM for outcomes considered were included in this review. GDM
was defined as fasting glucose level ranging from 4.8 mmol/l (86 mg%) to 7 mmol/l
(126 mg%) or 2hr glucose level regardless of 75 or 100g OGTT between 5.6 mmol/l
(101 mg%) to 11 mmol/l (198 mg%) of which upper limits were regarded as impaired
fasting glucose or impaired glucose tolerance in type 2 diabetes population.
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iii) Type of intervention
Metformin or comparator treatment (insulin, glibenclamide) must be first-line
treatment for women with GDM who failed to achieve target glucose level with
lifestyle changes (nutritional therapy and/or exercise). However, the outcomes of
metformin group compared to dietary intervention alone were also considered if they
were reported separately. For metformin failure studies, if there were separate report
of metformin and metformin failure groups on maternal characters and pregnancy
outcomes, they were considered eligible. Moreover, metformin must be introduced
only after diagnosis of GDM with the aim of achieving glycemic control. Studies with
co-intervention or mixed intervention using other oral hypoglycemic agents without
separate analysis of metformin were not considered. Trials with metformin compared
to lifestyle intervention or insulin or any other oral hypoglycemic agents were
included. Interventions with metformin using insulin either at baseline or after
metformin failed to achieve glycemic control (metformin failure) were also included.
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iv) Type of outcome measures
Any primary outcome was not specified. But, the specific focus was on important
outcome measures relevant to sequales of gestational diabetes and potential side-
effects of metformin.
Important clinical outcomes and their clinical definition
1. Foetal birth weight (BWt) in grams
2. Macrosomia (BWt> 4000g)
3. Large for gestational age (LGA) > 90 percentiles for gestational age
4. Small for gestational age (SGA) > 10 percentiles for gestational age
5. Stillbirth/peri-natal mortality rate(intrauterine foetal death after 20 weeks
gestation)
6. Birth trauma
7. Shoulder dystocia
8. Caesarean section rates instrumental delivery
9. Neonatal respiratory distress
10. Gestational age at delivery
11. Premature baby(<37 weeks gestation)
12. Neonatal hypoglycemia
13. Pre-eclampsia
14. Induction of labour
15. Neonatal jaundice
16. Admission to special care baby unit(SCBU)/neonatal intensive care
unit(NICU)
17. Maternal fasting glycaemic control during pregnancy
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18. Maternal postprandial glycaemic control during pregnancy
19. 5 minutes APGAR score <7
20. Arthropometric measures at birth
21. Maternal weight gain
The following outcomes were also described although they were only relevant to
metformin
1. GDM with tolerability of treatment
2. Metformin-treated GDM with additional insulin
3. Risk of any side-effects necessitating action
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2.2.2 Search methods for identification of studies
Depending on the objectives of systematic review, the search was devised into a
series of search concepts.
The main concepts used were “metformin”, “gestational diabetes” and “impaired
blood glucose” during “pregnancy”. We did not restrict the search to the outcomes
to be as inclusive as possible. Studies included in this review must be the primary
studies. Alternative terms for the main 3 concepts were thoroughly searched and
applied. Search terms tabulated as follows:
Table 2.1 Initial search terms used
1.Health condition gestational diabetes, glucose intolerance,
abnormal blood/plasma glucose, impaired blood
glucose/glucose level/glucose control, abnormal
blood sugar level/control, blood glucose or blood
sugar impairment, insulin resistance,
hyperglycemia, pregnancy-related/induced
diabetes
2.Population pregnancy, second trimester, third trimester, late
pregnancy
3.Intervention metformin, glucophage, diabex, gliphage,
glafornil, merckfomin, risidon, dianben,
dimethylbiguanide, dimethylbiguanidium,
dimethylguanylguanidine, glumetza, fortamet,
glycomet, diaformin, diformin, bolamyn, riomet
4.Design No restriction of study design for sensitivity rather
than precision
The search terms were applied in 5 electronic databases (Ovid MEDLINE,
EmbaseClassic+Embase1947 onwards, Cochrane collaboration resources, The
Nursing & Allied Health (CINAHL) database, Web of Science). Ongoing trials
were also searched in the ISRCT Registry (www.controlled-trials.com). Medical
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Subject Heading (MeSH) searches were applied for each general search term and
the initial results of each search term including alternatives were combined using
Boolean search terms ‘AND’ or ‘OR’ as appropriate. The details strategies of search
term applied to each database were described in Appendix 9.1.1. No restriction to
language, country and date was applied. Moreover, reference lists of related
systematic reviews and included studies were also hand-searched. Finally,
electronic email updates were registered. The search strategy was last updated in
May, 2015.
2.2.3 Selection of studies
Initially, screening of relevant studies was done by scanning the titles in each
database. At this stage, a low threshold of inclusion criteria was applied with the
aim of high sensitivity for detected citations, i.e. titles stating the use of metformin
during diabetic pregnancies were all included if they seemed to be primary studies
or reviews. Then, the results were downloaded to the bibliographic database
software, Endnote. Following duplicate removal, abstracts were scanned and
potentially relevant citations were grouped into primary studies. Then, the
eligibility criteria were applied to the included primary studies, and the references
of second-stage included primary studies and systematic reviews were hand
searched for other relevant citations. The details of the flow of study selection were
described in figure 2.1.
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Figure 2.1: PRISMA flow chart of study selection
Of the 1607 identified articles, 1370 did not match our selection criteria based on
review of their titles conducted by two authors (MOK & MV). After abstract
scanning, 148 records were removed and the reasons for exclusion were that the
articles were not primary studies (67 studies) and did not use metformin in
pregnancy (81 studies). These two authors then independently reviewed the full text
2044 records identified by
five electronic database
searching and downloaded
1588 citations left after
duplicate removal
1370 citations removed
by title scanning
218 records left for
abstract access
67 – Not primary studies
81 – Did not use metformin
in pregnancy
70 relevant abstracts
identified.
6 did not meet criteria
8 – Systematic review
20– Not GDM
4 – combination therapy
with other OHAs
32 abstracts included: 9
conference
proceedings; 23
identified as articles
and included in data
synthesis
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of the remaining 70 articles to determine inclusion or exclusion (Figure 2.1). When
duplicate data were identified, only the most up-to-date, larger series was included.
Of the remaining 70 citations, 23 published articles were deemed eligible for
inclusion. These articles consisted of 12 individual Randomised Controlled Trials
(RCTs) of metformin in GDM compared to insulin (with three continuation
report)(Moore et al 2007; Rowan et al 2008; Rowan et al 2011; Ijas et al 2010; Ijas
et al 2015; Hassan et al 2012; Niromanesh et al 2012; Spaulonci et al 2013;
Mesdaghinia et al 2013; Tertti et al 2013; Ruholamin et al 2014; Battin et al 2015)
and 8 individual Non RCTs (Tertti et al 2008; Balani et al 2009; Rai et al 2009,
Goh et al 2011; Gandhi et al 2012; Iftakhar et al 2012), 3RCTs studies compared
to glibenclamide (Moore et al 2010; Silva et al 2013; George et al 2015), one study
compared to diet alone (Balani et al 2012)and one study for predictor of metformin
failure (Corbould et al 2013). Any disagreements about study eligibility were
resolved by consensus, with arbitration by the other authors (SG & PS) if necessary.
2.2.3 Data Extraction and analysis
Data were extracted using a predefined data extraction proforma sheet with explicit
instructions (Appendix 9.1.2). The main data collected were methods of selection
and characteristics of participants potentially related to baseline comparability,
detailed intervention carried out for assessment of performance bias, outcome
measures with explicit definition for comparability in-between studies and for
assessment of detection bias and any statistical analysis including subgroup
analysis. The study conclusion, ethical approval, funding and any conflict of
interest were also extracted. An attempt to obtain missing data was done and
included in this review. The outcomes from duplications of the primary studies were
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also examined and presented(Silva et al 2010; Silva et al 2013). Pilot testing of the
data proforma sheet and risk of bias tool were performed on a few studies (2
observational and 2 randomized studies) by the first reviewer (MOK) and checked
by the second (MV) and third reviewers (PS). Then, the agreed sheets were used by
the first reviewer to apply on remaining studies. Any disagreement was resolved by
discussion. No significant changes were made to the proforma sheet and bias tool.
2.2.4 Assessment of quality of included studies
The general and specific bias items were assessed using pre-specified agreed risks
of bias tools with explicit criteria(Appendix 2.2) separately for RCTs and NRCTs,
created based on PRISMA statement (Liberati et al 2009) and Cochrane handbook
(Higgins et al 2011). The general categories of items assessed for internal validity
for both randomized controlled trials (RCTs) and non-randomized controlled trials
(NRCTs) were on selection of population (eligibility, inclusion and exclusion
criteria and general clinical management before metformin was given),
performance of clinical care (comparable clinical monitoring, follow-up and
delivery plan after medication was initiated until delivery), detection of outcomes
(blinding of outcome assessors), intention-to-treat anlaysis/ attrition of samples
(analysis of all GDM treated with specified medication within study time frame),
number of outcomes reported (inclusion of all the important outcomes specified in
this review) and other possible biases (e.g. interim analysis). For external validity,
separate items on population, intervention and explicit outcomes were justified to
examine how transparent in information for replicability and comparability across
studies. Basically, studies were assessed with careful consideration of reporting
important issue by each author.
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2.2.5 Data synthesis
Raw data were tabulated to illustrate the differences in population selection,
intervention undertaken and other design features that varied between studies. The
risk of bias tables were also created to compare the heterogeneity in between studies
for reliability of assumptions of outcome estimates for this review. When clinically
and methodologically appropriate, RevMan 5.1 meta-analysis software was used to
pool the results separately depending on their study design. Chi-squared test was
used to detect the heterogeneity between studies and p value was used to determine
the statistical significance. The outcome estimates of RCTs and NRCTs were
combined separately using a random effect meta-analysis model. I2 was used to
quantify the inconsistency. If I2≥20%, individual clinical data and methodological 
features on each included study were carefully accessed to determine the source of
the heterogeneity. The subgroup analysis was done and reported separately
according to 75g or 100g OGTT diagnosis test if there were adequate number of
studies. Differences in GDM diagnosis, criteria for medical intervention and brief
overview among the studies were compared and tabulated. A table was also
constructed to compare the differences in studies, published in conference
proceedings.
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2.3 Results
The diagnostic criteria and target glucose levels among 20 different studies were
described in table 2.2 and 2.3.
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Table 2.2: Criteria for diagnosis of GDM
Study ID 1step
or
2
steps
OGTT Number needed
to be abnormal
FBS mmol/l
(mg/dl)
1hr
mmol/l
(mg/dl)
2hr
mmol/l
(mg/dl)
3hr
mmol/l
(mg/dl)
Balani 2009 1 75 g ≥1 ≥7.8 
Balani 2012 1 75g ≥1 >6 >7.8
Corbould 2013 2 75g ≥1 >6 >7.8
George 2015 1 100g ≥2 ≥5.3 ≥10 ≥8.6 ≥7.8 
Goh 2011 2 75 g ≥1 ≥5.5 ≥9 
Gandhi 2012 1 75 g ≥1 >6 ≥7.8 
Hassan 2012 2 75 g ≥2 out of 3 >5.3 ≥10 ≥8.6 
Iftakhar 2012 1 75 g ≥1 insulin >6 ≥9 
metfor
min
>6 ≥7.8 
Ijas2010 1 75g ≥1 >5.3 >11 >9.6
Moore 2007 2 100 g ≥2 >5.8(105) >10.6(
190)
>9.2 >8.1
Moore 2010 2 100 g ≥2 >5.3 >10 >8.6 >7.8
Mesdaghinia
2013
2 100 g
(2 step)
≥2 > 5.3(95) >10(18
0)
> 8.6
(155)
> 7.8
(140)
Niromanesh
2012
2 100 g ≥2  ≥5.3(95) ≥10(18
0)
≥8.6 
(155)
≥7.8 
(140)
Rowan2008 1 75 g ≥1 >5.5 >8(Aus
)
>9(NZ)
Rai 2009 2 100 g ≥2 ≥5.3 (95) ≥10 
(180)
≥8.6 
(155)
≥7.8 
(140)
Ruholamin 2014 1 75g ≥1 5.1 10 8.5
Silva 2012 1/2 75 g
100 g
≥2 ≥7 
≥5.3 ≥10 
≥11.1 
≥8.6 ≥7.8 
Spaulonci 2013 1 75/100
g
≥2  ≥5.3(95) ≥10(18
0)
≥8.6 
(155)
≥7.8 
(140)
Tertti 2008 1 75g 2 out of 3 ≥4.8 ≥10 ≥8.7 
Tertti 2013
2013(2006-08)
2008-2010
1
75g
75 g
2 out of 3
2 out of 3
≥4.8 
≥5.3 
≥10 
≥10 
≥8.7 
≥8.6 
1 step – Screened by demographic high risk factors followed by 75/100g OGTT
2 steps – Screened by 50g Oral Glucose Challenge Test (OGCT) followed by 75/100g
OGTT
70
Table 2.3 : Criteria for starting medical intervention
Study ID Number
needed to be
abnormal/
1-2weeks
Fasting
Glucose
mmol/L
(mmol/L)
Postprandial Glucose
mmol/l(mg/dl)
Maximum
Metformin
dose
(mg/day)
Metformin
Failure rate
(%)
Timing Abnormal
Balani 2009 ≥3 ≥6 1hr
2hr
≥8 
≥7 
2500 10.2
Balani 2012 ≥3 >5.6 1hr
2hr
>8
>7
3000 11.7
Corbould 2013 ≥3 >5.6 1hr
2hr
>8
>7
2000® 30.4
George 2015 ≥1 ≥5.5 and ≤7.2 2hr ≥6.7 and 
≤13.9 
2500 0
Goh 2011 ≥1 >5 2hr >6/6.5 2500
(3000 for
morbidly
obese)
46.5
Gandhi 2012 ≥1 >6 1hr >8 2000 21
Hassan 2012 ≥1  ≥5.5 1.5hr ≥7 3000 24
Iftakhar 2012 ≥3 ≥5.5 2hr ≥7 2000 41.8
Ijas2010 ≥1 ≥5.3 1.5hr ≥6.7 2350® 31.9
Moore 2007 ≥1 ≥5.8 (105) 2hr ≥6.7 (120) 2000 0
Moore 2010 ≥2 >5.8 (105) 2hr >6.7 (120) 2000 34.7
Mesdaghinia
2013
≥1 ≥5.28(95) 2hr ≥6.67(120) 2500 22
Niromanesh
2012
≥2 ≥5.3(95) 2 hr ≥6.7(120) 2500 14
Rowan2008 ≥1 >5.4 2hr >6.7 2500 46.3
Rai 2009 ≥2 ≥5.6 (100) 2hr ≥7.2 (130) 2000 7
Ruholamin
2014
≥2 ≥5.28(95) 2hr ≥6.67(120) 1500 3
Silva 2012 ≥2  >5 (90) 1hr >6.7 (120) 2500 21
Spaulonci
2013
>30% >5.3(95) 2 hr >6.7(120) 2550 26.08
Tertti 2008 ≥2 ≥5.5 1.5hr ≥7.8 1500 18
Tertti 2013 ≥1 ≥5.5 1 hr ≥7.8 2000® 20.9
® = Extended-release metformin
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2.3.1. Comparison 1: Metformin vs Insulin
Table 2.4. Quality assessment of included RCTs studies (Metformin vs Insulin)
Study Internal Validity External validity Potential
biasSelection Performance Detection Attrition Reporting Others
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Moore 2007 + + - + - + + - - - + + + - Moderate
Rowan2008 + + - + + + + + + - + + - + Low
Ijas2010 + ? - + - + - - - - + + - + High
Hassan 2012 - - - + - - ? ? - + + + - + High
Niromanesh 2012 + + ? + + + + + + - + + + + Low
Spaulonci 2013 ? - - - - + + + - + + + + - High
Mesdaghinia 2013 + + ? + + + - ? - + + + + - Moderate
Tertti 2013 - ? - - - + - - - ? + + - + Low
Ruholamin 2014 + - ? + + + - - - + + + + + Moderate
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2.3.1.1. Quality assessment of included studies compared to insulin (Table 2.4)
2.3.1.1.1 Randomized studies
Randomization and allocation concealment was adequately performed in 4 out of 9
RCTs (Moore et al 2007; Rowan et al 2008; Niromanesh et al 2012; Mesdaghinia et
al 2013). Although 3 studies were reported to perform double-blinded, they did not
mention in details. As insulin and metformin have different routes of administration,
it should be reported in details about how the intervention was blinded from
participants (Niromanesh et al 2012; Mesdaghinia et al 2013; Ruholamin et al 2014).
The RCTs done by Spaulonci 2013 and Ruholamin 2014 excluded metformin failure
group from metformin arm and thus the same baseline comparability should be
suspected. Only 4 out of 9 RCTs blinded outcome assessors from treatment(Rowan et
al 2008; Niromanesh et al 2012; Mesdaghinia et al 2013; Ruholamin et al 2014).
Although sample size was determined in 8 studies, the appropriate case analysis was
performed in only 3 studies (Rowan et al 2008; Niromanesh et al 2012; Spaulonci et
al 2013). The important clinical outcomes of GDM considered in this review were
reported completely by Rowan 2008 and Niromanesh et al 2012. In addition, three
studies did interim analysis(Moore et al 2007; Rowan et al 2008; Niromanesh et al
2012) and one study was blocked randomization with un-blinded trial (Ijas et al 2010).
Regarding reproducibility of studies, information on insulin intervention was very
limited and adequate information were only available in only 5 studies (Moore et al
2007; Niromanesh et al 2012; Spaulonci et al 2013; Mesdaghinia et al 2013;
Ruholamin et al 2014). Furthermore, 3 studies did not report explicitly on operational
definition of some outcomes being reported (e.g. neonatal hypoglycemia) (Moore et
al 2007; Spaulonci et al 2013; Mesdaghinia et al 2013).
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Table 2.5.Quality assessment of NRCTs studies (Metformin vs Insulin)
(‘+’ means appropriate, ‘-’ means not done or not mentioned or not appropriate or ‘?’ means inadequate data to justify that the study was done
appropriately. For baseline comparability and favours group, there were 2 separate items being consider:1) whether the maternal baseline which
were considered important in GDM(Age, BMI, parity, glucose levels at OGTT, ethnicity, smoking, previous history of still-birth were considered
and reported and 2) if they were unequal across arms, which group could be potentially advantaged out of this biases? D= Diet, I= Insulin,
M=metformin, G=glibenclamide, MF= Metformin Failure
Study ID Internal Validity External Validity Potential
biasSelection Performance Detection Attrition Reporting Others
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Tertti2008 - + - + M - + + + - + + - + High
Balani 2009 + - - + M - - - - - - + - + High
Rai 2009 + ? ? - M - - + - - + + - + High
Goh 2011 - - - + M - - + - - + - - + High
Gandhi 2012 - - + + + - - + - - - - - - High
Iftakhar 2012 + ? - - M - - + - - + + - + High
74
2.3.1.1.2 Observational Studies (Table 2.5)
Three out of six studies were recruited all eligible GDM in defined setting and time
frame. However, one study excluded metformin failure group from metformin arm;
one study had compulsory insulin criteria; one study had mixed population with diet
alone group in non-metformin arm. Moreover, Rai 2009 study included type 2 diabetes
(<20%) but the percentage was not comparable across 2 groups. Expectedly, only one
study had fulfilled to have comparable maternal baseline characters between
metformin and insulin groups whereas other studies have less insulin resistant group
in metformin arm. Moreover, only Tertti 2008 study performed power calculation. Yet,
5 out of 6 studies analysed all women in either group as they were initially allocated.
The pregnancy outcomes reported were found to be complete in only one study to
detect birth weight and incidence of hypoglycemia. Although some studies considered
to have controlled on some of the confounders (e.g. studies done by Tertti et al and
Balani et al, all eligible women for metformin in the study period were included with
only case-matched number of insulin-treated participants (stratified by BMI and age),
and equal number of participants, respectively), any of 6 NRCTs did adequate
confounder controlled for any of their outcome measures. For extrapolation of the
findings, the information on any of 6 studies were not adequate.
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2.3.1.2 Description of characteristics of studies compared to insulin
Total of 15 studies with 18 relevant articles (2 studies with 3 extended offspring
follow-up publications) were identified according to the selection criteria used in this
review. Of these studies compared to insulin, 9 were RCTs and the rest 6 were NRCTs.
A brief description on population involved and intervention strategy were given in
table 2.6 and 2.7. Relevant abstracts are described in Appendix 2.3.
Population: There are a total of 15 studies, studying pregnancy outcomes of metformin
in GDM compared to insulin (9 RCTs and 6 NRCTs). Out of 9 RCTs, 6 RCTs used 75
OGTT test to identify GDM whereas 5 out of 6 NRCTs applied (Table 2.3) whereas
the other studies used 100 g OGTT to diagnose GDM. Two groups had conducted both
RCTs and NRCTs, one each, with similar intervention strategy (Goh et al 2011; Tertti
et al 2013; Rowan et al 2008; Tertti et al 2008). All the studies included all GDM
diagnosed by OGTT tests (i.e. both moderate and severe hyperglycemic GDM), except
Tertti 2013 study where GDM diagnosed above FPG >7 mmol/L and 2hr
PP>11mmol/L excluded from randomization. Moreover, there was compulsory insulin
to GDM with FPG >7 mmol/L and PP >10mmol/L in Tertti 2008 NRCTs study. It
should also be noted that 13% (8/60) women included in Rai 2009 study were type 2
diabetes, with 2/30(6.7%) in metformin arm and 6/30(20%) in insulin arm. Moreover,
GDM women included in both arms were conducted in the same setting except Tertti
2008, Iftakhar 2012 study and Rai 2009 study.
Intervention: The maximum dose of metformin varied from 1500 to 3000 mg. In all
RCTs and majority of NRCT studies, insulin was given to metformin-treated GDM
only after maximum dose of metformin failed to meet the target glycemic levels.
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However, in one NRCTs, e.g. Goh 2011, insulin was given to GDM with FBS
>6mmol/L at initiation of metformin. In all studies, all GDM who received metformin
(i.e metformin alone or metformin plus supplementary insulin) were included in
metformin arm whereas all GDM included in non-metformin/insulin arm were diet-
failed GDM with insulin therapy. Yet, in some studies, e.g Balani 2009, Mesdaghinia
2013 and Ruhoalmin 2014, GDM with metformin therapy alone were included in
metformin arm,but some of the outcomes of metformin plus insulin group in Balani
2009 study were separately reported and presented in combination in our meta-
analysis. Moreover, metformin was started as 500mg od/bd and titrated against blood
glucose levels over a week or two in almost all studies, except Ijas 2010 study where
metformin was given as rather fixed dose administration for 3 weeks. Furthermore,
Ijas 2010 and Tertti 2013 studies described that extended-released metformin was
used. In addition, Tertti 2013 was the only study out of 15 studies included where
vitamin B12 plus vitamin supplements given to metformin arm.
Comparator - The types of insulin used in insulin arm were a combination of
long/intermediate acting insulin with regular insulin, but most of the studies did not
report doses of insulin used. Among 5 studies with the dose and strategy reported,
Tertti 2013 study used rather ‘targeted approach’method, i.e, if long/intermediate
acting insulin was given to GDM women with higher fasting whereas short acting
insulin was given to those with higher postprandial glucose. It should be noted that
Ijas 2010 RCT, the dose of insulin requirement was higher in metformin group than
insulin group (mean dose: 43 IU vs 30 IU, p=0.05). In this study, as described earlier,
there was 3-weeks of titration period for metformin group before insulin was given.
On the contrary, insulin dose requirement was higher in insulin group in the NRCT
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studies of Iftakhar 2012 (mean±SD: 42.9±32.7 vs 60.8±39.9 units) and Gandhi 2012
(34.3±43.2 vs 41.3±32.8 units) whereas Tertti 2008 NRCT found no difference
(median dose: 11 vs 10 units).
Outcomes: The primary outcomes considered varied from study to study(Table 2.6 and
2.7). The most frequent primary outcomes were neonatal birthweight and maternal
glycaemic control.
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Table 2.6. Description of RCTs studies (Metformin vs Insulin)
Study ID
(study design)
Setting Sample
size
Participants’ characters Metformin Insulin Primary outcomes
Moore 2007
(RCT)
United states,
University hospital
of Missisippi
Medical Centre
63 24-30 weeks gestation,
screened by 50g OGCT
1hr≥140mg/dl,  
500 mg bd, increased as necessary(maximum
1000mg bd).Insulin was started if metformin was
failed(maximum dose with 2 glucose values
exceeded target for 2 consecutive weeks); monitor 3
times daily
0.7units/kg of actual BWt(2/3 morning &
1/3 evening); a combination of regular
insulin and NPH insulin; monitored 3 times
daily
FBS, 2hrPP, MOD, incidence of
shoulder dystocia, incidence of
PPH
Rowan 2008
(RCT)
10 New Zealand &
Australian urban
obstetrical hospital
733 18- 45 years, singletons,
20-33 weeks GA, met
hospital usual criteria for
insulin treatment, more
specific criteria avoided
(Metomin, Diaformin) started at 500 mg od/bd with
food, increased over 1-2 weeks to meet glycemic
targets up to maximum of 2500mg/d; stopped if
maternal contraindications(liver or renal impair or
sepsis) or FGR developed.Insulin added if target was
not achieved with metformin.
Insulin prescribed according to ususal
practice, typically SA insulin analog before
meals and intermediate insulin once or
twice daily
Composite outcome(neonatal
hypoglycaemia, respiratory
distress, birth trauma, APGAR < 7
and preterm)
Ijas 2010
(RCT)
Finland,
Tertiary Oulu
hospital &
secondary Kainuu
Central hospital
97 12-34 weeks GA,
singletons, risk factor
based screening(over 40
years old, BMI > 25
kg/m2, glycosuria, prior
GDM, previous baby
BWt> 4500 g, current
suspected macrosomia)
Metformin(Diformin retard®) initiated at 750 mg od
for 1st wk, bd for 2nd wk, tds from 3rd week
onwards; stopped if significant side effects, such as
diarrhoea developed.
Supplemental insulin was added if normoglycemia
was not achieved with maximum metformin daily
dose in 1-2 wks
LA insulin(Protaphan®) for FBS and RA
insulin(Humalog®) for PP control
according to hospital guidelines
incidence of macrosomia, LGA
using Finnish sex specific charts
adjusted for gestational age
Hassan 2012
(RCT)
Pakistan, Lyari
General Hospital,
Dow University of
Health Sciences
and private
maternity hospitals
150 18-45 years of age,
singleton pregnancy, 20-
36 weeks of gestation,
those with high risk
factors offered 50 g OCT,
if ≥ 140 mg/dl --> 75 g 
OGTT
Metformin started at 500 mg, increased up to
maximum of 3000 mg/day as patients' tolerance and
glucose levels; stopped if significant preelampsia,
sepsis, pregnancy cholestasis or IUGR developed or
with drug intolerance due to GI SE.Insulin added if
not control with metformin alone in 1-2 weeks; a
combination of regular and intermediate human
insulin before meals twice daily.
NR macrosomia(>4000g)
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Table 2.6. Description of RCTs studies (Metformin vs Insulin)
Study ID
(study design)
Setting
(Number)
Sample
size
Participants’ characters Metformin Insulin Primary outcomes
Niromanesh
2012
Women Hospital,
The Shariati
Hospital and the
Valiasr Hospital,
University of
Tehran, Iran
172 Screening by 50g
OGCT;18-40 years old
singletons between 20
and 34 weeks; excluded
mothers with history of
systemic underlying
diseases(cardiovascular,
renal, liver and
autoimmune), substance
abuse, overt diabetes
mellitus(except previous
GDM history) and major
foetal malformation
Started at 500 mg bd; increased by 500-1000 mg ½
wks against target up to maximum of 2500 mg
divided dose with meal, continued until delivery and
added insulin if glycemic control not achieved with
maximum metformin dose; 4 times/day monitor
Started with NPH 0.2units/kg for high FBS
and short-acting insulin for high PP(1 unit
for every 10 mg/dl over target) and if both
high, total insulin dose of 0.7 units/kg(2/3
is NPH: 2/3 before breakfast and 1/3 before
bedtime) and 1/3 is regular insulin:2/3
times), titrated against daily glucose
monitoring; 4 times/day monitor
Maternal glycemic control and
birth weight
Spaulonci 2013 Obstetrics Clinic
Hospital, Sao
Paulo, Brazil
92 Singletons, absence of
risk factors for lactic
acidosis(renal failure,
chronic liver disease,
severe chronic
pulmonary disease,
coronary insufficiency,
history of
thromboembolic
phenomena) and absence
of anatomic and/or
chromosome anomalies
of the conceptus detected
by ultrasonography
Started at 850 mg tds and if not controlled, 850 mg
qid; if still not controlled, added insulin; monitored
4 times/day
Started with NPH of 0.4 units/kg /day with
half given before breakfast, ¼ before lunch
and ¼ at 22 hours; monitor 7 times per day;
adjusted weekly against glucose levels; if
only postprandial is high, regular insulin
added ½ hr before meal in addition.
Glycaemic control
Tertti 2013 Turku University
Central Hospital,
Finland
217 GDM diagnosed
according to current
criteria and selected if
failed to diet therapy, and
normal renal, liver and
cardiac function and no
metformin use 3 months
prior and during this
pregnancy
Started at metformin (Diformin retard®) 500 mg od
for 2 days, 500 mg bd for 1 week, titrated up to
maximum of 1 g bd; monitored 4 times daily 3 days
a week; vitamin B compound containing 0.4 mg
folic acid initiated along with metformin.
Initiated using NPH insulin(Protaphane®,
Novo Nordisk, Bagsvaerd, Denmark)
and/or rapid-acting insulin lispro
(Humalog®, Lilly, Indianapolis, IN, USA)
or insulin aspart (Novorapid®, Novo
Nordisk)
Birthweight
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Table 2.6. Description of RCTs studies (Metformin vs Insulin)
Study ID
(study design)
Setting Sample
size
Participants’ characters Metformin Insulin Primary outcomes
Mesdaghinia
2013
Shabih Khani
Hospital, Isfahan,
Iran
200 18-45 years of age, single
pregnancy, without
history of diabetes prior
to pregnancy with GA of
24-34 weeks; GDM
screened by GCT and
diagnosed by
OGTT;poor glycemic
control on lifestyle
modification for a week
500 mg initially and adjusted up to 2500 mg/day;
metformin-treated GDM who needed insulin were
excluded from the study and replaced with new
patients.
0.5IU/kg/day (2/3 NPH insulin and 1/3
regualar). And 2/3 given in the morning and
1/3 in the afternoon.; 1IU of NPH or regular
insulin added appropriately for every
10mg/dl increase in blood glucose
Unclear
Ruholamin2014 Alzahra and
Shahid beheshti
hospital, Iran
100 18 500mg bd and adjusted up to 1500 mg/day; stopped
if maternal contraindications(such as liver/renal
impairment or sepsis), PIH or PE were developed.
Metformin-treated GDM who required insulin were
excluded from the study(n=2).
0.2IU/kg/day insulin, titrated to meet
glycemic targets
Pregnancy-induced hypertension
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Table 2.7. Description of NRCTs studies (Metformin vs Insulin)
Study ID Setting
(Number)
Sample
size
Participants’ characters Metformin Insulin Primary outcomes
Tertti 2008
(retrospective
cohort)
Finland,
Turku
University
central
hospital
90 11- 32 weeks GA, singletons,
screening - BMI ≥25kg/m2, ≥40 
years, previous macrosomia,
glycosuria during pregnancy,
previous GDM, suspected foetal
macrosomia in current pregnancy,
Metformin started at 500 mg od to 750 mg bd,
if FBS > 7 mmol/l and/or PP > 10 mmol/l, insulin was
always started.
Intermediate acting insulin was usually
started.
BWt, incidence of
hypoglycemia
Rai 2009
(prospective
cohort)
India, 2
different
obstetric
units
60
mothers
/61
babies
Screening by 50g OGCT 1hr ≥ 140 
mg/dl
Also included type 2 diabetes (6.7%
in metformin grop and 20% in
insulin group)
Metformin - started at 500 mg tds, titrate to a maximum
of 2000mg/day
Intermediate acting(Mixtard) and short
acting insulin (Actrapid) used whenever
required
Maternal glycemic
control
Balani 2009
(Prospective
cohort)
United
Kingdom,
University
hospital
227 28 weeks GA Metformin 500 mg bd with food initially, subsequently
titrated up to maximum of 2500 mg daily, patients
attended AN clinic after dose titration and remained in
close contact with diabetes specialist team.Insulin added
if control was not achieved depite maximum metformin
dose. Included cases exclusively with metformin alone
Basal-bolus regimen of insulin aspart
with meals and insulin glargine once
daily(from case record data who had
been managed by same diabetic and
obstetric team according to same GDM
care pathway)
Principal maternal
outcome: weight gain
from enrolment to
delivery, preeclampsia
and pregnancy-induced
hypertension.
Goh 2011
(prospective
cohort)
New
Zealand,
national’s
women
health
864
mothers
/877
babies
After 20 weeks GA, screening – 50
g OGCT 1hr plasma glucose ≥ 7.8 
mmol/l
Dose on metformin was not reported. if FPG ≥ 6 mmol/l, 
bedtime isophane insulin was supplemented at baseline.
SA insulin analogue was prescribed for metformin failure
-
maximum daily dose of metformin 2500 mg (3000 mg for
morbidly obese), over 1-2 weeks failed to achieve targets.
bedtime Intermediate acting insulin
analogue + premeal SA insulin analogue
NR
82
Table 2.7. Description of NRCTs studies (Metformin vs Insulin)
GA- gestational age, AC – abdominal circumference, BWt – Birth weight, BP – blood pressure, GI SE – GI sideeffects, NR – Not reported, OGCT – Oral Glucose Challenge test, OG – obstetricians and gynaecologists,
USG – Ultrasound, LFT – Liver function tests, FGR – Foetal growth restriction, AN clinic – antenatal clinic, SA insulin – short-acting insulin,RA insulin – rapid acting insulin, F-up – Follow up, USG – ultrasound,
Study ID Setting
(Number)
Sample
size
Participants’ characters Metformin Insulin Primary outcomes
Gandhi 2012
(retrospective
cohort)
United
Kingdom,
Royal
hallamshire
hospital
592 NICE guidelines Metformin initiated at diagnosis of GDM: 500 mg bd with
food, increased to 1g bd, if tolerated, clinically
appropriate with no side-effects, 1 week after; metformin
was stopped if any side effects or obstetric
complications(preeclampsia, cholestasis, IUGR)) was
developed.
glycemic control was considered to be abnormal if FBS >
6 mmol/l and/or 1hr PP > 8 mmol/l(145 mg/dl)
Non-metformin
(subcutaneousinsulin±lifestyle advice)
NR
Iftakhar 2012
(Retrospective)
Retrospecti
ve
historically
controlled
93 < 34 weeks gestation at initiation of
treatment; Insulin cohort(2006-07)
and metformin cohort(2010);
higher 2hrPP and increased
proportion of previous GDM
history in insulin group
Maximum of 2000 mg/d; median- 7 week duration, range
500-2000 mg
Isophane insulin at bedtime, short-acting
insulin before meal
Weight gain and
insulin requirement
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2.3.1.3 Pregnancy outcomes (Metformin vs Insulin)
Maternal Outcomes
1. Maternal weight gain
There was reduced maternal weight gain with metformin treatment. The pooled
estimates of 5 RCTs revealed Weighted Mean Difference (WMD) of -1.59 (-2.48, -
0.70)kg and that of 3 NRCTs was WMD of -1.57(-3.11, -0.02) kg. Moreover, there
was significantly lower weight gain was observed when the weight gain was limited
to during medication period, WMD of 4RCTs -1.23(-1.72, -0.73) and that of 2NRCTs
-1.78z9-1.92, -1.65). (Figure 2.2)
Sensitivity analysis: The statistical heterogenetiy (I2) was 70% in random-effect RCT
meta-analyses) where the effect estimates of Ijas 2010 and Tertti 2013 were found to
be much different. These two studies were reported to use extended-release metformin
in compared to other RCTs. When these two studies were excluded, the summary
effect estimate changed to WMD of -2.29(95%CI: -2.75, -1.83) kg with I2 of 0%. In
NRCTs metaanalyses, I2 was 34% which was much attributable to Tertti 2008 study.
Although the study did not mention about the type of metformin use, considering being
conducted by the same group of Tertti 2013 study and having comparable outcome to
them, it was likely that they might use extended release metformin and thus excluded
for sensitivity analysis. After exclusion, the pooled effect estimate of total weight gain
was found to be WMD of -2.31 (95%CI : -4.37, -0.25) with I2 of 0%.
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Figure 2.2. Forest-plots of Maternal Weight Gain (kg)
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2. Glycaemic control
Average Fasting glycaemic control : Four RCTs (n=1048) and one NRCT (n=60)
reported the effects of metformin on fasting plasma glucose (FPG) control (Fig 2.3 A).
There was no clear difference in maternal fasting glucose levels between the groups in
the RCTs (WMD 0.34[95%CI -1.74, 2.42]) mg/dL. Three of them assessed glycemic
control as a primary outcome measure (Moore et al 2007; Niromanesh et al 2012;
Spaulonci et al 2013).
Average Postprandial glycaemic control: Metformin use could be possibly associated
with a lower postprandial maternal glucose in 4 RCTs (n=1048), (WMD -2.29 mg/dl
[95% CI -4.65, 0.07]) The issue with the NRCT has been discussed above. The largest
RCT found a significantly lowered postprandial glucose with metformin treatment
[178](Fig 2.3 B).
Sensitivity analysis: There was large (>40%) statistical heterogeneity in RCTs meta-
analyses of FPG and PP results. It might be due to differences in insulin dose
administration in insulin arm (i.e. start dose and type of insulin use). The largest
Rowan 2008 RCT did not describe any information on details of insulin use. Moreover,
as described in description of intervention, in Niromanesh 2012 study, target approach
of insulin was used.
Glycaemic control 1 week after randomization: 2RCTs have reported on glycemic
levels of 1 week after randomization. It was found that GDM women with metformin
had lower 2hr post-prandial glycemic levels in 1 week after randomization[WMD -
3.25(95%CI: -5.34, -1.16)mg/dL] although there was no observed difference in fasting
glucose levels [WMD 0.52 (95%CI: -2.12, 3.16) mg/dL] .
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Figure 2.3 Forest-plots of glycaemic control
A) Average Fasting Plasma Glucose Control (mg/dL)
B) Average Postprandial Glucose Control (mg/dL)
C) Fasting Plasma Glucose Control 1-week after randomization (mg/dL)
D) Postprandial Glucose Control 1-week after randomization (mg/dL)
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3. Hypertenison in Pregnancy
The reports on outcomes of hypertension in pregnancy varied: some studies reported
pregnancy-induced hypertension (PIH) only or pre-eclampsia only or both.
The incidence of preeclampsia in association with metformin use was examined in 5
RCTs (n=1082) and 4 NRCTs (n=1241) (Fig 2.4). There was no difference in the
incidence of preeclampsia between the two treatment arms (OR 0.81 [95%CI
0.53,1.23]) and (OR 0.71 [95% CI 0.41, 1.25]) for RCTs and NRCTs respectively
(Figure 2.4 A).
However, there was significant difference in metaanalyses of PIH with 2 RCTs (OR:
0.52 [95%CI : 0.29 vs 0.94]) with reduction in metformin arm. (Figure 2.4 B)
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Figure 2.4. Forest-plots of hypertension in Pregnancy
A) Pre-eclampsia
B) Pregnancy-induced hypertension (PIH)
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5. Caesarean section rates
Eight RCTs (n=1612) and 3 NRCTs (n=1154) were examined to assess the effects of
metformin treatment on caesarean section rates (Figure 2.5). Caesarean section rate
was found to be high in treated GDM in all included studies. Up to half of them
delivered by caesarean section. Caesarean section rates were not a primary outcome
measure in any of the studies and only 2 studies had reported emergency caesarean
section rates (CSR) separately. Among total CSR, there was no difference in caesarean
section rates between the two treatment arms in either the RCTs group (odds ratio 0.90
[95% CI 0.64, 1.25]) or the NRCTs group (odds ratio 0.81 [95% CI 0.58, 1.14]).
Among emergency CSR, although there was similar CS rates in RCTs meta-analysis,
the NRCTs meta-analysis showed that there was reduced CS rates with metformin
treatment with OR of 0.72(95% CI 0.54, 0.97).
Sensitivity analysis: There was high heterogeneity in RCTs meta-analysis of total CSR
(I2=45%) which was mainly contributed by Ijas 2010 study and Hassan 2012 study. It
should be noted that fixed dose metformin administration was offered in Ijas 2010
study over 3 weeks whereas the highest maximum dose of metformin dose 3000mg
was used in Hassan 2012 study. After exclusion, the pooled effect was similar with
reduced confidence interval [OR 0.91(95%CI 0.73, 1.15)]. In NRCTs meta-analysis of
total CSR, the heterogeneity was attributable to Tertti 2008 study. In this study,
metformin was not offered to GDM women with FPG >7 mmol/L and PP >10mmol/L.
Interestingly, despite presumably higher proportion of much higher glycemic levels in
insulin arm, the CS rate was lower. In contrast, as mentioned before, Goh 2011 study
had compulsory insulin to certain GDM group with metformin initiation and it was
found that the CS rates was significantly reduced in metformin arm. This might
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indicate that if metformin is offered to GDM women with much higher FPG levels,
earlier insulin initiation might have favourable CS rates.
Figure 2.5. Forest-plot of Caesarean Section Rates
91
6. Induction of labour
No difference in the rate of induction of labour was detected, in either RCTs meta-
analysis (OR 0.89 (95% CI 0.61, 1.28) and NRCTs meta-analysis (OR 1.24 (95% CI
0.84, 1.82), reported by 5 RCTs and 3 NRCTs .
Sensitivity analysis: The heterogeneity of I2=38% in RCTs meta-analysis was
attributable to Tertti 2013 study. This group had done one RCT and one NRCT (Tertti
2008) with similar GDM management strategy and reported much different results.
The Tertti 2013 study was different from other included studies in that it excluded
GDM women with FBS > 7mmol/L or 1hr PP > 11 mmol/L from randomization. This
means that the population included only GDM women with moderate hyperglycaemia.
Thus, metformin effect might be exaggerated in this study. After exclusion of this
study, the effect changed to OR of 0.98 (95%CI 0.76, 1.27) with nil heterogeneity.
We are unable to synthesise the data for the other maternal outcomes due to non-
reporting or relative heterogeneity in their outcome definition.
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Table 2.8. Important maternal outcomes of GDM (Metformin vs Insulin) stratified by 75g/100g OGTT
Outcomes Types of
studies
Sample
size
WMD/RR I2 Subgroup
analysis (n)
WMD/RR I2
1. Maternal weight gain
i) Total weight gain RCTs 716 -1.59(-2.48,-0.70) 70%
75g (4) -1.32(-2.48,-0.17) 76%
100g(1) -2.40(-3.47,-1.33)
NRCTs 200 -1.57(-3.11,-0.02) 34% 75g(2) -2.00(-6.16,2.16) 58%
100g(1) -1.90(-3.34,-0.46)
ii) Specific weight gain RCTs 1098 -1.23(-1.72,-0.73) 61% 75g(3) -1.22(-2.01,-0.44) 74%
100g(1) -1.20(-1.68,-0.72)
NRCTs 150 -1.78(-1.92,-1.65) 0% 75g(2) -1.76(-2.07,-1.45) 5%
2. Glycaemic control
i) FPG RCTs 1048 0.34(-1.74,2.42) 48%
75g(2) 1.79(0.18,3.41) 0%
100g(2) -1.42(-4.72,1.88) 37%
NRCT 60 -12.70(-14.24,
-11.16)
100g(1) -12.70(-14.24,-11.16)
ii) PP RCTs 1048 -2.29(-4.65,0.07) 40% 75g(2) -3.64(-5.50,-1.78) 0%
100g(2) -0.01(-2.70, 2.68) 0%
NRCT 60 -14.33(-16.01,
-12.65)
75g(1) -14.33(-16.01,-12.65)
iii)HbA1c RCTs 1294 -0.00(-0.15,0.15) 86% 75g(3) 0.06(-0.15,0.28) 91%
100g(2) -0.12(-0.37,0.14) 75%
3. Pregnancy induced
hypertension(PIH)
RCTs 893 0.52(0.29,0.94) 0% 75g(2) 0.59(0.31,1.10) 0%
100g(1) 0.33(0.10,1.09)
NRCTs 1154 1.34(0.82,2.19) 0% 75g(3) 1.34(0.82,2.19) 0%
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Table 2.8. Important maternal outcomes of GDM (Metformin vs Insulin) stratified by 75g/100g OGTT
Outcomes Types of
studies
Sample
size
WMD/RR I2 Subgroup
analysis (n)
WMD/RR I2
4. Pre-eclampsia RCTs 1299 0.81(0.53,1.23) 0% 75g(4) 0.83(0.53,1.30) 0%
100g(1) 0.70(0.21,2.29)
NRCTs 1241 0.71(0.41,1.25) 1% 75g(3) 0.65(0.30,1.40) 32%
100g(1) 1.0(0.13,7.60)
5. Caesarean section rate
i) Total RCTs 1612 0.90(0.60,1.25) 45%
75g(6) 0.96(0.62,1.47) 59%
100g(2) 0.76(0.46,1.36) 0%
NRCTs 1154 0.81(0.58,1.14) 29% 75g(3) 0.81(0.58,1.14) 29%
ii) Emergency RCTs 893 1.18(0.58,2.40) 67% 75g(1) 0.87(0.59,1.29)
100g(1) 1.82(0.88,3.75)
NRCTs 1064 0.72(0.54,0.97) 0% 75g(2) 0.72(0.54,0.97) 0%
6. Induction of labour RCTs 0.89(0.61,1.28) 38% 75g(4) 0.88(0.59,1.29) 49%
100g(1) 3.04(0.12,75.69)
NRCTs 1.24(0.84,1.82) 0% 75g(3) 1.24(0.84,1.82) 0%
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Neonatal outcomes
1. Neonatal Hypoglycaemia
Among 8 studies, 6 RCTs (n=1295) and 4 NRCTs (n=1165) reported the outcome.
Whilst the definition of neonatal hypoglycaemia varied from less than 1.6 to 2.6
mmol/l or the need to inject IV dextrose, all these studies,except Niromanesh 2012
study, reported decreased risk of neonatal hypoglycaemia with metformin treatment.
Yet, there was no statistical heterogeneity in summary outcome estimate. It should be
noted that Niromanesh 2012 did not mention to collect the outcome in their method
section though they reported the outcome in the results. Random effect meta-analysis
of both RCTs and NRCTs revealed that the rate of neonatal hypoglycaemia was
significantly lower in infants born to metformin treated mothers than those to insulin-
treated mothers, (OR 0.69 [95% CI 0.52, 0.91) in RCT and (OR 0.42 [95% CI 0.27,
0.64) for the NRCT group (Figure 2.6).
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Figure 2.6. Forest-plot of Neonatal Hypoglycaemia
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2. Large for gestational age (LGA)
Definition of LGA was similar across the included studies, with birth weight greater
than 90th centile except the Ijas study which used birth weight of >2 standard deviation
(SD) of the mean.
6 RCTs (n=1502) and 3 NRCTS (n=1696) reported the outcomes (Figure 2.7. A). Only
the Ijas study examined LGA as a primary outcome measure. The RCTs did not show
any difference in the incidence of LGA (OR 0.77 [95% CI 0.55, 1.08]) whilst the
NRCTs showed a decreased incidence of LGA in the metformin treated group (OR
0.60 [95%0.46, 0.77]). It should be noted that Niromanesh 2012 and Spaulonci 2013
studies did not mention including LGA as outcome variable in their method section.
3. Small for gestational age (SGA)
Data on SGA were available from 7 RCTs (n=1548) and 4 NRCTs (n=1255) (Figure
2.7. B). There was no difference in pooled estimate risk of SGA in RCT meta-analyses
(OR 0.98 [95%CI: 0.64, 1.50]) between metformin and insulin treatment. The data
reported by NRCTs was found to be reduction in SGA risk with metformin than insulin
(OR 0.66[95% CI 0.46, 0.96]). The variation between RCTs and NRCTs could be due
to exclusion of metformin given to GDM women with possible intrauterine restricted
babies in one NRCTs(Goh et al 2011) and differences in population characters
favouring metformin arm (Rai et al 2009, Tertti et al 2008) which might paradoxically
increase the number of SGA in insulin arm.
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4. Macrosomia
Macrosomia was defined as > 4kg in 11 studies: 8 RCTs (n=1082) and 3 NRCTs
(n=909) (Figure 2.7. C). The random-effect meta-analyses showed possible difference
in the rate of macrosomia non-significantly (OR 0.71 [95%CI 0.46, 1.09]) in RCT
meta-analysis and significantly (OR 0.63 [95%CI 0.42, 0.93]) in NRCTs meta-
analysis. The Ijas and Hassan studies examined macrosomia as its primary outcome.
4. Foetal birthweight
Foetal birthweight was not significantly different between metformin and insulin
treated groups in 9 RCTs (n=1815) (WMD -58.38 [95%CI -119.09, 2.32] grams and 4
NRCTs meta-analyses (n=1255) (WMD -35.37 [95%CI -134.56, 63.82] grams (Figure
2.7. D).
Sensitivity analysis: The statistical heterogeneity of I2 of 33% was much influenced
by Ijas 2010 and Hassan 2012 studies which results were in opposite direction. The
methodology difference in these 2 studies were discussed in CS rate outcomes. After
exclusion of these 2 studies, the effect changed to WMD of -50.04(95%CI -100.73,
0.64) grams with I2 of 0%. Among NRCTs meta-anlaysis, I2 of 43% was attributable
to the result of Goh 2011 study. This was the study done by the same group as Rowan
2008 RCT study but the effects were found to be opposite. The strategy of metformin
administration was different in Goh 2011 study in that GDM women in this study were
not offered metformin if the foetal abdominal circumference was <10th percentile by
ultrasound and thus, might possibly reduce birth weight in insulin arm. After
exclusion, the effect of NRCTs meta-analysis changed to WMD of -98.59 (95%CI -
199.89, 2.71) grams.
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Figure 2.7. Forest-plots of Baby sizes at birth
A) Large for Gestational Age
B) Small for Gestational Age
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C) Macrosomia
D) Neonatal Birthweight (grams)
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6. Gestational maturity
There was in the reduction of gestational age at delivery with metformin therapy in
GDM in 7RCT meta-analysis (WMD -0.10(-0.29, -0.09) weeks whereas the summary
estimate of 3NRCTs showed significant difference with much mature babies in insulin
arm(WMD 0.4[95%CI 0.18, 0.62]) weeks (Figure 2.8. A). There was an increased risk
of preterm delivery (< 37 weeks) with metformin treatment with OR of RCTs meta-
analysis 1.22 (95% CI 0.63, 2.39) and that of NRCTs (OR 0.53 [95%CI 0.19, 1.49])
with high heterogeneity I2=40% and 42% respectively. (Figure 2.8. B)
Sensitivity analysis: Among RCTs, the Mesdaghinia 2013 study excluded metformin-
treated GDM with additional insulin group from metformin arm whereas all other
studies included them. Thus, sensitivity analysis was performed with exclusion of this
study and found that there was significant increased risk of prematurity with the odds
of 1.57(95% CI 1.05, 2.36) with I2=0% for RCTs meta-analysis. Similarly, among
NTCTs, Balani 2009 study included metformin monotherapy group in their metformin
arm whereas Goh 2011 study added supplementary insulin to GDM women with FBS
≥6mmol/L with metformin initiation. These two studies consistently reported that 
prematurity was increased in insulin-treated GDM compared to metformin-treated
GDM with 19.2% vs 12.5% in Goh 2011 study and 10% vs 0% in Balani 2009 study.
After exclusion of these 2 studies, the pooled estimated risk changed to OR of 0.68
(95%CI 0.14, 3.27).
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Figure 2.8. Forest-plots of gestational maturity at delivery
A) Gestational age at delivery (weeks)
B) Prematurity (<37 weeks)
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7. Neonatal jaundice
All the studies defined neonatal hyperbilirubinaemia or jaundice as the need for
phototherapy apart from Moore et al, who defined jaundice as a bilirubin>5mg/dl and
Rai et al who used >12mg/dl as a cut off(Moore et al 2007; Rai et al 2009). Analysis
of the 9 RCTs (n=1811) revealed a possible reduction in the risk of neonatal jaundice
with metformin use [OR 0.79; 95% CI 0.53, 1.18]. Analysis of the 3 NRCTs (n=378)
showed similar non-significant reduction with metformin treatment [OR 0.51; 95% CI
0.19, 1.42] (Figure 2.9). There was large statistical heterogeneity in effect sizes which
could be due to difference in characteristics of GDM population.
Sensitivity analysis: The heterogeneity in RCTs meta-analysis was much influenced
by Niromanesh 2012 study which was the only study favouring insulin arm. The
methodology of this study differed in that insulin was administered targeted approach
compared to other study. Among NRCTs meta-analysis, because of much variations
in studies conduct and paucity of number of NRCTs, the sensitivity was not performed.
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Figure 2.9. Forest-plot of Neonatal Jaundice
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Table 2.9: Important Neonatal outcomes (Metformin vs Insulin) stratified by 75g/100g OGTT
Outcomes Numbers
of studies
Sample
size
WMD/OR I2 Subgroup
Analysis(n)
WMD/OR I2
1. Weight at birth
iii) Birth weight 9RCTs 1498 -58.38(-119.09,2.32) 33%
75g(6) -59.96(-146.37,30.44) 55%
100g(3) -63.59(-154.74,27.57) 0%
4NRCTs 1255 -35.37(-134.56, 68.82) 43% 75g(3) -18.71(-133.68,96.27) 51%
100g(1) -120.00(-320.79,80.79)
iv) Macrosomia 8RCTs 1082 0.71(0.46,1.09) 17% 75g(5) 0.83(0.43,1.62) 37%
100g(3) 0.50(0.27,0.95) 0%
3NRCTs 909 0.63(0.42,0.94) 0% 75g(3) 0.63(0.42,0.94) 0%
v) LGA 6RCTs 1502 0.77(0.55,1.08) 21% 75g(4) 1.0(0.73,1.37) 0%
100g(2) 0.49(0.30,0.82) 0%
3NRCTs 1696 0.60(0.46,0.77) 0% 75g(3) 0.60(0.46,0.77) 0%
vi) SGA 7RCTs 1548 0.98(0.64, 1.50) 0% 75g(6) 0.96(0.62,1.48) 0%
100g(1) 1.52(0.25,9.35)
4NRCTs 1255 0.66(0.45,0.95) 0% 75g(3) 0.70(0.48,1.02) 0%
100g(1) 0.23(0.04,1.20)
2. Neonatal hypoglycaemia 9RCTs 1811 0.69(0.52,0.91) 0% 75g(6) 0.67(0.48,0.94) 8%
100g(3) 0.68(0.32,1.44) 0%
4NRCTs 1165 0.42(0.27,0.64) 0% 75g(3) 0.43(0.28,0.65) 0%
100g(1) 0.18(0.01,3.93) 0%
3. GA at birth 7RCTs 1512 -0.10(-0.29,0.09) 37% 75g(5) -0.18(-0.33,-0.03) 0%
100g(2) -0.10(-0.38,0.18) 0%
3NRCTs 743 0.40(0.18,0.62) 0% 75g(2) 0.38(0.14,0.62) 0%
100g(1) 0.50(-0.08,1.08)
4. Premature baby 6RCTs 1502 1.22(0.63,2.39) 40% 75g(4) 1.49(0.97,2.29) 0%
100g(2) 0.44(0.01,24.48) 85%
4NRCTs 1139 0.53(0.19,1.49) 42% 75g(3) 0.39(0.11,1.41) 55%
100g(1) 2.0(0.17,23.29)
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Table 2.9: Important Neonatal outcomes (Metformin vs Insulin)stratified by 75g/100g OGTT
Outcomes Numbers
of studies
Sample
size
WMD/OR I2 Subgroup Outcomes Numbers
of studies
5. Neonatal jaundice 9RCTs 1811 0.79(0.53,1.18) 31% 75g(6) 0.79(0.55,1.15) 0%
100g(3) 0.78(0.22,2.75) 79%
3NRCTs 378 0.51(0.19,1.42) 73% 75g(2) 0.49(0.10,2.39) 86%
100g(1) 0.61(0.21,1.78)
6. Foetal distress at birth
i) Respiratory distress 9RCTs 1811 0.78(0.50,1.22) 0%
75g(6) 0.79(0.46,1.38) 0%
100g(3) 1.07(0.27,4.31) 63%
3NRCTs 1194 1.23(0.52,2.91) 0% 75g(3) 1.23(0.52,2.91) 0%
ii) Cord blood pH 6RCTs 857 0.00(-0.01,0.01) 0% 75g(5) 0.01(-0.01,0.02) 0%
100g(1) 0.0(-0.02,0.02)
1NRCT 90 0.00(-0.04,0.04) 75g(1) 0.00(-0.04,0.04)
7. NICU admission rate 8RCTs 0.69(0.50,0.95) 23% 75g(5) 0.79(0.60,1.04) 0%
100g(3) 0.63(0.18,2.15) 60%
5NRCTs 0.57(0.40,0.82) 28% 75g(4) 0.63(0.47,0.84) 0%
100g(1) 0.19(0.05,0.75)
8. APGAR at 5 minutes 6RCTs 778 0.03(-0.12,0.18) 12% 75g(2) 0.05(-0.15,0.26) 29%
100g(4) -0.06(-0.34,0.21) 0%
1NRCT 90 -0.10(-0.52,0.32) 75g(1) -0.10(-0.52,0.32)
9. Shoulder dystocia 7RCTs 1570 0.60(0.29,1.25) 0% 75g(4) 0.48(0.20,1.23) 0%
100g(3) 1.16(0.26,5.10) 10%
2NRCTs 317 2.40(0.25,23.38) 75g(2) 2.40(0.25,23.38)
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8. NICU admission rate
Data on rates of NICU admission was found in 13 studies, 8 RCTs and 5 NRCTs.
Analysis of the RCTs meta-analysis revealed reduction of NICU admission is
association with metformin usage (OR 0.69 [95% CI 0.50, 0.95]). The NRCT analysis
also showed a significant reduction with (OR 0.57 [95% CI 0.40, 0.82]).
Sensitivity analysis: Among RCTs, GDM women in Mesdaghinia 2013 study and
Ruholamin 2014 study were included metformin monotherapy group in metformin
arm and this might exaggerate the summary estimate. After exclusion of these 2
studies, the effect was no longer significant with OR of 0.82 (95%CI 0.62, 1.07). In
NRCT analysis, there was imbalanced Type 2 diabetes population in Rai 2009 study
with 6.7% and 20% in metformin and insulin arm respectively and it was reported that
the average duration of hospital study also differed with 2.5 days and 6.5 days
respectively. After exclusion, the I2 changed from 28% to 0%, and effect was still
significant.
9. Perinatal mortality
Because of small number of incidence of perinatal mortality rates in GDM, Generic
Inverse Variance Model was applied to combine the effect estimate. Analysis of 6
RCTs and 3 NRCTs revealed no difference in perinatal mortality rates between either
of the treatment arms in the RCTs (OR 1.00 [95%CI 0.10, 9.72]) or the NRCTs (OR
0.21 [95% CI 0.02, 1.92]) .
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Other outcomes
8. Birth trauma
The number of birth trauma among treated GDM was found to be very low (0.03%).
Data on birth trauma was specifically reported in 4 RCTs (n=1197) and 1 NRCT
(n=90).
1 large RCT (Rowan et al 2008) reported birth trauma (mild if bruises or abrasions at
birth but resolved before 6 weeks postpartum) in 16 out of 363 infants born by
metformin-treated women with mild birth trauma and 17 out of 370 (15 mild and 2
severe) infants born to insulin-treated women, both numbers were considerably higher
than data reported by 1 small RCT (Ijas et al 2010) where 2 out of 50 infants in insulin
group (attributable to clavicular fractures due to shoulder dystocia) with no incidence
of birth trauma in metformin group were observed. Another RCT did not find any case
of birth trauma in both groups (n=150) (Hassan et al 2012) One retrospective cohort
reported 2/45 in insulin and 1/45 in metformin group (1 clavicular fracture in each
group and 1 Erb’s palsy in insulin group) (Tertti et al 2008). One prospective cohort
also observed an increased risk of birth trauma in the insulin-treated mothers although
the exact number was not reported (Rai et al 2009), the interpretation of this result
should be sceptical because of higher proportion of type 2 diabetes mothers.
9. Major or minor congenital abnormality
Ijas et al reported that there was one oesophageal atresia in the metformin arm whereas
one baby with congenital ovarian cyst was observed in insulin group. One
observational study reported specific congenital defects. In the metformin group, there
is one case of a baby born with trisomy who subsequently died at 2 months (Tertti et
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al 2009). Niromanesh group found one with ventricular septal defect, one with talipes
equinovarus and one with moderate bilateral hydronephrosis in insulin group whreas
they observed one with small ventricular septal defect, one with atrial defect, two with
talipes equinovarus and one with unilateral cleft lip.
10. Tolerability of treatment
Discontinuation of treatment was reported as being low in 4 studies (the largest
proportion <8%)(Rowan et al 2008; Moore et al 2010; Ijas et al 2010; Gandhi et al
2012). The commonest reason was GI side-effects and less frequent reasons were
worsening liver function tests, sepsis, hypoglycaemia, migraine, skin rash, obstetric
complications including severe preeclampsia and obstetric cholestasis. The dose of
metformin needed to be reduced in 4 studies (the greatest proportion <9%) (Rowan et
al 2008; Ijas et al 2010; Gandhi et al 2012; Rai et al 2009). The only reported reason
was GI intolerance. In contrast, despite high dose of metformin (3000mg), Hassan
2012 study reported to have no GI intolerance.
11. Arthropometric measurements of babies
The largest RCT by Rowan et al reported the primary outcome as a composite measure
(neonatal hypoglycaemia, respiratory distress, need for phototherapy, birth trauma, 5-
minute Apgar score below 7 or premature birth) where they found no significant
differences between metformin and insulin treatment (OR 0.99; 95% CI 0.80 to 1.23).
They also reported no significant difference on cord blood ‘C’ peptide levels (but not
mention the actual value) and no significant differences in anthropometric measures at
birth between the treatments. However, data on anthropometric measures at 2 year
follow-up with 50% follow-up rate performed by the same research group (MiG
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TOFU) revealed no significant differences in the distribution of fat measured by waist-
to-hip ratio and DEXA-calculated abdominal-to-thigh fat ratios but an increased
measure of upper-arm circumference and increased thickness of biceps and
subscapular skinfolds in toddlers born to metformin-treated mothers (Rowan et al
2011). Similarly, Niromanesh 2012 group has observed that significantly lower head,
arm and chest circumferences with metformin treatment.
12. Other pregnancy outcomes at birth
There was no significant difference in other neonatal outcomes: respiratory distress,
APGAR at 5 minutes, the risks of APGAR <7 at 5 min, serious perinatal outcomes
(shoulder dystocia, nerve palsy, fractures, perinatal death), duration of NICU
admission, antepartum complications, peripartum complications, postpartum impaired
glucose tolerance and maternal hypoglycaemia.
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13. Outcomes of follow-up studies
There are three articles which reported the follow-up offspring outcomes of metformin
in GDM (Ijas et al 2015; Rowan et al 2011; Battin et al 2015). Data on weight, height
and head circumference were available from both studies at toddler follow-up. The
meta-analyses showed that children born to metformin-treated GDM women were
heavier than those delivered by insulin-treated GDM women. (WMD: 0.44 (95%CI
0.04, 0.84)) kg. There was no difference in height and head circumference. Moreover,
Rowan and her group have found that metformin treatment favoured more peripheral
deposition of fat than central adiposity. The systolic and diastolic blood pressures of
2-years-old exposed to intrauterine metformin were similar to those of insulin treated
women. Moreover, there was no difference in child’s motor, linguistic and social
development at 18 months of age between metformin and insulin groups.
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2.3.2. Comparison 2: Metformin versus Glibenclamide
Table 2.10. Quality assessment of RCTs (Metformin vs Glibenclamide)
(‘+’ means appropriate, ‘-’ means not done or not mentioned or not appropriate or ‘?’ means inadequate data to justify that the study )
Study Internal Validity External validity Potential bias
Selection Performance Detection Attrition Reporting Others
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George 2015 + + - + + + - - - - + + + + Low
Moore 2010 + + - + - + + + - + + + + + Moderate
Silva 2012 + ? - + - - - - - + + + + + Low
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2.3.2.1 Quality assessment of included studies (Metformin vs Glibenclamide)
Out of three RCTs, randomization and allocation concealment was appropriately
conducted except Silva 2012 study where ‘brown’ envelope, rather than opaque, was
used for allocation(Table 2.10). Information on blinding of health care professionals
and participants were not reported by any of 3 studies. The diagnostic and target
glycaemic levels and management were comparable between metformin and insulin
groups in all 3 studies. Only George 2015 mentioned that outcome assessors were
blinded from intervention. Although sample size was determined before the conduct
of trial, only one study was adequately reported to have done interntion to treat
analysis[78]. None of 3 studies reported all outcomes considered important in this
review. George 2015 study did interim analysis. The explicit information on
population selected, intervention given both on metformin and glibenclamide and the
reported outcomes were available in all 3 studies.
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2.3.2.2. Characteristic of studies
A brief description on population included, intervention and GDM management were
described in table 2.10.
Population: Majority of the GDM being diagnosed by 100g OGTT test. All 3 studies
included were RCTs. In all 3 studies, GDM women who failed to achieve target
glucose by medical nutrition therapy were randomized. The target glycemic targets
were similar across the studies.
Intervention: The maximum dose of metformin was 2000 mg in one study Moore et al
2010 and 2500 mg in other 2 studies (Silva et al 2013; George et al 2015) whereas the
maximum dose of glibenclamide was 15mg in one study (Silva et al 2013) and 20 mg
in other two (Moore et al 2010; George et al 2015).
Outcomes: Glycemic control was main outcomes in 2 studies and the rest study used
composite outcome measures. Data on pregnancy outcomes such as foetal birth
weight, caesarean section rates, neonatal hypoglycemia, hypertensive complications
of pregnancy, gestational age at birth, maternal fasting and postprandial glycemic
control comparing metformin and glibenclamide were available from 3 RCTs.
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Table 2.10. Characteristics of included studies (Metformin vs Glibenclamide)
Study ID Setting
(Number)
Population Care pathway Metformin Glibenclamide Reported side
effects
necessitating
action(n)
Target level Primary
outcomes
Inclusion Exclusion
Moore
2010
(RCT)
[152]
United states,
University of New
Mexico,
75 metformin : 74
glibenclamide
11-33 weeks GA,
Screening : 50 g OGCT
1hr ≥130 mg/dl 
History of significant
renal or hepatic disease,
chronic hypertension
requiring medication or
history of substance
abuse
prenatal care provided by university
pregnancy diabetic group(OG, diabetes
nurse educators and dietiticians. monthly
US, twice wkly antenatal testing starting
at 28 weeks, elective delivery planned at
38 weeks by IOL or repeat CS, monitored
by memory-based glucometer(read within
10% of serum glucose reading),readings
correlated with serum glucose each
trimester, tested FBS and 2hrPP each
meal, compliance accessed by polling the
meter and by meeting with diabetes
educator at each visit regarding
medication use, diet and amount of
exercise, weekly reviewed glucose level.
Metformin started at
500 mg/d in divided
dose, increased as
necessary to
maximum 2g/d.
Glibenclamide started
at 2.5 mg bd, increased
as necessary to
maximum of 20 mg/d
GI SE (1) increased
medication if ≥ 2 
glucose levels in
the same meal
exceeded target
values by 10
mg/dl/> for 2
consecutive weeks
glycemic
control
Oral medication was discontinued when insulin
started.
Taking maximum dose of either metformin or
glyburide with ≥ 2 glucose levels in the same 
mean exceeded target values by 10 mg/dl/> for
2 consecutive weeks was considered to be
treatment failure.
Silva 2010,
2012
[122],[191]
(RCT)
Brazil, Donal
Helena hospital,
UNIMED hospital
centre,
32 metformin : 40
glibenclamide
GA 11-33 weeks, ≥18 
years old, singletons,
AC(>10% and < 75%),
no maternal and
neonatal conditions
likely to affect
outcomes;
High risk group
selection by WHO
criteria
maternal intolerance to
hypoglycaemic
medications or
unwillingness to
participate, foetal AC >
97% or < 5% normal,
lack of F-up during
pregnancy,
malformation on
delivery
Multidisciplinary care (nutritionists,
physiotherapists, psychologists, nurses,
obstetricians, and endocrinologists) met
patients every 15 days, monitored by 7
days after instruction, self-assessed FBS
and 1hr after breakfast, lunch and dinner
using a home capillary glucose
monitoring device.
Metformin(Glifage,
Diaformin, Dimefor,
Glucoformin)
500mg at breakfast
and dinner and
increased by 500-
1000 mg each week
until control or
maximum of 2500
mg
Glibenclamide(Daonil,
Aglucon, Lisaglucon)
2.5 mg before
breakfast & dinner and
increased by 2.5-5 mg
each weeek until
control, or to
maximum of 20mg/d
Frequent GI
complaints, 9
UTI, 7
chronic
arterial
systemic
hypertension
Acceptable upper
values (FBS 90
mg/dl and PP 120
mg/dl); if 2 points
abnormal,
considered
impaired.
glucose
control, birth
weight and
neonatal
glucose
levels
If not control with maximum dose, replaced by
insulin(
Insulin 0.7 IU /kg /d (1/3 regular insulin before
breakfast, 1/4 regular insulin before lunch &
dinner and 1/6 NPH at bedtime.)
115
Table 2.10. Characteristics of included studies (Metformin vs Glibenclamide)
OGCT – oral glucose challenge test, GA – gestational age, NPH insulin – isophane insulin, GI SE – gastrointestinal side-effects, CS – cesarean section, USG – ultrasound, IOL – induction of
labour, UTI – urinary tract infection, GI – gastrointestinal, AC – abdominal circumference, F-up – follow-up, OG – obstetricians and gynaecologists
Study ID Setting
(Number)
Population Care pathway Metformin Glibenclamide Reported side
effects
necessitating
action(n)
Target level Primary
outcomes
Inclusion Exclusion
Geroge
2015
(RCT)
South India; large
tertiary centre, 79
metformin:80glibe
nclamide
Women who failed to
meet glycaemic targets
with medical nutrition
therapy(MNT)
Declined to participate;
obstetrician declined to
allow participation
Home glucose monitoring with
glucometer(minimum 4times/week – 1
fasting +3 2hr PP), hypoglycemic events
being recorded, regularly checked by
research officer
Metformin(glycipha
ge) 500mg od,
maximum of
2500mg/day
Glibenclamide(Daonil
) 2.5 mg given 30 min
before meal(started
before dinner if
uncontrolled fasting;
before breakfast if
uncontrolled postmeal
control); to maximum
of 15mg
3 maternal
hypoglycaemi
a; 1 epigastric
burn
glycemic targets-
≤5.3mmol/L and 
2hr PP
≤6.7mmol/L if 
maximum dose
failed to achieve
normoglycemia,
within 2-3 weeks
they were switched
over to insulin
Composite
outcome(one
of more of
outcomes
such as
macrosomia
>3700grams,
hypoglycemi
a, need for
phototherapy
, respiratory
distress,
neonatal
death/stillbirt
h, birth
trauma)
dose increased in stepwise approach if any two
values of fasting ≥6.2mmol/L or PP ≥8.3 
mmol/L within a week;
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2.3.2.3. Pregnancy outcomes
Metformin-treated mothers were more likely to deliver babies with lower birth weight
than those born to glibenclamide-treated mothers (WMD -44.51 grams [95% CI -
98.83, 9.82], n=508, I2=90%) (Figure 2.10. A). Similarly, the risk of macrosomia was
nonsignificantly lower in metformin group (OR 0.57, 0.22, 1.46); I2=5%) (Figure
2.10.B). The variation in the pooled outcome estimate was attributable to George 2015
study. Among the included RCTs, the George 2015 study had reported GDM with
increased triglyceride levels in metformin group. After exclusion this study for
sensitivity analysis, the I2 changed to 0% and the WMD of birthweight -249.13
grams(95%CI -355.88, -142.38) and OR of macrosomia 0.32(95%CI 0.08, 1.21).
Newborns of women who had received metformin developed less neonatal
hypoglycemia than those born to glibenclamide-treated GDM women (OR
0.48[95%CI 0.24,0.98];n =508; I2=61%) (Figure 2.10.C). The large heterogeneity of
effect estimates was attributable to the George 2015 study, which included only GDM
with moderate hyperglycemia. This might explain exaggeration of metformin effect
on the risk of neonatal hypoglycaemia.
The prematurity rate was comparable between metformin and glibenclamide treated
GDM [OR 1.59 (95%CI 0.49, 4.80)] (Figure 2.10.D).
The maternal FPG control was better with glibenclamide than metformin with the
weighted mean difference(WMD) of 2.40(95%CI 0.21, 4.60); n=508 and I2=0%
whereas there was no significant difference in postprandial glycemic control (WMD:
0.58[95%CI:-2.63, 3.79]; n=508; I2=0%)(Figure 2.11.A and B).
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There was non-significant increased risk of caesarean section with metformin
treatment (OR 1.39 [95%CI 0.63, 3.06], n=508, I2=64%) (Figure 2.11. C) which was
largely contributed by Moore 2010 study. In this study, there was a significantly
increased in number of metformin-treated women undergoing non-elective caesarean
section indicated for non-reassuring fetus.
Maternal weight gain was reported only by Silva 2012 study that there was less
maternal weight gain of 2.06 (95%CI 3.98 to 0.14) kg with metformin therapy than
glibenclamide in GDM.
Among 3 studies, the failure rate of metformin was increased in the Moore 2010 study
whereas glibenclamide failure rate was higher in the Silva 2012 and George 2015
studies. In Moore 2010 study, the target fasting glucose was 5.8 mmol/L in contrast to
5 mmol/L in other 2 studies. As mentioned above, glibenclamide can have much
greater reduction on FPG than metformin. Thus, this study had high metformin failure
rate. It should also be noted that in considering therapy failure rate, the maximum dose
of the drug should also be taken into account.
There was no significant difference in hypertensive complications of pregnancy,
respiratory distress, neonatal jaundice, NICU admission rate, birth trauma and neonatal
jaundice.
The following outcomes were not reported: small for gestational age, cord blood “C”
peptide, neonatal hypocalcaemia, and anthropometric measures and results of
postpartum OGTT test.
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Figure 2.10. Forest plots of important neonatal outcomes
A) Neonatal Birth weight (grams)
B) Macrosomia
C) Neonatal Hypoglycaemia
D) Gestational age at birth (weeks)
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Figure 2.11. Forest plots of important maternal outcomes
A) Fasting Plasma Glucose Control
B) Postprandial Plasma Glucose Control
C) Caesarean Section Rates
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2.3.3. Comparison 3: Metformin vs Diet
Table 2.11. Quality assessment of included studies (Metformin vs Diet)
(‘+’ means appropriate, ‘-’ means not done or not mentioned or not appropriate or ‘?’ means inadequate data to justify that the study was done
appropriately. For baseline comparability and favours group, there were 2 separate items being consider:1) whether the maternal baseline which
were considered important in GDM(Age, BMI, parity, glucose levels at OGTT, ethnicity, smoking, previous history of still-birth were considered
and reported and 2) if they were unequal across arms, which group could be potentially advantaged out of this biases? D= Diet, I= Insulin,
M=metformin, G=glibenclamide, MF= Metformin Failure
Study ID Internal Validity External Validity Potential
biasSelection Performance Detection Attrition Reporting Others
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Balani 2012 + - - + D - - + - - + + - + High
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2.3.3.1. Quality assessment of included studies
The information on maternal baseline and pregnancy outcome data were available in
only 3 observational studies separately. In all three studies, metformin was introduced
to GDM women only after diet and lifestyle intervention was failed to meet target
glucose levels. Thus, women in diet group were more insulin resistant than those in
metformin group which might introduce selection bias. However, all GDM women in
each study were treated under the same clinical team and they have similar target
glucose levels and pregnancy management. Except Tertti 2008 studies, other 2 studies
included all GDM women received diet or metformin within specified time frame were
included in analysis. None of the 3 studies have reported comprehensive outcomes for
this review and they did not perform any confounder adjustment. For external validity,
any of 3 studies did not have enough information on diet strategy.
2.3.3.2. Characteristics of studies
Population: Women in metformin group were found to have significantly higher BMI
and higher blood glucose at OGTT as well as be earlier gestational age at OGTT ,less
likely to be nulliparous and more likely to have family history of diabetes.
Intervention and Comparator: The maximum dose of metformin (3000mg) was used
in Balani 2012 study and obese GDM women in Goh 2012 study. None of the studies
reported information on lifestyle modification strategy (i.e diet treatment).
Outcomes: Only Tertti 2008 study described primary outcomes which were birth
weight and incidence of neonatal hypoglycaemia.
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Table 2.12. Characteristics of included studies (Metformin vs Diet)
Study ID Intervention Glucose level at which intervention was
started/How each group was formed?
Baseline characters(p<0.01)
Diet Metformin Diet Metformin Diet Metformin
Tertti[175]2008
(83 diet : 45
metformin)
dietary counselling
on low glycemic
index and low
saturated fat
eucaloric diet,
dietary record and
exercise diary on
glucose
measurement days
kept
Described in
Table 2.7
2 out of 3 75g
OGTT value(fasting
≥ 4.8, 1hr ≥ 10, 2hr 
≥ 8.7 mmol/l) 
Fasting ≥5.5 mmol/l at least 
twice/fasting ≥5.5mmol/l at 
least once and 90 min PP ≥ 
7.8 mmol/l/fasting < 5.5
mmol/l but 90 min PP ≥7.8 
mmol/l at least twice within
a week of monitoring
glucose(4times
At OGTT
0hr(mmol/l)
1hr(mmol/l)
2hr(mmol/l)
Hb A1c (%)
GA(wk)
Primipara n (%)
5.5±0.3
11±0.9
7.7±1.1
5.5±0.3
27.1±2.4
38(46)
5.9±0.7
11.7±1.7
8.3±1.8
5.7±0.4
24.8±5.5
10(22)
Each metformin subject was matched with 2 diet
subjects stratified by age and BMI (except 7
metformin, matched by 1:1).
Goh 2011[187]
(371 diet : 465
metformin)
Lifestyle advice and
capillary glucose
monitoring was
initiated.
Described in
Table 2.7
Fasting ≥ 5.5 
mmol/l (OR)
2hr≥ PP 9 mmol/l at 
75g OGTT
Fasting> 5 mmol/l±
2hr PP > 6/6.5 mmol/l
within a week of
monitoring
glucose(4times/day)
Booking BMI (%)
<18.5,
18.5-24.9,
25-29.9,
≥30 
Ethnicity (%)
European
Maori
Pacific
Indian
Other Asian
Other
OGTT(mmol/l)
Fasting
2hrPP
History of chronic
hypertension (%)*
8.1
48.8
23.7
19.5
30
4.6
7.6
13.5
39.4
5.1
4.5±0.7
9.5±1.1
3.5
2.2
24
28.5
45.3
22
10.1
20.9
19.1
24.3
3.7
5.3±0.8
9.4±1.6
5.4
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Table 2.12. Characteristics of included studies (Metformin vs Diet)
GA – gestational age, PP – postprandial, BMI – body mass index, * (p0.001), FGR – Foetal Growth Restriction
Study ID Intervention Glucose level at which intervention was
started/How each group was formed?
Baseline characters(p<0.01)
Diet Metformin Diet Metformin Diet Metformin
Balani 2012
(175 diet:324
metformin)
Individualized
dietary advice from
a specialist dietician
500mg with meals
to maximum of
3G;withdrawn if
FGR <10centile
and
oligohydramnios
or reduced end
diastolic flow
Fasting > 6 mmol/l
(OR)
2hrPP > 7 mmol/l at
75g OGTT
Fasting> 5.6 mmol/l±
1hrPP>8mmol/L±
2hrPP>7mmol/l within a
two-week period of
monitoring
glucose(4times/day)
HbA1c at entry
BMI
Family history of
diabetes
5.4±0.5
27.2±5.8
42(24)
5.6±0.6
30.2±7.1
131(40.4)
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2.3.3.3. Results
The summary estimates of the pregnancy outcomes reported by all three studies and
analysed in meta-analyses were foetal birth weight, small-for-gestational age, neonatal
hypoglycemia, prematurity, NICU admission rates, pre-eclampsia and caesarean
section rates.
The pooled risk of small-for-gestational-age was significantly reduced in the
metformin group compared to dietary intervention alone (OR 0.63 (95% CI 0.44, 0.89)
(n=1478, I2=0%)). There was no significant difference in the pooled estimates of foetal
birth weight (WMD 20.11 [95%CI -39.43,79.65] grams, n=1478, I2=24%) and large
for gestational age(reported by 2 studies).
GDM women receiving metformin were more likely to have induction of labour (OR
1.48 [95% CI 1.04,1.72]; n=627, I2=0%) and caesarean section (OR 1.35 [95%CI
1.03,1.76], n=1478, I2=10%). There was marginally significant increase in the pooled
risk of neonatal hypoglycemia (OR 1.44 [95% CI 1.0, 2.09]), n=1477, I2=4%). There
was nonsignificant likelihood that metformin groups had increased risk of babies with
neonatal jaundice than diet monotherapy (OR 2.78 [95% CI 0.58, 13.02]), n=627,
I2=71%).
The risks of prematurity, preelampsia and NICU admission rates were not significantly
different between metformin and diet alone groups.
The possible difference between metformin and diet treatment was observed in the risk
of induction of labour with odds of 1.6 (95%CI 0.99, 2.58) in favour of metformin,
using random effect meta-analysis (n=524).
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Tertti et al reported significant difference in Apgar score at 5 minutes with mean
difference of -0.3(95% CI -0.57, -0.03) favoring diet.
Figure 2.12 Forest plots of neonatal outcomes
A) Small for gestational age
B) Neonatal Birth weight
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2.3.4.Comparison 4: Metformin Success(metformin alone) vs Metformin Failure(metformin+insulin)
Table 2.13. Quality assessment of included studies (Metformin Monotherapy vs Metformin Failure)
(‘+’ means appropriate, ‘-’ means not done or not mentioned or not appropriate or ‘?’ means inadequate data to justify that the study was done
appropriately. For baseline comparability and favours group, there were 2 separate items being consider:1) whether the maternal baseline which
were considered important in GDM(Age, BMI, parity, glucose levels at OGTT, ethnicity, smoking, previous history of still-birth were considered
and reported and 2) if they were unequal across arms, which group could be potentially advantaged out of this biases? D= Diet, I= Insulin,
M=metformin, G=glibenclamide, MF= Metformin Failure
Study ID Internal Validity External Validity Potential
biasSelection Performance Detection Attrition Reporting Others
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Goh 2011 + - - + M - - + - - + - - + High
Tertti 2013 + - - + M - - + - - + + - + High
Spaulonci 2013 + - - + M - - + - - + + + - High
Corbould 2013 + - - + M - - + - - + + - - High
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2.3.4.1. Quality of included studies (Table 2.13)
There are 5 studies which presented metformin alone and metformin plus insulin
groups separately (Ijas et al 2010; Goh et al 2011; Tertti et al 2013; Spaulonci et al
2013; Corbould et al 2013). Although three of them were sub study of RCTs, they
were qualitatively assessed against NRCTs ROB tools because randomization did not
intend for metformin and metformin failure groups. All the women in metformin
failure group were received additional insulin when they failed to achieve target
glucose levels with maximum dose of metformin. Among all studies, GDM women
were more insulin resistant in metformin failure group. All the women who received
metformin alone or with supplementary insulin were included for analysis (intention
to treat analysis). Neither of NRCTs had blinded the outcome assessors.
2.3.4.2. Characteristics of studies (Table 2.14)
Population: Characters of women who failed to achieve target glucose with metformin
were observed in 3 studies.
The RCT performed by Ijäs et al reported that metformin failure women were more
likely to have BMI ≥ 30kg/m2, more likely to be high risk group of gestational 
diabetes, had higher fasting glucose level at diagnosis and were more likely to have a
history of chronic hypertension compared to the metformin alone treatment group.
Similarly, one retrospective observational study undertaken by Goh et al observed that
the higher the BMI, the greater the proportion of metformin failure; there was
significantly higher fasting glucose level (5.7±0.9 vs 5±0.6 mmol/L) and higher
proportion of chronic hypertension (8.8% vs 2.4%) in metformin failure group and
metformin monotherapy group respectively. Corbould and the group with small
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sample size have reported that if fasting glucose at OGTT≤5.2 mmol/L, 13 out of 14 
(93%) responded well to metformin (i.e. not require insulin addition). All the women
in Tertti 2013 received vitamin supplementation together with metformin.
Data on ethnicity were obtained from 9 studies (Table 2.15). High metformin failure
rates of 46.3% and 46.5% were reported by Rowan et al and Goh et al, respectively. It
was found that the study with greater percentages of high risk ethnic groups had
metformin failure rate.
Intervention and Comparator: In all 5 studies, metformin failure group was formed
when the maximum dose of metformin (ranging from 1500-3000mg) to meet target
glucose levels was used. (Tertti et al 2013, Ijas et al 2010 and Corbould et al 2013).
Extended release metformin was given in 3 out of 5 studies. In Goh 2011 study,
compulsory baseline insulin was given to GDM with fasting ≥ 6 mmol/L at initiation 
of metformin and the maximum dose of metformin given to obese women were higher
than that to normal (3000mg vs 2500 mg). Except Ijas 2010 study where fixed dose
strategy of metformin was applied for 3 weeks, the other 4 studies have 1-2 weeks of
titration period before insulin was given. In Corbould et al 2013 study, insulin was
commenced after stopping of metformin compared to insulin addition therapy in other
4 studies.
Outcomes: Neonatal birthweight and macrosomia were primary outcome measure in
Tertti 2013 study and Ijas 2010 study respectively whereas Spaulonci 2013 considered
glycaemic control for main outcome measure.
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Table 2.14. Description of included studies (Metformin monotherapy vs Metformin Failure)
Study ID How metformin failure group was formed? Baseline characters
Metformin Metformin + insulin
Ijäs 2010
(32 metformin : 15
metformin +insulin)
If target glucose level (fasting < 5.3 mmol/l and 1.5hr PP <6.7
mmol/l) was not achieved with maximum metformin dose
(2350mg) in 1-2 weeks, insulin was added.
Booking BMI*
Fasting*
2hrPP
GA at metformin initiation*
29.6±5.3
5±0.5
8±1.8
31±3.
35.7±7.2
6.1±1.1
8.7±2.2
26±5.9
Goh 2011
(249 metformin :
216 metformin +
insulin)
If fasting ≥ 6 mmol/l, supplemental bedtime isophane insulin 
was added at the time of metformin initiation.
If women failed to achieve target glucose level(fasting 4-5
mmol/l and 2hr PP 4-6/6.5 mmol/l) with maximum metformin
dose(2500mg, 3000mg for morbidly obese), they were advised
to take supplemental insulin 1/> times/day as required.
Booking BMI (%)*
<18.5,
18.5-24.9,
25-29.9,
≥30 
Ethnicity (%)*
European
Maori
Pacific
Indian
Other Asian
Other
OGTT(mmol/l)*
Fasting
2hrPP
History of chronic
hypertension (%)*
4.1
33.2
32.8
29.9
21.3
8.4
14.5
21.7
30.9
3.2
5±0.6
9.4±1.4
2.4
13.5
23.7
62.8
22.7
12
28.2
16.2
16.7
4.2
5.7±0.9
9.3±1.9
8.8
Spaulonci 2013 If target glucose level (fasting < 5.3 mmol/l and 1.5hr PP <6.7
mmol/l) was not achieved with maximum metformin dose in 1-
2 weeks, insulin was added.
Booking BMI
GA at OGTT*(weeks)
HbA1c at OGTT(%)
Fasting glucose at
OGTT(mg/dL)
29.01±5.73
31.4±2.36
5.82±0.53
98.05±19.03
27.73±5.35
27.55±5.25
6.11±1.17
113.98±26.2
Corbould 2013
(16 metformin : 7
metformin+insulin)
If glucose targets (≤5.0mmol/L fasting ≤6.7 mmol/L at 2hr 
postprandial) were not achieved with diet/exercise, extended
release metformin 500 mg was started with evening meal up to
a maximum of 2g over 2 weeks; if then failed, metformin was
switched over to insulin.
Fasting glucose at OGTT
mmol/L
5.0±0.5 5.6±0.3
AN – Antenatal, * (p0.001), Results described as % or mean ± SD
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Table 2.15 Metformin failure rates among different ethnic groups
Study ID
(sample size)
Ethnicity % % of Metformin failure
Rowan 2008 48.2 White
20.1 Polynesian
10.5 Indian
13.5 Chinese/Southeast Asia
7.7 Others
46.3%
Balani 2009 44.9 Caucasian
26 Asian
7.9 African
10.2%
Moore 2010 88 Hispanic
1 African American
3 Native American
8 White
34.7%
Moore 2007
(Interim result)
63 African American
34 Native American
3 Caucasian
0 %
Goh 2011 22 European
10.1 Maori
20.9 Pacific
19.1 Indian
24.3 Other Asian
3 Others
46.5%
Gandhi 2012 58.7 White
25.6 Asian
4.4 Middle-east
11.3 African
21%
Silva 2012
(approximate)
80 White 25%
Tertti 2008
(approximate)
90 White
10 Arab
18%
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2.3.4.3. Results
A total of five studies reported outcomes on metformin failure.
A random effect meta-analysis on 4 studies (n=584) reported that neonates born to
women with metformin alone were likely to have lower birth weight than than those
to metformin failure mothers with the weighted mean difference of -115.96(95%CI -
244.41, 12.50) grams (Figure 2.13.A). Similarly, there was likelihood that the risk of
large for gestational age could be reduced in metformin alone therapy group with the
odds of 0.60 (95%CI 0.36, 1.07) (Figure 2.13.B)
Sensitivity analysis: In Goh 2011 study, basal insulin was introduced at time of
metformin initiation if fasting plasma glucose (≥6mmol/L) in comparison to other 
studies where insulin was only initiated even after maximum dose of metformin failed
to reach optimal glycaemic control. Thus, the glycaemic control was expectedly better
in Goh 2011 study than other 3 studies and thus the difference in birth weight between
two arms was smaller than other studies.
There was no significant difference in risk of macrosomia, small for gestational age,
neonatal hypoglycaemia, caesarean section and respiratory distress.
The following outcomes were not reported: risks of induction of labour, weight gain,
maternal hypoglycaemia, birth trauma, major or minor congenital abnormality and
cord blood C peptide/insulin level.
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Figure 2.13. Forest plots of pregnancy outcomes
A) Neonatal Birth weight
B) Large for gestational age
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2.4. Discussion
2.4.1 Metformin versus Insulin
All the studies used standard 75g/100g oral glucose tolerance test (OGTT) to diagnose
GDM. Similar to previous reports by meta-analyses, we found metformin improved
the following outcomes when compared to insulin: maternal weight gain, neonatal
hypoglycaemia, NICU admission rates, pregnancy-induced hypertension and heavier
weight of 1-2 years old babies (Balsells et al 2015; Kitwitee et al 2015). However, we
did not observe any reduction in risk of pre-eclampsia in our analyses. We also noted
a possible reduction in postprandial glycaemia, cesarean section rates, neonatal
jaundice and neonatal birth weight, macrosomia and large for gestational age. All other
outcomes were comparable between metformin and insulin therapy. Babies born by
metformin-treated GDM mothers had earlier gestational age at delivery and they were
more likely to be premature. The exact mechanism of metformin-induced prematurity
is still unknown and the data on predictors of prematurity among these women are
scarce.
The beneficial effect of metformin on maternal weight gain was striking and similar
in both RCTs and NRCTs. This is despite the fact that the study by Hassan had high
risk of bias (Hassan et al 2012). The observed heterogeneity in analyzing the studies
might be explained by either the duration of metformin treatment, which was not
explicitly reported by any of the included studies; or, the dose of metformin. Our
findings agree with the noted beneficial effects of metformin on maternal weight gain
in women with PCOS (Vanky et al 2010). Our data provides a rationale for using
metformin in GDM. As maternal weight gain has been shown to independently predict
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LGA, SGA, preeclampsia and caesarean section risks in pregnancy (Kiel et al 2007),
the use of metformin in GDM may offer additional benefits. Furthermore, as
gestational weight gain can strongly predict the metabolic risks of mothers and their
babies (Oken et la 2007; Fraser et al 2010), it is plausible that metformin can have
potential benefit on the long run. There is also evidence that metformin can have better
lipid profiles in women and much more favourable fat distribution in the offspring
(Niromanesh et al 2012; Lord et al 2006; Rowan et al 2011). Despite significant
benefit on maternal weight reduction, there was no increased risk of SGA with
metformin use in pregnancy.
In addition to the reduction in maternal weight gain, we noted that metformin use
resulted in a possible reduction in post-prandial glucose levels. This is consistent with
the findings in type 2 diabetes, where metformin significantly decreases postprandial
glucose levels (Howlett et al 1999). These decreases in post prandial glucose levels
could be ascribed to stimulation of glucagon like peptide-1 (GLP-1) secretion by
metformin, which has been noted in animal studies (Yasuda et al 2002). Additionally,
metformin is known to inhibit dipeptidyl peptidase-IV (DPP-IV) activity in type 2
diabetes patients (Lindsay et al 2005). Studies in type 2 diabetes also show a less
marked but significant reduction in fasting glycaemia (Howlett et al 1999), which we
did not observe in our analysis. This may be because the underlying pathology of
increased insulin resistance among these two populations are different or metformin
may have slower onset of action on fasting glucose levels.
Similar to previous meta-analyses, we also observed a significantly lower incidence of
neonatal hypoglycaemia in metformin treated mothers. This was a robust observation
noted in both RCTs and NRCTs. This finding might explain the trend of lower
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admission to NICU which we also observed. We speculate that the decreased incidence
of neonatal hypoglycemia may be due to lower maternal glycemic variability as
observed by the more favourable post prandial glucose levels. Another possibility is
that the placental transfer of metformin and similar levels of metformin in amniotic
fluid means that metformin could be swallowed by intrauterine fetus and helps it adapt
to maternal hyperglycemia in the uterine environment.
On the other hand, both RCTs (5RCTs) and NRCTs (4NRCTs) metaanalyses of
preeclampsia in our study do not show any difference, which is different from previous
analyses. This might be due to difference in definition of pre-eclampsia in systematic
review. We separately analysed pregnancy-induced hypertension and preeclampsia.
The meta-analysis of PIH including 2 RCTs was found to be different. We have
included one more recent RCT in our analyses than the most recent meta-analysis but
this did not change any statistical heterogeneity (Kitwitee et al 2015).
We saw a beneficial effect of metformin on birth weight, LGA and macrosomia in
NRCTs, we did not see this in the RCTs. This may be due to the fact that the population
chosen to be given metformin in NRCTs could be influenced by physician’s choice.
On the other hand, it should be noted that the sensitivity analysis of RCT meta-analyses
with exclusion of 2 trials for using extended release metformin have shown significant
reduction in birth weight with metformin therapy than insulin. Thus, the effects of
metformin on baby’s sizes need to be justified by future randomized studies with
adequate power to detect the birth weight difference.
In addition to these outcomes, metformin therapy is not only significantly cheaper in
terms of drug costs but is also less labour intensive to initiate (Lai et al 2008).
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Metformin does have a number of side effects, the principal one being GI irritation
(Scarpello et apl 2001), whilst insulin is known to be associated with greater incidence
of hypoglycemia. Despite these issues, there is evidence that metformin therapy is a
more acceptable treatment than insulin (Rowan et al 2008).
Our meta-analysis suggests that metformin appears to improve a number of significant
clinical outcomes for both mother and baby. More intriguing to us, were those findings
in the NRCTs (not replicated in the RCTs) that suggested that metformin was superior
to insulin. However, it should be noted that the GDM population who received
metformin in NRCTs were not always comparable as in RCTs in that women with
higher fasting glucose were added on insulin together with metformin initiation (Goh
2011 study) or they were excluded from metformin group (Tertti 2008 study). It might
therefore be expected that the metformin-treated GDM women in NRCTs had better
glycaemic control than those in RCTs. We would suggest that future studies should
consider these facts when designing the study.
2.4.2 Metformin versus Glibenclamide
Based on three randomized studies, our meta-analysis revealed that metformin and
glyburide were likely to have similar effectiveness on GDM outcomes. Although
glyburide was found to achieve lower fasting glycemic targets than metformin, there
was no difference in important clinical outcomes. On the other hand, metformin-
treated GDM mothers were likely to have infants with less neonatal hypoglycaemic
risk, lower birth weight and decreased macrosomia than glyburide-treated mothers.
These might be possibly related to placental transfer to metformin which is accessible
for intrauterine babies and might help them with better handling of hyperglycemic
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blood from maternal placental transfer. However, there is possibility of increased non-
elective cesarean section rates with metformin, although the number observed was not
large enough to draw a valid conclusion. On the other hand, the outcome measure,
cesarean section, is criticized to be rather subjective as it could differ with individual
caregivers and healthcare settings. In fact, the study was open label study and was
carried out in US where glibenclamide was an approved drug in GDM whereas
metformin was still in development stage. Thus, it is likely that the clinicians might
scrutinize over metformin cases that might increase the increased observation events
of non-reassuring fetuses.
We did not find any difference in the treatment failure rate which was found to be one
of the factors favoring glibenclamide over metformin in GDM management. The dose
of insulin after treatment failure, reported only by Silva et al, was not found to be any
difference. In fact, if metformin was given to GDM with moderate hyperglycemia and
certain ethnic groups like African American, the failure rate was found to be zero
(Moore 2010, George 2015). Thus, it would be of great advantage if predictors of
metformin responders are identified and metformin is given accordingly.
3.4.3 Metformin versus Diet
Even though baseline characters of metformin treated mothers were found to be higher
insulin resistance than those with diet treatment alone, metformin could significantly
reduce the risk of small for gestational age than diet monotherapy. Thus, women who
are likely to develop foetal growth restriction in late pregnancy in GDM, metformin
could be initiated early. Moreover, there is possibility that one trial used metformin at
the diagnosis of GDM and they found that early use of metformin could reduce the
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dose of insulin requirement without any increase in the risk of adverse pregnancy
outcomes over non-metformin group which composed of women on diet or insulin
treatment (Gandhi et al 2012). On the contrary, one RCT has reported that women who
failed metformin needed much higher dose of insulin to meet glycemic targets than
those who were already on insulin (Ijas 2010). Hence, if GDM who are at risk of
metformin failure are able to be detected early in pregnancy, they can be initiated with
insulin medication and thus could save them from unnecessary exposure to higher dose
of insulin.
3.4.4 Predictors of metformin failure
All the included studies except Moore2007 study included participants who
experienced metformin failure during pregnancy, ranging from 6.7% to 46.5%.
Predictors of metformin failure in type 2 diabetes, conducted by Brown et al, reported
that higher HbA1c, longer history of diabetes and younger age of onset before therapy,
were proportionately associated with higher rate of metformin failure (Brown et al
2010). In line with this finding in type 2 diabetes, Goh 2011 study, Ijäs 2010 studyand
Corbould 2013 study have all reported that metformin failure women were
characterized by higher pre-pregnancy BMI and higher glucose levels at diagnosis,
indicating higher insulin resistance.
The possible explanation to high metformin failure rate in the MiG trial was suggested
by Denice S Feig where he stated that it might be related to greater percentage of high
risk ethnic group (Feig 2008). Similarly, in recent study conducted by Farrar et al, it
was suggested that South Asians were more likely to have lower threshold for insulin
resistance than the White (Ferrar et al 2015). In our review, the highest failure rates of
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metformin was observed in the studies of Rowan et al and Goh et al with 46.3% and
46.5% respectively. In both studies, the majority (>50%) of samples were high risk
ethnicity of gestational diabetes in contrast to <25% of high risk ethnicity in studies
done by Balani 2009 study and Gandhi 2012 study, which had low failure rates of
10.2% and 21% respectively. A relatively high failure rate, 34.7%, was observed in
the study of Moore 2010 study which was mainly composed of Hispanic population.
At the same time, study reported by Gandhi et al with almost 60% Caucasian in each
group found significant difference in proportion of women with metformin failure
where only 21% of treatment failure were observed. Even in high risk ethnic
population, we have found that their contribution to the percentage of treatment failure
could differ. All in all, we speculated that ethnicity might be a modifiable factor of the
potency of metformin in gestational diabetes mothers and it is possible that the failure
of metformin may be linked to certain characters of ethnicity.
3.4.5 Metformin Success vs Metformin Failure
The finding of increased proportion of respiratory distress might be probably
associated with higher insulin resistance in infants of women with treatment failure.
Generally, metformin failure women had increased adverse outcomes than those with
metformin alone even though it is still uncertain whether the risk was attributable to
impact of either insulin addition or underlying hyperinsulinaemia. In fact, the average
dose of insulin after metformin failure reported by 2 studies was around 7-8 units
which was significantly higher than average dose of insulin treatment alone (Gandhi
et al 2012; Ijas et al 2010).
3.4.6 Limitation of this review
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Regarding effect of metformin compared to insulin, some outcome estimates, like
LGA, maternal FPG, SGA and gestational age at birth, were varied between RCT and
NRCT results. We should be sceptical in interpretation of evidence from
methodologically poor observational studies. In only one out of 6 NRCT (Tertti et al
2008), age and BMI were reported to be matched. Neither of other studies considered
any confounders in both design and analysis stages. In addition, the representativeness
of samples could not be justified as the participants were allocated according to their
preference. Although assignment was performed depending on obstetric units in the
Rai study, they were managed with different consultants and there was unequal
distribution of type 2 diabetes in metformin and insulin arms. Moreover, there were
certain cutoff glucose levels for insulin treatment in 2 studies, leading to increased
number of more severe GDM in insulin arm. Because of the fact that the robustness of
evidence of systematic review is determined by the quality of the included studies, the
reliability of this review could be questioned. However, in some cases, the results of
NRCT could validate RCT evidence.
At the same time, among RCT, only 4 trials had enough statistical power to correctly
investigate the primary outcome. Therefore, methodological limitations of these
studies must be taken into account when drawing conclusions. Furthermore, as in
NRCTs, lack of blinding of outcome assessors might be a major threat to internal
validity. However, most of the outcomes were objective and were defined explicitly.
On the other hand, because of a wide range of clinically related operative definitions,
the generalizability of effect estimates (e.g. neonatal hypoglycemia) could be
upgraded. Likewise, inclusion of diverse ethnic groups across different countries with
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relatively interchangeable identification criteria and fairly similar intervention
implementation could give further credence to the applicability of the findings.
Specific issues that we considered when performing this analysis included different
diagnostic cut-off values, target glucose levels, intervention strategies, primary
outcomes considered and definition of outcomes (eg: macrosomia and LGA), some of
which differed from study to study. In order to mitigate this, a separate meta-analysis
was performed on RCTs and NRCTs. Moreover, the NRCTs had high risk of bias and
therefore only outcomes where RCTs alone or RCTs were in agreement with NRCTs
have been reported as positive findings.
As regards with conclusions of metformin to glyburide, caution should be taken
because of limited number of included studies. However, there were no significant
differences in the study quality, design and methods and thus, the combination of these
two trials using fixed effect meta-analysis did not result in any conflict findings in-
between.
Although we did thorough literature search without limiting language and date, there
might be a possibility of publication bias. However, small unpublished studies would
probably not alter our conclusions as there was relative similarity in concluded
findings in between two included studies. A funnel plot was not adopted as small-
study-effect might give a misleading result towards publication bias.
3.4.7 Clinical implications
The clinical aim of GDM management is to have the glycaemic levels within target
limits which are reported to be associated with reduction in adverse outcomes of GDM.
As metformin can have better and faster postprandial glycaemic control than insulin,
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metformin could be a more favourable option for GDM diagnosed with postprandial
hyperglycemia. However, there is risk of prematurity with metformin therapy. On the
other hand, among studies with moderate hyperglycemia or with supplementary
insulin for fasting hyperglycaemia at metformin initiation or with exclusion of
metformin failure group from metformin analysis group, prematurity risk was higher
in insulin group. Thus, it should be noted that GDM with high fasting hyperglycaemia,
insulin or glibenclamide should be given or initiated earlier together with metformin.
The glycaemic levels at which additional non-metformin therapy should be added to
those risk of metformin failure is not yet determined.
Moreover, compared to insulin, metformin can significantly lower the incidence of
maternal weight gain. Thus, among GDM with increased BMI or obese mothers,
metformin could be a preferable option to offer. Furthermore, among available GDM
medication, metformin is the best anti-diabetic agent on the risk of neonatal
hypoglycaemia. This might suggest that metformin can have better reduction in
hyperglycemia of both mothers and intrauterine babies. In addition to positive effects
on immediate outcomes, the implementation of low-cost, highly efficient metformin
as a first-line measure has potential to address the increasing prevalence of GDM and
the rising trend of metabolic diseases in the long run. Thus, every GDM mother, who
does not have any contraindication to metformin, should receive metformin with
appropriate add-on therapy. For this, the treatment algorithm for metformin in GDM
is necessary to develop.
At the same time, the current evidence is still limited and in certain outcomes, the
benefits of metformin have not been well-established. Therefore, methodologically
robust further studies with proper intervention strategy are still necessary. Moreover,
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although the data on outcomes beyond pregnancy have been reported, long-term safety
of metformin is still needed to be evaluated.
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CHAPTER 3
OVERVIEW OF CLINICAL STUDIES
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This chapter describes the characteristics of all 299 GDM women included in this
thesis which were sub-divided to be used in 2 different clinical chapters namely:
1. Chapter 4 - Predictors of metformin failure in GDM women (STUDY 2)
2. Chapter 5 – Maternal Vitamin B12, Folates and Homocysteine as Determinants
of Glycaemia and Birth weight in GDM (STUDY 3)
3.1.Setting
This retrospective review included all consecutive pregnant women with newly
diagnosed GDM, according to NICE criteria, attending a GDM clinic in a District
General Hospital (George Eliot Hospital, Nuneaton), United Kingdom between
January 2009 to December 2012. If the woman had more than one pregnancy during
the period, each pregnancy was considered as a separate case. The inclusion and
exclusion criteria applied are as follows:
3.2. Study Population
Inclusion criteria
1. Age 18-45 years
2. Singleton pregnancy delivered at GEH hospital
3. GDM newly diagnosed by OGTT
Exclusion criteria
1. Pre-gestational diabetes mellitus (type 1 or 2)
2. History of preeclampsia
3. Medical conditions contraindicated to metformin (like impaired liver and
renal function)
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4. Women with multiple pregnancies
In this hospital, all high-risk pregnant women (BMI ≥ 30 kg/m2, previous GDM, 
previous unexplained still birth or baby > 4.5 kg, first degree relative with diabetes,
ethnic minority group (South Asians, Middle-Eastern, Afro-Caribbean)) attending
antenatal clinic were given 75-grams oral glucose tolerance test (OGTT) between the
gestational weeks of 24 and 28 if they were not pre-diabetic. GDM was diagnosed if
the fasting glucose of ≥6 mmol/l or/and 2hr postprandial glucose of ≥7.8 mmol/l as 
per modified WHO 1999 criteria. The GDM clinic was run over this study period,
adhering similar GDM management guidelines. All the newly identified GDM were
taught by a specialist dietitian and were advised to do home glucose monitoring up to
7 times a day. Capillary blood glucose levels were self-monitored by gluco-meter
which were checked regularly and HbA1c levels were accessed every month. The
target fasting glucose levels were 4-6 mmol/l and 1hr post meals of < 7.8 mmol/l. All
new GDM women were firstly managed with lifestyle modification and if necessary,
medication was offered. If 10-20% of either fasting or 2hr postprandial glucose were
out of target, the treatment was escalated. The medication used were insulin
(intermediate-acting insulin/humulin at night and/or rapid acting insulin with meals)
and/or metformin. The allocation of treatment was done by patients agreement upon
the use of metformin after consultation. For most women who failed diet and lifestyle
treatment, metformin was limited unless rapid control of blood glucose levels were
required. The metformin-treated GDM were reviewed after 1 week and titrated against
daily blood glucose to the maximum of 2000 mg a day. Metformin was initiated with
500mg once daily at bedtime and increased against glycemic levels up to 2000mg/day.
If they failed to achieve target glucose with metformin alone or if they required met,
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appropriate insulin was added. And, these metformin-treated GDM women with on
top insulin were defined as metformin failure group. Metformin was stopped if there
were side-effects.
3.3. Data collection
The data set from PEER study group who collected complete data on pregnancy
women from booking to delivery of babies was obtained (Age, BMI, weight in
kilograms, parity, ethnicity, smoking status, socioeconomic status, birth weight,
gestational age at delivery, mode of delivery, shoulder dystocia, preeclampsia,
neonatal intensive care admission). The data set on glucose levels at OGTT during
pregnancy and postpartum was obtained from the GEH laboratory. The unique ID was
created for each eligible GDM and was matched against these 2 data and combined.
The missing data were then completed by manual data collection using pre-defined
data collection sheet (appendix 9.2.1). There were very few data on the availability of
maternal hypoglycaemia and thus they were excluded in analysis. Data on glycated
haemoglobin (HbA1c), vitamin B12, folate and homocystine levels were also recorded
from electronic clinical investigation results manually. Then, the data were entered
into excel sheet with respective ID. Finally, all the data were combined in one excel
spreadsheet.
3.4. Statistical analysis
All statistical analysis were performed by using SPSS version 22.0 (SPSS Inc.,
Chicago, IL, USA). Non-normally distributed data were log-transformed and
appropriate statistical tests were applied. ‘p’ value of <0.05 were considered as
statically significant. The detailed analysis for each chapter were described separately
in relevant chapter.
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3.5. Data Presentation
The categorical variables were described as frequency and percentage and compared
using chi-squared test. Based on distribution of data, the continuous variables were
presented as mean±standard deviation (normal distribution) and median and
interquartile range (non-normal distribution).
3.6. Definition of Clinical Terms used
1) Macrosomia - ≥4000 grams 
2) Low birth weight (LBW) - <2500 grams
3) Centiles – calculated using Gestational Related Optimal Weight(GROW)
centile chart(adjusting for gestational age, gender, maternal BMI, ethnicity and
parity)
4) Large for gestational age(LGA) ->90%
5) Small for gestational age(SGA) - <10%
6) GA – Gestational age
7) OGTT – Oral Glucose Tolerance test
8) MOD – Mode of delivery
9) NSVD – Normal spontaneous vaginal delivery
10) HbA1c – Glycated haemoglobin
11) Premature - <37 weeks
12) Postdate - >42 weeks
149
13) HbA1c control
1)Good (decrease in HbA1c)
2)Neutral (no change)
3)Not Good (increase in HbA1c)
14) Vitamin B12 (pmol/L)
1)low - <150 pmol/L
2)normal - ≥150pmol/L 
15) Folate (ug/L)
1)low - <3.8 ug/L
2)normal – 3.8-16 ug/L
3)high - ≥ 16 ug/L 
16) Homocysteine (umol/L)
1)normal - <14umol/L
2)high - ≥14umol/L
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Table 3.1 Characteristics of 299 GDM women
Characters(n) All cases (299) Diet(31) Diet+Insulin(46) Diet+Metformin
(62)
Diet+Metformin+
Insulin(89)
Unknown(71)
Age(years)(299) 31(27, 35) 29(25, 32)(31) 31.5(27, 36.3)(46) 30(25, 34)(62) 32(29, 36)(89) 30(27, 34)(71)
Ethnicity(262)
1) European
2)South Asian
3)Others
Unknown
226(75.6)
23(7.7)
13(4.3)
37(12.4)
26(83.9)
2(6.5)
1(3.2)
2(6.5)
35(76.1)
3(6.5)
2(4.3)
6(13.1)
47(75.8)
7(11.3)
1(1.6)
7(11.3)
70(78.7)
5(5.6)
5(5.6)
9(10.1)
48(67.6)
6(8.5)
4(5.6)
13(18.3)
Parity(254)
1) Nullip
2) Multip(≥2) 
3) Neither
Unknown
96(32.1)
64(21.4)
94(31.4)
45(15.1)
11(35.5)
6(19.4)
11(35.5)
3(9.7)
16(34.8)
10(21.7)
12(26.1)
8(17.4)
21(33.9)
11(17.7)
22(35.5)
8(12.9)
28(31.5)
24(27)
25(28.1)
12(13.5)
20(28.2)
13(18.3)
24(33.8)
14(19.7)
BMI(254)
1)<30
2)≥30 
Unknown
30.5(26.0,36.3)
117(39.1)
137(45.8)
45(15.1)
27.5(22.8,32.8)
17(54.8)
11(35.5)
3(9.7)
30.1(27.2,33.6)
18(39.1)
20(43.5)
8(17.4)
31.6(27.5,38.0)
20(32.3)
35(56.5)
7(11.3)
31.3(27.6,38.2)
33(37.1)
45(50.6)
11(12.4)
29.3(24.0,36.7)
29(40.8)
22(36.6)
16(22.5)
Smoking
Unknown
30(10)
76(25.4)
2(6.5)
7(22.6)
5(10.9)
11(23.9)
6(9.7)
15(24.2)
8(9.0)
18(20.2)
9(12.7)
25(35.2)
Weight(223)(kg)
Unknown
80(68, 97)
76(25.4)
73(60.3, 91) (24)
7(22.6)
80(73, 91)(35)
11(23.9)
84(75, 99)(47)
15(24.2)
84(70, 107)(71)
18(20.2)
75(62, 94)(46)
25(35.2)
Treatment type
1)Diet only
2)Diet+Insulin
3)Diet+Metformin
4)Diet+Metformin+Insulin
Unknown
31(10.4)
46(15.4)
62(20.7)
89(29.8)
71(23.7)
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Table 3.1 Characteristics of 299 GDM women
Characters(n) All cases
(299)
Diet(31) Diet+Insulin
(46)
Diet+Metformin
(62)
Diet+Metformin+
Insulin(89)
Unknown(71)
OGTT (mmol/L)
1)fasting(299)
Missed
2)2hr postprandial(294)
Unknown
4.9(4.5, 5.5)
0
8.5(8, 9.4)
5(1.7)
4.5(4.2,5)
0
8.1(7.8, 8.8)
0
5(4.6, 6.1)
0
4.6(4.4, 5)
1(2.2)
4.6(4.4, 5)
0
8.4(8,9.1)
0
5.2(4.6, 5.8)
0
8.6(8.1, 9.4)
2(2.2)
4.8(4.3, 5.7)
0
8.5(8, 10.3)
2(2.8)
GA at OGTT(weeks)(223)
Unknown
26+6(26,29+6)
76(25.4)
30+3(26+5,34)
7(22.6)
27+5(26,31+6)
11(23.9)
26+5(26+1,28+1)
15(24.2)
26+3(22,27+4)
18(20.2)
27+5(26+1,31+6)
25(35.2)
Average HbA1c(220)(%)
Unknown
5.5(5.3,5.7)
79(26.4)
5.3(5.0,5.5)
14(45.2)
5.6(5.5,5.9)
14(30.4)
5.4(5.2,5.6)
11(17.7)
5.5(5.2,5.7)
12(13.5)
5.6(5.3,5.9)
28(39.4)
HbA1c at OGTT(298)(%)
Unknown
5.5(5.2, 5.7)
1(0.3)
5.4(5.1,5.5)(31)
0
5.6(5.4,5.8)(46)
0
5.3(5.2,5.6)(62)
0
5.5(5.3,5.8)(88)
1
5.5(5.2,5.9)(71)
0
Average HbA1c after
treatment (221)(%)
Unknown
5.5(5.2, 5.8)
78(26.1)
5.3(5,5.6)
14(45.2)
5.7(5.5,6)
14(30.4)
5.4(5.1,5.7)
11(17.7)
5.5(5.2,5.7)
11(12.4)
5.5(5.1,5.9)
28(39.4)
HbA1c control(220)
1)Good
2)Neutral
3)Not Good
Unknown
105(35.1)
24(8)
91(30.4)
79(26.4)
7(22.6)
3(9.7)
7(22.6)
14(45.2)
8(17.4)
3(6.5)
21(45.7)
14(30.4)
24(38.7)
4(6.5)
23(37.1)
11(17.7)
45(50.6)
8(9)
24(27)
12(13.5)
21(29.6)
6(8.5)
16(22.5)
28(39.4)
PIH
PE
Unknown
7(2.3)
3(1)
76(25.4)
0
0
7(22.6)
1(2.2)
0
11(23.9)
2(3.2)
0
15(24.2)
2(2.2)
3(3.4)
18(20.2)
2(2.8)
0
25(35.2)
Postnatal OGTT(mmol/L)
1)Fasting (115)
Missed
2)2hrpostprandial(115)
Unknown
4.9(4.5, 5.2)
184(61.5)
5.4(4.6, 6.4)
184(61.5)
4.4(4.3,4.9)(11)
20(64.5)
5.4(5.1, 5.5)(11)
20(64.5)
5(4.6, 5.4)(17)
29(63)
5.9(5.2,7.3)(17)
29(63)
4.8(4.4, 5.3)(25)
37(59.7)
5.4(4.6, 6.4)(25)
37(59.7)
4.9(4.7,5.2)(39)
50(56.2)
5.3(4.5,6.2)(39)
50(56.2)
5.1(4.5, 5.7)(23)
48(67.6)
5.7(4.7,7)(23)
48(67.6)
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Table 3.1 Characteristics of 299 GDM women
Characters(n) All cases (299) Diet(31) Diet+Insulin(46) Diet+Metformin(62) Diet+Metformin+
Insulin(89)
Unknown(71)
Birthweight(277)(grams)
1) Macrosomia
2) LBW
3) Normal
Unknown
3210(2950,3560)
18(6)
18(6)
241(80.6)
22(7.4)
3240(2840,3550)
2(6.5)
3(9.7)
22(71.0)
4(12.9)
3225(3042.5,3460)
0
2(4.3)
42(91.3)
2(4.3)
3190(2928.8,3542.5)
2(3.2)
3(4.8)
51(82.3)
6(9.7)
3260(2965,3618)
5(5.6)
6(6.7)
75(84.3)
3(3.4)
3180(2885,3580)
9(12.7)
4(5.6)
51(71.8)
7(9.9)
GA at delivery(weeks)(283)
1)premature
2)normal
3)postdate
Unknown
38+3(38+0,38+6)
34(11.4)
248(82.9)
1(0.3)
16(5.4)
38+6(38+0,39+4)
2(6.5)
27(87.1)
0
2(6.5)
38+3(38+0,38+6)
4(8.7)
40(87)
0
2(4.3)
38+3(38+0,38+6)
5(8.1)
52(83.9)
0
5(8.1)
38+1(37+1,38+4)
20(22.5)
66(74.2)
0
3(3.4)
38+4(38+0,39+4)
3(4.2)
63(88.7)
1(1.4)
4(5.6)
Centiles (272)
1)SGA
2)Normal
3)LGA
Unknown
42.8(17.0,74.7)
41(13.7)
203(67.9)
28(9.4)
27(9)
6(19.4)
19(61.3)
2(6.5)
4(12.9)
4(8.7)
36(78.3)
3(6.5)
3(6.5)
8(12.9)
43(69.4)
3(4.8)
8(12.9)
10(11.2)
63(70.8)
12(13.5)
4(4.5)
13(18.3)
42(59.2)
8(11.3)
8(11.3)
MOD(222)
1)NSVD
2)Assisted
3)CS
i)Emergency
ii)Elective
iii)Unknown
Unknown
122(40.8)
21(7)
79(26.4)
33(41.8)
45(57)
1(1.3)
77(25.8)
13(41.9)
5(16.1)
6(19.4)
3(50)
3(50)
0
7(22.6)
23(50)
3(6.5)
9(19.6)
3(33.3)
6(66.7)
0
11(23.9)
29(46.8)
5(8.1)
12(19.4)
4(33.3)
8(66.7)
0
16(25.8)
35(39.3)
7(7.9)
29(32.6)
12(41.4)
16(55.2)
1(3.4)
18(20.2)
22(31)
1(1.4)
23(32.4)
11(47.8)
12(52.2)
0
25(35.2)
NICU admission(195)
Unknown
1(0.3)
104(34.8)
0
9(29)
0
17(37)
1(1.6)
20(32.2)
0
24(27)
0
34(47.9)
Shoulder dystocia(153)
Unknown
3(1)
146(48.8)
0
17(54.8)
0
25(54.3)
2(3.2)
28(45.2)
1(1.1)
33(37.1)
0
43(60.6)
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Table 3.1 Characteristics of 299 GDM women
Characters(n) All cases (299) Diet(31) Diet+Insulin(46) Diet+Metformin
(62)
Diet+Metformin+
Insulin (89)
Unknown(71)
GA at B12(weeks)(174)
Unknown
28+1(25+6,30+5)
125(41.8)
30+1(27+5,34+1)
18(58.1)
29+1(27,32+1)
21(45.7)
28(25+6,30+6)
20(32.3)
27+2(21+2,29+5)
21(23.6)
28+5(26+7,33+4)
45(63.4)
Vitamin B12 (207)
pmol/L
1)low
2)normal
Unknown
165.3(136.5,212.5)
64(21.4)
143(47.8)
92(30.8)
187.5(136.5,218.4)
4(12.9)
11(35.5)
16(51.6)
169.7(134.3,212.5)
11(23.9)
16(34.8)
19(41.3)
156.8(132.8,214.9)
15(24.2)
35(56.5)
12(19.4)
163.8(134.7,201.5)
26(29.2)
55(61.8)
8(9)
170.9(144.7,215.1)
8(11.3)
26(36.6)
37(52.1)
Folate(188) ug/L
1)low
2)normal
3)high
Unknown
9.7(6.8, 13.4)
6(2)
150(50.2)
32(10.7)
111(37.1)
10.4(7.7,16.5)
2(6.5)
8(25.8)
4(12.9)
17(54.8)
9(6,15.6)
20(43.5)
6(13)
20(43.5)
10(5.5,13.4)
3(4.8)
36(58.1)
6(9.7)
17(27.4)
9.7(6.8,13.3)
1(1.1)
61(68.5)
12(13.5)
15(16.9)
9.8(7,13.2)
25(35.2)
4(5.6)
42(59.2)
Hcy(115) umol/l
1)Normal
2)High
Unknown
5.7(4.9, 7)
114(38.1)
1(0.3)
184(61.5)
5.2(5.8)
9(29)
22(71)
6(5,7)
12(26.1)
34(73.9)
6(4.75, 8)
30(48.4)
32(51.6)
5(4,7)
43(48.3)
1(1.1)
45(50.6)
5.5(4,7)
20(28.2)
51(71.8)
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CHAPTER 4
PREDICTORS OF METFORMIN FAILURE
IN GESTATIONAL DIABETES MELLITUS
(STUDY 2)
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4.1.Introduction
Based on our systematic review in earlier chapter, it is evident that metformin is clearly
shown to be superior to insulin in some pregnancy outcomes, whereas glyburide is
found to be inferior to metformin in GDM (Balsells et al 2015). Moreover, women
preferred metformin over insulin. However, there are up to 50% of metformin-treated
GDM that are at risk of requiring additional insulin for optimal glycaemic control
(referred as metformin failure). If these women are able to be identified at GDM
diagnosis, it will enable healthcare professionals to target these women with much
more stringent glycaemic control (i.e. metformin given together with appropriate
insulin). Consequently, the better glycaemic control can reduce the related adverse
outcomes of GDM, while the effect of metformin on less maternal weight gain might
help pregnancy outcomes. Hence, it could result in overall improvement in GDM
management.
The studies on the maternal characters in relation to metformin failure are still very
limited. Some studies have reported that metformin-treated women with GDM who
needed insulin have higher BMI and are possibly more insulin resistant (higher fasting
& postprandial glucose and fructosamine at diagnosis)(Tertti et al 2013, Ijas et al 2010,
Goh et al 2011. Spaulonci et al 2013). One small study reported that GDM with fasting
glucose at OGTT ≤5.2 mmol/l can achieve optimal glycaemic levels with metformin 
alone (Corbould et al 2013). Moreover, it could be assumed that being European
ethnicity have lower risk of metformin failure than Hispanic or South Asians (Moore
et al 2010; Rowan et al 2008). Recently, one small study on predictors of metformin
failure has suggested that if fasting glucose levels at OGTT is greater than 5.2 mmol/L,
the response to metformin is decreased by two-thirds (Corbould et al 2013). Thus, it
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is possible that metformin response is reduced in GDM women with increased insulin
resistance at enrolment.
Being slow-onset in action, it can be hypothesized that if metformin is given as soon
as after GDM is diagnosed, the response rate might be better and its benefit on maternal
weight gain could be enhanced. In addition, one cohort study which compared
metformin to diet therapy in GDM has reported that metformin has a beneficial effect
on the rates of macrosomia and small-gestational-age (SGA) despite inclusion of
increased number of more hyperglycemic and obese women in metformin group
(Balani et al 2012). This might indicate that metformin initiation at diagnosis could
improve GDM outcomes. Furthermore, it would also be helpful for healthcare
professionals in remote areas to identify the GDM cases which might need referral to
tertiary centre for insulin treatment. This could further save healthcare resources.
Clearly, it is necessary to establish a GDM treatment algorithm with metformin.
Therefore, we carried out a study to identify maternal characters that can predict
metformin failure in GDM.
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4.2.Methods
4.2.1 Study population and data collection
All the GDM who received metformin in our centre during the study period were
eligible. They were included if they received metformin for at least 2 weeks, continued
metformin until delivery and delivered a single live baby at this hospital. GDM
diagnosis and management has already described in chapter 3.
In this centre, metformin was given as an alternative option to GDM women who failed
diet and lifestyle treatment. Metformin was offered as first-line unless rapid control of
blood glucose levels was required. The metformin-treated GDM were reviewed after
1 week and titrated against daily blood glucose to the maximum of 2000 mg a day. If
they failed to achieve target glucose with metformin alone, either intermediate-acting
insulin (humulin) at night or rapid-acting insulin with meals were added accordingly.
Metformin was stopped if there were side-effects.
Demographic characters and all pregnancy and birth data including HbA1c throughout
pregnancies were recorded. The outcome variables considered were: birth weight
(BWt), macrosomia (BWt≥4000grams), low birth weight (LBW) (BWt<2500 grams), 
centiles using GROW (Gestation related optimal weight) chart, Large-for-gestational-
age(LGA)(>90centiles), SGA(<10centiles), gestational age at delivery,
prematurity(<37 weeks), APGAR at 1 and 5 minutes, Mode of delivery, Shoulder
dystocia, Preeclampsia, NICU admission rates, Total duration of metformin, postnatal
fasting and 2hr postprandial and HbA1c during treatment. Metformin failure group
was defined as metformin-treated GDM women with add-on insulin therapy, whereas
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metformin monotherapy group was defined as GDM women with metformin alone
treatment.
4.2.2 Statistical analysis
Statistical analysis were performed using SPSS programme version 22.0 (SPSS Inc.,
Chicago, IL, USA). Skewed data were log-transformed and analysed as below.
Continuous data were described in mean±standard deviation (SD) and categorical data
were described in number (n) and percentages(%). P value of 0.05 was considered as
statistically significant.
4.2.2.1 Question being addressed
1. What are the maternal characters associated with metformin failure?
Statistical model applied to compare the maternal characters between
metformin failure and metformin monotherapy groups:
i) Log-transformed data were used in independent ‘t’ tests to examine the
difference in maternal characters (Age, BMI, fating glucose at OGTT,
2hr postprandial glucose at OGTT, HbA1c at OGTT, GA at OGTT, GA
at metformin initiation)
ii) Chi-squared tests to examine the difference in the percentages of
ethnicity and smoking status
2. Are pregnancy outcomes of GDM women with metformin failure comparable
to those with metformin monotherapy?
Statistical model applied to compare the pregnancy outcomes between
metformin failure GDM group and metformin monotherapy GDM group
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i) Log-transformed data were used in independent ‘t’ tests to examine the
difference in pregnancy outcomes (birth weight, centiles, gestational
age at delivery, APGAR scores at 1 and 5 minutes, duration of
metformin, average HbA1c during treatment, fasting glucose at
postnatal OGTT and 2hr postprandial glucose at postnatal OGTT)
ii) Chi-squared tests to examine the difference in the percentages of babies
with macrosomia, , LBW, LGA, SGA and prematurity, Caesarean
section rates (Elective and Emergency), Shoulder dystocia and NICU
admission rates
3. What is the strongest maternal character to predict metformin failure?
Statistical model applied:
Receiver-Operator Curve (ROC) to examine the areas under curve (AUC) of
the four significant maternal characters identified in question (1) which are in
match with previous studies (age, fasting glucose at OGTT, HbA1c at OGTT,
GA at dietary failure) to predict metformin failure and to establish the value
with best sensitivity and specificity
4. What is the best criterion to identify GDM women with high risk of metformin
failure in current study?
Statistical model applied:
Regression model to determine the sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV) of the maternal characters
that can best identify the GDM with metformin failure
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5. Are there any difference in the outcomes between metformin failure GDM and
insulin treated GDM women?
Statistical model applied to compare the pregnancy outcomes between
metformin failure GDM group and insulin treated GDM group
i) Log-transformed data were used in independent ‘t’ tests to examine the
differences in pregnancy outcomes (continuous variable mentioned in
item (1))
ii) Chi-squared tests to examine the difference in the percentages of
categorical outcome variable stated in item (1))
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4.3.Results
Figure 4.1: An overview of participants included in the study
4.3.1 Characteristics of GDM women included
During the study period, there were 299 GDM identified, data on 71 women were
failed to record in the chart. Out of 228 GDM women with available treatment data,
197(86.2%) GDM women on diet needed additive therapy. 151(66.2%) received
metformin as first-line. Among metformin-treated GDM women, three were multiple
pregnancies and 10 stopped metformin before delivery for GI intolerance and changed
to insulin, thus, they were excluded from the analysis. Multiple pregnancies were
excluded from both mother and infant outcomes because hormonal disturbances due
to increased placental size in multiple pregnancies can increase the insulin resistance
of mothers and also they can also interfere with infant birth size. Of the included 138
metformin-treated GDM, 77(55.8%) needed supplementary insulin (metformin
failure). The starting dose of metformin was 500 mg od, the maximum dose was 2000
mg and the median dose at delivery was 1500mg.
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4.3.2 Metformin monotherapy vs Metformin Failure:
The maternal characters and outcomes of GDM on metformin monotherapy were
compared with metformin failure group.
4.3.2.1.Maternal baseline characteristics of GDM women with metformin
monotherapy and metformin failure
The baseline characteristics of GDM women between the metformin failure and
metformin success groups were compared in Table 4.1. There was no difference in
pre-pregnancy body mass index (BMI), parity, ethnicity, smoking status and 2hr
postprandial glucose at OGTT. The average age of GDM women with metformin
failure group were older (30.0 vs 32.4years, p<0.001). They were more likely to have
higher fasting glucose (4.83 vs 5.32mmol/L, p<0.05) and HbA1c at OGTT (5.38 vs
5.32%, p<0.05) as well as GA at OGTT (27 vs 25 weeks, p<0.05) and GA at dietary
failure/metformin initiation (29+3 vs 26+2 weeks) (Table 4.1).
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Table 4.1. Maternal baseline characteristics of GDM with metformin monotherapy vs
metformin failure
Characters Metformin
monotherapy
(61)
Mean±SD; n(%)
Metformin
Failure (77)
Mean±SD; n(%)
Mean
Difference/Odds
Ratio(95% CI)
Age(years) 30±5.9 32.4±5.5* -2.3(-4.22, -0.38)
BMI 32.4±7.1 32.7±7.1 -0.27(-2.83, 2.30)
Ethnicity
European
South Asian
46(75.4)
7(11.5)
60(77.9)
3(3.9)
Parity
Nullip
Multip(≥2) 
21(34.4)
11(18)
23(29.9)
22(28.6)
1.15(0.50, 2.66)
2.10(0.82, 5.36)
Smokers 6(9.8) 7(9.1) 0.87(0.27, 2.78)
GA at OGTT(weeks) 27±5+0 25±6+1 1.1(1.0, 1.19)days
OGTT
Fasting(mmol/l)
2hr postprandial(mmol/l)
4.83±0.66
8.59±1.18
5.4±0.92
8.87±1.5
-1.1(-1.15, -1.05)
-1.02(-1.07, 1.02)
HbA1c at OGTT(%) 5.4±0.33 5.6±0.48 -1.05(-1.07, -1.01)
GA at metformin
initiation (weeks)
29+3±4+0 26+2±6+4 1.12(1.1, 1.2)days
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4.3.2.2.Pregnancy outcomes of GDM women with metformin monotherapy and
metformin failure
The pregnancy outcomes were similar between the two groups except gestational age
at delivery (Table 4.2). HbA1c levels during treatment were available only in
84.1%(116) after OGTT/during metformin treatment of GDM women and the
glycemic levels were similar between the groups. Metformin failure mothers delivered
babies at earlier gestational age (-1.02 (95%CI -0.29, -1.01) days and the risk for
prematurity was significant (OR: 3.24(1.01, 10.39) (Table2). Weights and centiles of
babies born to GDM women with metformin failure were similar to those on
metformin alone therapy. There was no difference in the percentages of other neonatal
outcomes such as caesarean section rate, neonatal intensive care admission rate,
APGAR scores at 0min and 5min atdelivery and sholulder dystocia.
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Table 4.2: Pregnancy outcomes between metformin monotherapy and failure
NS = Not significant; SD=standard deviation; CI= confidence interval; n=number
Outcomes Metformin monotherapy
(61)Mean±SD; n(%)
Metformin Failure (77)
Mean±SD; n(%)
Mean Difference/Odds Ratio
(95% CI)
Birthweight(grams)
Macrosomia(≥4500 grams) 
LBW(<2500 grams)
3217.4±533.3
2(3.8)
3(5.7)
3265.8±496.8
4 (5.2)
5(6.5)
-48.39(-228.98, 132.2)
1.54(0.27, 8.74)
1.28(0.29, 5.62)
Centile
LGA(>90%)
SGA(<10%)
42.08±27.28
3(6.5)
7(11.5)
53.0±32.3
10(13)
8(10.4)
-10.87(-21.97, 0.23)
2.61(0.68, 10.06)
0.89(0.30, 2.66)
GA at delivery(weeks)
Prematurity(<37 weeks)
38+2±1+3
5(8.9)
37+5±1+5
15(19.5)
3.96(0.07, 7.86)days
3.24(1.01, 10.39)
APGAR at 1 minute
APGAR at 5 minutes
8.6±1.0
9.0±0.5
8.6±0.97
9.1±0.38
0.03(-0.34, 0.41)
-0.10(-0.27,0.06)
Caesarean section
Emergency
Elective
12(19.7)
4
8
26 (33.8)
11
14
2.05(0.89, 4.69)
Shoulder dystocia 2(5.9) 1(1.3) 0.96(0.88, 1.06)
Preeclampsia 0 3(3.9) 1.05(0.99, 1.11)
NICU admission 1(1.6) 0 0.98(0.93, 1.02)
HbA1c after OGTT(%) 5.45±0.42 5.5±0.46 -0.20(-0.34, -0.06)
Duration of metformin(days) 63.11±28.28 78.98±40.62 -15.87(-30.35, -1.38)
Postnatal OGTT
Fasting
2hr postprandial
n=25
4.8(4.4,5.3)
5.6±1.5
n=35
5.0±0.51
5.4±1.5
-0.21(-0.47, 0.05)
0.23(-0.57, 1.02)
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4.3.2.3.Predictors of metformin failure in GDM women
A number of different cut-off points for 4 significant maternal characters(age,
gestational age at OGTT, fasting at OGTT and HbA1c at OGTT) between metformin
failure and metformin monotherapy were accessed in receiver-operator curve (Figure
5.2) and the best predictive cut-off value was determined(Table 4.3 & 4.4). The best
stand-alone predictors for screening were fasting level at OGTT>4.8
mmol/l(sensitivity 69%, specificity 62%), age≥30 years at booking (sensitivity 71.4%, 
specificity 47.5%) and HbA1c at OGTT >5.5%(sensitivity 71.1%, specificity 52.5%).
If the fasting level of ≥5.1 mmol/l (IADPSG fasting criteria) was used, the positive 
predictive value of metformin failure was 78%. If the criteria 1) fasting glucose at
OGTT >4.8 mmol/l OR 2) fasting glucose at OGTT ≤4.8mmol/l & gestational age at 
dietary failure≤27+5 were used, the metformin failure was predicted with a sensitivity
of 87% and specificity of 64% and a positive predictive value of 74% and a negative
predictive value of 70%. We applied this criteria in our population (Table 4.5).
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Figure 4.2 Receiver Operator Curve (ROC) of potential predictors of metformin
failure
A) Fasting glucose levels at OGTT
B) Gestational age at OGTT
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Table 4.3: Area Under Curve (AUC) of maternal characters of metformin failure
Table 4.4: Characteristics Predictive of metformin failure
Table 4.5: Criteria for predicting metformin failure after dietary failure
GDM diagnosed when 1) fasting at OGTT≥4.8mmol/l or 2) fasting at OGTT<4.8 
mmol/l but gestational age at dietary failure was ≤27+5 weeks. p value for this table
calculated by x2 test is <0.05.
Maternal Predictors AUC(95% Confidence
Interval)
p value
1. Age at booking 60.4 (50.8-69.9) 0.037
2. GA at dietary failure 32.6 (22.5-42.7) 0.002
3. Fasting level at OGTT 69.4 (60.7 - 78.2) <0.001
4. HbA1c at OGTT 62.8(53.8-72.2) 0.01
Criteria Sensitivity Specificity PPV NPV
1. Age≥30 years at booking 71.4% 47.5% 63% 57%
2. Fasting OGTT > 4.8 mmol/l 69% 62% 71% 60%
3. Fasting OGTT
     ≥ 5.1 mmol/l(IADPSG 
fasting criteria)
     ≥ 5.6 mmol/L(NICE 2015  
Fasting criteria)
53%
35%
80%
87%
78%
77%
56%
50.1%
4. GA at dietary failure ≤ 27
+5
weeks
50% 80% 78% 54%
5. Fasting OGTT > 4.8 mmol/l,
     OR ≤ 4.8 & GA at dietary 
    failure ≤ 27
+5
weeks
88% 85% 63% 70%
6.HbA1c at OGTT >5.5% 7.1% 52.5% 65.1% 59.3%
Fulfils criteria
Metformin group Yes No Total
Metformin success
Metformin failure
Total
40
68
108
21
9
30
61
77
169
4.3.2.4.Pregnancy outcomes of GDM women with metformin plus insulin
(metformin failure) and insulin alone therapy
Compared to insulin alone therapy group, women in metformin plus insulin group
were diagnosed GDM at later gestational age by average of 25.5 days(Table 4.6 and
Table 4.7). However, their glycaemic control after diagnosis of GDM were lower than
those with insulin monotherapy. The other baseline characteristics including fasting
and postprandial glucose levels at OGTT were comparable between the two groups.
After adjusting for gestational age at OGTT , there was still significant difference in
average HbA1c levels between insulin alone and metformin failure groups (p<0.01).
There was no difference in pregnancy outcomes between women with metformin
failure and those with insulin alone therapy.
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Table 4.6. Baseline characteristics of GDM women between metformin failure and
insulin alone groups
Table 4.7. Pregnancy outcomes of GDM women between metformin failure and
insulin alone groups
NS = Not significant; SD=standard deviation; CI= confidence interval; n=number
Characters Metformin Failure
(77)
Mean±SD; n(%)
Insulin Alone
(45)
Mean±SD; n(%)
Mean Difference/Odds
Ratio(95% CI)/’p’value
Age(years) 32.4±5.5 31.7±5.9 0.64(-1.46,2.74)
BMI 32.7±7.1 30.9±6.1 1.81(-0.92,4.53)
Ethnicity
European
South Asian
60(77.9)
3(3.9)
35(77.8)
3(6.7)
NS
NS
Parity
Nullip
Multip(≥2) 
23(29.9)
22(28.6)
16(35.6)
10(22.2)
NS
NS
Smokers 7(9.1) 5(11.1) NS
GA at OGTT(weeks) 25+0±5+3 28+4±4+5 -25.5(-40.7,-10.32)days
OGTT
Fasting(mmol/l)
2hr postprandial(mmol/l)
5.4±0.92
8.87±1.5
5.3±1.0
9.2±1.64
0.02(-0.33,0.37)
-0.28(-0.86,0.29)
HbA1c at OGTT(%) 5.6±0.48 5.63±0.44 -0.28(-0.20,0.14)
Outcomes Metformin Failure
(77) Mean±SD; n(%)
Insulin Alone (45)
Mean±SD; n(%)
Mean Difference/Odds
Ratio (95% CI)/’p’ value
Birthweight(grams)
Macrosomia(≥4500 grams) 
LBW(<2500 grams)
3265.8±496.8
4 (5.2)
5(6.5)
3231.3±388.2
0(0)
2(4.4)
NS
NS
NS
Centile
LGA(>90%)
SGA(<10%)
53.0±32.3
10(13)
8(10.4)
46.1±27.4
3(6.7)
4(8.9)
6.88(-4.78, 18.53)
2.09(0.54, 8.03)
1.19(0.34, 4.19)
GA at delivery(weeks)
Prematurity(<37 weeks)
37+5±1+5
15(19.5)
38+2±1+0
3(6.7)
-4.24(-7.56,-0.92)days
3.39(0.92, 12.43)
APGAR at 1 minute
APGAR at 5 minutes
8.6±0.97
9.1±0.38
8.7±0.73
9.1±0.37
-0.09(-0.47,0.28)
-0.004(-0.16, 0.16)
Caesarean section
i)Emergency
ii)Elective
26 (33.8)
11(14.3)
14(18.2)
9 (20)
3(6.7)
6(13.3)
1.31(0.97, 1.78)
Shoulder dystocia 1(1.3) 0 NS
Preeclampsia 3(3.9) 0 NS
NICU admission 0 0 NS
HbA1c after OGTT (%) 5.5±0.46 5.8±0.42 -0.31(-0.50, -0.12)
Postnatal OGTT
Fasting
2hr postprandial
n=35
5.0±0.51
5.4±1.5
n=17
5.2±0.95
5.9±1.7
-0.20(-0.61, 0.20)
-0.49(-1.45, 0.46)
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4.4 Discussion
This chapter observed that over three-fourths (76.7%) of GDM women chose
metformin as their first-line therapy in our centre between 2009 and 2012. Over 80%
(127 out of 151) metformin-treated GDM women were diagnosed as GDM by higher
post-prandial hyperglycaemia alone. Metformin has been included in NICE GDM
guidelines as second choice (i.e. with women’s consent) since 2007. It is in accordance
with MiG trial which reported that women preferred metformin over insulin (76.6%
vs 12.6% respectively) (Rowan et al 2008). Moreover, meta-analyses from different
sources indicate that metformin benefit GDM more than insulin in terms of less
maternal weight gain and neonatal hypoglycaemia. Thus, it is reasonable to include
metformin as first-line agent in GDM management and advice every GDM to receive
metformin. However, there is increased risk of failure rate and prematurity with
metformin therapy. This leads us to answer the question: how should metformin be
given to benefit GDM the most?
In our study, over half of metformin-treated GDM women (55.8%) were required to
add appropriate insulin for optimal glycaemic control. The rates reported by previous
studies of metformin in gestational diabetes range from 0 to 46.6%, which is lower
than our study (Chapter 2: Table 2.3). This could be due to variatons in target pre-meal
and post-meal glucose levels. Tertti and his group have aimed for similar pre and post
meal glucose targets(<5.5 mmol/L and <7.8 mmol/L, respectively) as our study where
the failure rate was found to be 18% which is 3 times less than the failure rate in our
study. This might be due to differences in diagnostic glucose values where they used
fasting and 2hr postprandial values of less than 4.8 and 8.7 mmol/L respectively. Thus,
they might have much more patients started on metformin therapy, but with similar
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target as our study and thus, this might possibly have affected the failure rates.
Moreover, the failure rate in our study was almost doubled than the study done by
Corbould group (36%) (Corbould et al 2013). They used extended-release metformin,
whereas our GDM women received normal metformin. An RCT done by Ijas et al also
gave metformin retard to GDM women aiming at the target fasting levels of less than
5.3 mmol/L and reported 32% failure rates (Ijas et al 2010). Hence, it could be assumed
that the type of metformin drug should be taken into consideration if we would increase
the success rate of metformin monotherapy. It has been suggest that large proportion
of high-risk ethnic group can increase the percentages of failure rate (Chapter 2: Table
2.13). Almost 80% of GDM women in our study are Europeans but the failure rate was
much higher than those with similar proportion of European population (Tertti et al
2008; Niromanesh et al 2012). This also meant that the greater percentage of women
in our study were exposed to poor glycaemic period before insulin was added on. The
pregnancy outcomes in metformin failure group were poorer than metformin alone
group, e.g. higher percentages of prematurity in metformin failure arm. Yet, the
outcomes were favourable than insulin alone group and even showed better glycaemic
control in metformin failure group.
Our study has illustrated the characters of GDM women that could differentiate the
groups of patients on metformin who are likely to add supplementary insulin. GDM
women who were older at booking, who initiated metformin earlier, higher fasting
glucose and glycated haemoglobin at mid-pregnancy, required additional insulin. The
RCT study of Ijas and his group in metformin in GDM group have reported that higher
BMI at first antenatal visit and higher fasting glucose at OGTT are associated with
metformin failure group (Ijas et al 2010). Similarly, the prospective study with large
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sample sizes (n=465) done by Goh et al has found that raised levels of fasting and
postprandial glucose at OGTT, higher BMI and GDM women with history of chronic
hypertension are more likely to need supplementary insulin (Goh et al 2011). The
causal factors involved in metformin failure among type 2 diabetes are extensively
studied by Brown and his group and they have suggested that initiating metformin
soon after diagnosis can preserve beta cell function and along prolong the effectiveness
of metformin (Brown et al 2006). Historically, metformin is effective for decreasing
fasting hyperglycaemia because of its action on reduction of hepatic glucose output.
The high rates of metformin failure among GDM with higher fasting group in our
study could be due to the slower onset of action of metformin. If metformin is initiated
early in pregnancy, there may be lesser failure rate. Thus, if the treatment strategy of
metformin is developed based on the maternal characters at the time of diagnosis, it
can ensure consistent proper glycaemic control by addition of appropriate insulin to
those with high chance of treatment failure.
We noted that the three most significant predictors of metformin failure were fasting
glucose at OGTT, glycated haemoglobin at OGTT and age at booking. These three
indicators are clinically useful because the information are easily applicable for
healthcare providers who are keen to initiate metformin. With this criteria, GDM with
high risk of metformin failure are easily identified and can be better prepared for
insulin use. One small study reported that if fasting glucose was ≤5.2 mmol/l at OGTT, 
93% of GDM could be controlled on metformin alone where their target fasting
glucose was ≤5 mmol/l[71]. Likewise, we found that fasting glucose at OGTT for 
metformin failure >4.8 mmol/L detected with 69% sensitivity and 62% specificity.
Moreover, we also reported stand-alone criteria with HbA1c at OGTT (>5.5%) and
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age (≥30 years) which could be the best alternative for fasting glucose at OGTT at its 
convenience. We also established the best criteria for metformin failure which could
provide the maximum sensitivity over metformin failure with minimal effect on
specificity. The criteria were as follows: 1) GDM whose fasting glucose was ≥4.8 
mmol/l at OGTT or 2) if fasting glucose was<4.8 mmol/l but gestational age at dietary
failure was ≤27+5weeks. With this criteria, the sensitivity and specificity for metformin
failure in GDM were 87% and 64%, respectively. We believe that these indicators
have practical benefit as it is based on readily available and uncomplicated information
to health care professionals who are keen to start metformin. This protocol can enable
healthcare professionals at primary centre to treat GDM more confidently and can also
reduce the numbers of GDM referred to tertiary centre for insulin treatment. Moreover,
this may also allow reallocation of budgets dedicated for insulin care to other important
areas such as dietary and lifestyle education for these GDM women.
In the near future, the prevalence of GDM will be tripled if IADPSG criteria is
accepted widely (Liao et al 2014). We found that if those GDM identified by new
IADPSG fasting glucose criterion which is ≥5.1mmol/l are given metformin, almost 
80% of them are like to develop metformin failure. Likewise, the new 2015 NICE
criterion (fasting ≥5.6mmol/L) which have identified similar prevalence of GDM as 
IADPSG and found the same positive predictive power for failure rate with metformin.
This implies that for these newly identified GDM, increased risk of metformin failure
could be expected. Being a convenient and better alternative to insulin, the use of
metformin should not be restricted; but rather, for these particular GDM with high risk
of failure, we should carefully monitor their glycaemic levels and educate them early
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about the risk of metformin failure. Alternatively, addition of insulin to those with high
chance of metformin failure could avoid unnecessary risky titration period.
Rowan and her group have found the increased risk of prematurity metformin
treatment than insulin with the odds of 1.60 (95% confidence interval: 1.02 to 2.52),
although they did not state the reason behind. We found that increased risk of
prematurity among metformin failure than metformin alone groups (20.3% vs 8.9%).
It could be possibly related to 1) gastrointestinal side-effects of metformin which
mimic labour pain leading to delivery or 2) longer duration of suboptimal glycaemic
control during escalation of metformin, thereby, promoting pre-eclampsia or similar
adverse pregnancy outcomes necessitating immediate labour or 3) alteration of
calcium metabolism in the gut, resulting in disturbance in uterine contractility (Rowan
et al 2010; Bauman et al 200; Durnwald et al 2011). Previously, metformin failure in
GDM population was studied by Corbould et al group where they did not find any
relationship between metformin non-responders/failure groups and prematurity
(Corbould et al 2013). The probable reason for differences could be that all the
metformin failed GDM women in Corbould group study were switched to insulin
treatment and they defined this group as metformin non-responders, whereas the
failure group in our study are those with addition of insulin on top of metformin. This
finding was controversial as this study included only 25 metformin users and may not
have enough sufficient statistical power. Moreover, they did not report glycemic
control after treatment. We also have found similar glycated haemoglobin (HbA1c)
levels between these two groups and thus the prematurity rate was higher in metformin
failure group. In Goh 2011 study where insulin was initiated at the introduction of
metformin, the prematurity rate of metformin was similar to diet alone group and also
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lower than insulin alone group (Goh et al 2011). Moreover, the prematurity in the
metformin failure group was comparable to those in metformin monotherapy group.
Thus, it is hoped that if certain GDM with potential high risk of requiring insulin
addition earlier in pregnancy, it might possibly reduce the associated prematurity risk
of metformin therapy in GDM. However, the confidence interval of prematurity in our
study was very wide and thus, we would suggest that the association between
metformin failure group and prematurity risk and the possible risks imposed should be
further examined by a future prospective study.
We found that the average glycaemic control was better in metformin failure GDM
women than in insulin therapy alone. As metformin failure women were diagnosed
earlier, this might probably due to the fact that women with metformin plus
supplementary insulin were on intensive glycaemic treatment earlier. Yet, the effect
was found to be significant after adjusting gestational age at OGTT. Thus, another
possibility could be that women on metformin will have more stable day-to-day
glycaemic levels than insulin alone group. Regarding risk of prematurity risk,
metformin failure group were almost 3 times more likely to deliver premature babies
than insulin monotherapy group, although the effect did not reach the significant level.
Thus, the costs and benefits to offer metformin to those with potential risk of
metformin failure are still controversial.
Strengths and Limitations
As all the available eligible GDM women with diverse ethnicity were included, the
criteria can be widely applicable. Moreover, we applied insulin addition strategy to the
metformin failure GDM population, which are adapted intervention strategies in
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several countries. This might allow easy application to clinical practice. However, our
studies have a number of limitations. Firstly, the protocol for metformin failure was
developed from retrospective cohort data and thus, a prospective study using our
criteria to validate our findings are required. Secondly, despite our effort to exclude
history of pre-gestational diabetes in the study, our population might have mixed with
hidden pre-gestational diabetes whose signs and symptoms are undetected early in
pregnancy. This should be considered in future prospective studies. Furthermore,
because of the nature of research questions, we did exploratory analysis rather than
hypothesis testing. Moreover, although we found possible association of metformin
failure and prematurity, our study may not have enough power to detect differences in
other important pregnancy outcomes. Thus, a well-designed prospective or
randomized study with adequate sample size should be conducted to confirm our
results before implementing these findings into practice. In addition, we would advise
the following duplicate studies to include important outcomes of metformin like
maternal weight gain and lipid profile.
In conclusion, there is high chance of metformin failure rate. Early initiation of
metformin at diagnosis of GDM would allow more GDM with metformin
monotherapy considering its slower onset. The early detection of those GDM with high
probability of metformin failure would allow physicians to enable individualized
treatment strategy but also help better prepare the mothers for insulin initiation.
Finally, the healthcare resources to GDM could be better reallocated if the number of
GDM women with insulin are reduced.
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CHAPTER 5
MATERNAL VITAMIN B12, FOLATE AND HOMOCYSTEINE AS
DETERMINANTS OF GLYCEMIA AND BIRTHWEIGHT IN GDM
(STUDY 3)
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5.1 Introduction
The adequate supply of micronutrients are very important in pregnancy for foetal
growth and development. Being major regulators of methionine:homocysteine (one
carbon transfer) cycle, the imbalance or inadequacy of vitamin B12 and folate is
important for DNA synthesis and repair. During pregnancy, folate insufficiency is
usually responsible for increased homocysteine levels rather than vitamin B12
deficiency (Yajnik et al 2005). Nevertheless, increased homocysteine levels due to any
cause in pregnancy are related to neural tube defects, small-for-gestational
age(SGA)(Hogeveen et al 2012), low-birth-weight(LBW)(Sukla et al 2013), pre-term
delivery (Knudtson et al 2004) and pre-eclampsia (Kahramaner et al 2013).
Because of short-term storage nature of folates in the body and the increasing concerns
of folate-deficiency induced hyperhomocysteinaemia-related adverse pregnancy
outcomes like neural tube defects, periconceptional folic acid (400ug-5mg) is
recommended to every pregnant woman in their early months in many countries. In
UK, women with planned pregnancy are encouraged to take folic acid 400ug/day
which is much higher than the dosage recommended for normal adult women
(100ug/day) before conception and throughout pregnancy. The higher folic acid
dosage of 5mg is given to those who are high risks such as previous history of neural
tube defects and diabetes in developed countries like UK. Whereas, in developing
countries like India, 5mg folic acid is recommended to every pregnant woman owing
to high prevalence of nutritional deficiencies. Regarding vitamin B12 intake during
pregnancy, it is not recommended usually because of large pool of vitamin B12 storage
in liver, but vitamin B12 deficiency is quite common during pregnancy due to
increased demand (Bawazeer 2011). This was seen in almost half of UK pregnant
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women despite non-restricted diet, probably related to increased intakes of frozen and
processed meat (Adaikalakoteswari et al 2015). Similarly, one Indian study with
majority of vegetarian population has also reported high prevalence of vitamin B12
deficiency in the presence of high folate levels during pregnancy (Krishnaveni et al
2009).
Therefore, there is much likelihood to have seen vitamin B12 deficiency at the high
levels of serum folates which might possibly change the physiological function during
pregnancy. There are also some data to support that high intakes or serum levels of
folate in vitamin B12 deficient state are associated with increased cardiovascular risks,
marked by hyperhomocystinemia (Selhub et al 2007), insulin resistance (Yajnik et al
2008) and obesity (Adaikalakoteswari et al 2014). Similarly, maternal high folate and
low vitamin B12 levels can increase low birth weight (LBW) (Gadgil et al 2014),
small-for-gestational-age(SGA) (Dwarkanath et al 2013), adiposity and insulin
resistance (Yajnik et al 2008). The possible mechanism of low vitamin B12-high folate
effects was postulated by Yajnik et al group that folic acid could not work at full
potential during vitamin B12 deficiency due to folate trap (also defined as functional
folate deficiency). At the same time, a meta-analysis of folate supplementation to type
2 diabetes has reported to be associated with reduction of average HbA1c by lowering
homocysteine levels (Sudchada et al 2012) which can possibly reduce cardiovascular
risks. On the other hand, high folate intakes during pregnancy can increase risk of SGA
in vitamin B12 deficient setting which may be due to be poor placental blood flow
(Dwarkanath et al 2013). Thus, it is likely for folic acid to have benefit on metabolic
outcomes, it is important to have adequate vitamin B12 levels.
181
Accordingly, to understand the role of micronutrients on both glycaemia and
pregnancy outcomes, gestational diabetes mellitus (GDM) is an useful population to
study. Folic acid supplementation and opportunistic fortification of folic acid is
common in UK. This may be the reason for low levels of folate deficiency in UK
(Adaikalakoteswari et al 2014). However, vitamin B12 deficiency is also common.
Therefore, this study aims to understand the association between serum folate levels
with plasma glucose levels and birth weight in normal and insufficient B12 GDM
women.
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5.2 Methods
5.2.1 Study population and data collection
The eligibility criteria for date and location setting of this study was described in
chapter 4. All GDM women with available vitamin B12 and folate levels were
included. If the woman had more than one pregnancy during the period, each
pregnancy was considered as a separate case. Multiple pregnancies, still-birth
pregnancies and pregnancies transferred to other hospital were excluded. The
diagnosis and management of the included GDM women were also described in
Chapter 3.
In our centre, all the pregnancies were given folic acid (400ug/day) at the time of
booking and is continued until delivery. Although it is reported that vitamin B12
deficiency (<150 pmol/L) is not uncommon in UK pregnant population, it is not
supplemented routinely yet. Similarly, the measurements of serum vitamin B12 and
folate levels were not included in antenatal care. In this hospital, one consultant mainly
in charge of GDM clinic regularly requested serum vitamin B12 and folate
measurement routinely because of the awareness of high prevalence of vitamin B12
deficiency in west midlands pregnancy since 2009. If the women was found to be
vitamin B12 deficient (<150 pmol/L), IM B12 injection of 1000 IU was given
successively and repeated as required. All available data of vitamin B12, folate and
homocysteine of these GDM women were collected from the hospital electronic
records and if the levels were measured more than one time during the same
pregnancy, the date closest to the OGTT date was included. Plasma vitamin B12 and
folate levels were determined by electrochemiluminescence immunoassay and binding
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assay (Elecsys and cobase immunoassay analysers, Roche Diagnostics, USA)
respectively and plasma total homocysteine by automated High Performance Liquid
Chromatography (HPLC) method.
The following maternal and neonatal variables were included: maternal vitamin B12,
folate and homocysteine levels, folic acid supplement dose and date, vitamin B12
injection date, gestational age at blood withdrawal, maternal age, height, weight,
ethnicity, parity, gestational age at OGTT, fasting and postprandial levels at OGTT
and postpartum, HbA1c throughout pregnancy, type of medication, smoking status,
birth weight, gender and gestational age at delivery. Vitamin B12 deficiency was
defined as above; low folate as <9 nmol/L and high homocysteine as ≥14umol/L. The 
ratio of folate:vitamin B12 was also done by dividing folate by vitamin B12 levels,
then multiplied by 1000. The GROW customized weight centiles was used to
determine the centiles of newborns and small for gestational age (SGA) and large for
gestational age (LGA) were defined by < 10% centiles and >90% centiles, respectively
(Clausson et al 2001; Mikolajczyk et al 2011). This growth chart was adjusted for
maternal height, weight, ethnicity, parity, gender and gestational age at delivery. There
is strong evidence that GROW customised growth charts were better predicted models
for perinatal morbidity and neonatal arthropometric measures (Gardosi et al 2004).
Moreover, SGA identified by individually adjusted growth centiles were better
representatives of IUGR (Clausson et al 2001).
184
5.2.2 Sample size calculation
A-priori statistical power analysis was performed using a software available
online[231]. The anticipated effect size used for this calculator was (f2) 0.02 for small,
0.15 for medium and 0.35 for large. A power analysis for multiple linear regression
with 4 predictors (folate:vitamin B12 ratio, age, BMI, parity) with 80% power and
significance levels of 0.05 required a sample size of 84 GDM to detect f2 of 0.15 in
normal vitamin B12 subgroup.
5.2.3 Statistical analysis
Statistical analysis were performed using SPSS programme version 21.0 (SPSS Inc.,
Chicago, IL, USA). Complete case analysis (serum vitamin B12, serum folate, glucose
levels at OGTT, birth weight, age, BMI, parity) was performed. The skewed data were
log-transformed and presented as mean and standard deviation. Among all continuous
data, only birth weight was normally distributed. The log-transformed data were used
in further analysis. Continuous data were described in mean±standard deviation (SD)
and categorical data were described in number(n) and percentages(%). P value of 0.05
was considered as statistically significant. Scatter-plot was used to reveal the
association between maternal micronutrient levels and glucose levels among normal
and deficient vitamin B12 groups.
5.2.3.1 Question being addressed:
1. What is the association between serum vitamin B12 and serum folate at mid-
pregnancy with BMI, serum homocysteine levels, plasma glucose levels
(fasting and 2hr postprandial) at mid-pregnancy and 6 weeks post-partum and
their babies’ birth weight or centiles in GDM women?
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Statistical model applied: Pearson’s correlation
2. Is there any difference in the association of serum folate levels at mid-
pregnancy with above mentioned dependent variables in question (1) between
low and normal vitamin B12 groups?
Three different analytical strategies using appropriate statistical models applied:
i) Vitamin B12 grouping – low (<150pmol/L) and normal (≥150pmol/L) and Pearson’s 
correlation model
ii) Serum folate levels divided by serum vitamin B12, then multiplied by 1000 and
Pearson's correlation model
3. Does the association between serum folate levels at mid-pregnancy with
plasma glucose levels change after controlling for age, BMI and parity (and
homocysteine)?
Statistical model applied: Multiple regression model
Analytical strategy:
Outcome variable: Plasma glucose (fasting and postprandial) at mid-pregnancy and 6-
weeks post-partum
Step 1: Serum folate levels
Step 2: Age, BMI, Parity and Serum folate levels
Step 3: Age, BMI, Parity, Homocysteine and Serum folate levels
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5.3.Results
Figure 5.1 Overview of selection of GDM women included
Out of 299 eligible GDM women, 207 women and 188 women had recorded data for
serum vitamin B12 and folate levels respectively. All the women who had serum folate
recorded had been measured together with serum vitamin B12. After exclusion of
GDM with no folate data, complete data were examined fasting and 2 hour glucose at
OGTT, parity, BMI, age, birth weight, gender and gestational age at delivery in 188
GDM women. Complete data for analysis were available for 156 GDM and included
(Figure 5.1)
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5.3.1 Demographic characteristics of GDM mothers and babies
The characters of mothers and babies including blood indices were presented in Table
5.1. Data on folic acid supplementation were available from 155 GDM. Majority
(85.8%) women had taken folic acid 400ug antenatally and 2 GDM took folic acid
other than 400ug. Out of 156, 80% of women lived in own or rent accommodation.
The prevalences of B12 and folate deficiency are 32.7% and 5.1% respectively at
median gestational age of 26+6 weeks. weeks(interquartile range(IQR)26+0, 29+2
weeks). If low and high folate groups were defined The prevalences of low and high
folate levels defined by <3.8ug/L and >16ug/L were 3.8% and 17.3% respectively.
There is only one GDM with high homocysteine (≥14umol/L). Over fourth-fifths 
(85.3%) of GDM women were Europeans. The incidences of LBW and SGA are 7.1%
and 14.1% respectively. Two-thirds of the women were on metformin and over half of
them needed additional insulin.
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Table 5.1 Characteristics of GDM women
n=156 Median (IQR) Mean±SD
Age (years) 31.0 (27.0,35.8) 31.09±5.6
Ethnicity (n=154)
i)South Asians
ii)European
iii)Others
10(6.4%)
133(85.3%)
11(7.1%)
Smoking 19(12.2%)
Parity
Nullip
Multip(>/=2)
60(38.5%)
38(24.4%)
Weight (kg) 82(70,99) 84.4±19.3
Height (cm) 163(159,168) 162.9±7.3
BMI 30.9(27.3,36.1) 31.8±6.8
Pregnancy-induced
hypertension(PIH)
6(3.8%)
Treatment type (n=134)
i)Diet
ii)Diet+Metformin
iii)Diet+Metformin+Insulin
iv)Diet+Insulin
13(8.3%)
39(25.0%)
59(37.8%)
23(14.7%)
Vitamin B12 (pmol/L)
B12 deficiency(<150 pmol/L)
223.0(184.3,290.5)
51 (32.7%)
247.1±91.9
Folate (ug/L)
Folate deficiency(<9 nmol/L)
9.9(6.6,14.0)
8 (5.1%)
10.5±4.7
(Folate:B12) x 1000 41.1(29.2,56.9) 45.1±21.5
Homocysteine(umol/L)(n=83) 5.0(4.0,7.0) 5.9±2.5
OGTT
i) Fasting (mmol/L)
ii) 2hr post prandial (mmol/L)
4.9(4.5,5.6)
8.6(8.0,9.5)
5.1±0.9
8.8±1.5
Post-partum(n=62)
i) Fasting (mmol/L)
ii) 2hr post prandial (mmol/L)
4.9(4.6,5.3)
5.4(4.6,6.7)
5.0±0.7
5.8±1.9
Gestational age (GA) at
Delivery (weeks)
38+2(38+0,38+5) 38+2±0+7
Birthweight (grams)
Low Birth weight(<2500g)
Macrosomia(≥4000g) 
3200(2958.8, 3557.5)
11 (7.3%)
6(3.8%)
3217.1±455.5
Centiles
Small-for-gestational age(SGA)
Large-for-gestational age(LGA)
35.4(16.5,71.3)
22(14.1)
12(7.7)
43.5±30.3
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5.3.2. Relation between serum folate, vitamin B12, their ratio and glucose levels
There was a significant association between serum glucose levels at diagnostic and
postpartum GTT with folate levels, but not with vitamin B12 levels (Table 5.2).
Among vitamin B12 subgroups, folates were inversely related to fasting glucose levels
at OGTT and postpartum GTT in normal vitamin B12 GDM subgroup only (Figure
6.2 and Figure 6.3) whereas average HbA1c levels were correlated with folates in
normal and deficient B12 GDM. The association was significant after adjusting the
confounders such as age, BMI and parity (Table 5.3) and the R2 change was increased
with inclusion of homocysteine in the model (Table 5.3). Among normal vitamin B12
GDM subgroup, the ratio of folate:vitamin B12 was associated significantly with
fasting glucose at mid-pregnancy and postpartum GTT (Table 5.2). Homocysteine
levels were strongly correlated with folate levels but not with vitamin B12 while
maternal BMI are negatively and significantly related with both serum vitamin B12
and folate levels. <3.8ug/L and >16ug/L. Serum B12 and folate are highly correlated
(r=0.341, p<0.001) but only folate levels are negatively associated with
homocysteine(r= -0.46, p<0.001, n=83). There was no difference in vitamin B12,
folate and homocysteine levels among diet, metformin, metformin+insulin and insulin
treated GDM (data described in Chapter 3).
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Table 5.2: Pearson’s correlation-plasma glucose, homocysteine, BMI and birth weight correlates with serum micronutrients levels
All GDM Normal B12GDM B12 insufficient GDM
Vitamin B12 Folates Folates (Folates:Vitamin B12)*1000 mid-
pregnancy
(n=51)
Postpartum
(n=19)
mid-
pregnancy
(n=156)
Postpartu
m (n=62)
mid-pregnancy
(n=156)
Postpartum
(n=62)
mid-pregnancy
(n=105)
Postpartum
(n=43)
mid-
pregnancy
(n=105)
Postpartum
(n=43)
fasting -0.10(NS) 0.09(NS) -0.19(<0.05) -0.27(<0.05) -0.21(<0.05) -0.36(<0.05) -0.18(NS) -0.30(<0.05) -0.06(NS) -0.16(NS)
2hr- PP -0.003(NS) -0.02(NS) -0.14(NS) -0.15(NS) -0.20(<0.05) -0.20(NS) -0.18(NS) -0.10(NS) -0.01(NS) 0.11 (NS)
Average
HbA1c
-0.069(NS) -0.21(<0.05)
tHcy -0.04(NS) -0.46(<0.001) -0.43(<0.001)
BMI -0.29(<0.01) -0.22(<0.001) -0.25(<0.01) -0.03(NS) -0.07(NS)
Birthweight -0.02(NS) 0.06(NS) 0.05(NS) 0.01(NS)
Centiles 0.09(NS) 0.15(NS) 0.05(NS) 0.03(NS)
NS= Not Significant
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Figure 5.2 Scatterplots of Relationship between Folates and Fasting glucose at mid-
pregnancy OGTT
Figure 5.3 Scatterplots of Relationship between Folates and Fasting glucose at post-
partum
GTT
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Table 5.3: Multiple regression for fasting glucose at diagnostic and postpartum glucose tolerance test
All GDM Normal B12GDM B12 insufficient GDM
folate mid-pregnancy
(n=156)
Postpartum
(n=62)
mid-pregnancy
(n=105)
Postpartum
(n=43)
mid-pregnancy
(n=51)
Postpartum
(n=19)
β -0.19(<0.05) -0.27(<0.05) -0.21(<0.05) -0.36(<0.05) -0.06(NS) -0.16(NS)
Adjusted β 
(Age, BMI, Parity)
-0.17(<0.05) -0.32(<0.05) -0.18(<0.05) 0.38(<0.05) -0.06(NS) 0.21(NS)
n=83 n=37 n=52 n=23 n=31 n=14
β -0.24(<0.05) -0.31(<0.05) -0.32(<0.05) -0.32(NS) 0.02(NS) -0.24(NS)
Adjusted β 
(Age, BMI, Parity)
-0.21(=0.09) -0.40(<0.05) -0.30(<0.05) -0.42(NS) 0.12(NS) -0.05(NS)
Adjusted  β  
(Age, BMI, Parity,
homocysteine)
-0.30(<0.05) -0.36(<0.05) -0.44(<0.01) 0.31(NS) 0.12(NS) -0.06(NS)
NS= Not Significant
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5.3.3. Relation between serum folate, vitamin B12, their ratio and birth weight
There was no association between serum folate, vitamin B12 and their ratio with birth
weight or centiles (Table 5.2) (Figure 5.4). There was no relationship of these
micronutrient levels with either SGA or LBW. However, there was a significant
negative linear correlation between maternal total homocysteine and centiles and birth
weight (r=-0.22, p<0.05 and r=-0.10, p=0.39). In multiple regression models, it was
found that homocysteine, age and smoking were major contributors of centiles and
after adjusting age and smoking, 1SD rise in homocysteine (2.5umol/L) can reduce
0.19% centiles (95% confidence interval (CI): -5.0, 0.32). Moreover, the odds ratio of
1.38 (95%CI: 1.06, 1.79) for SGA were greater than 1, indicating that for every one
umol/L increase in maternal homocysteine levels, it was 1.38 times likely to increase
SGA risk, controlling for age and smoking. The mean birth weight and centiles of
vitamin B12 deficient group were 64 g higher than normal B12 GDM (3260.4±487.0g
vs 3196.1±440.0g, p=0.41) (Figure 5.5).
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Figure 5.4: Scatter-plots of homocysteine, vitamin B12 and folate vs centiles and birth
weight. (The lines represent mean±standard deviation.)
A) Plasma Homocysteine levels vs Centiles and Birthweight
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B) Plasma Folate Levels vs Centiles and Birthweight
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C) Plasma Vitamin B12 Levels vs Centiles and Birthweight
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Figure 5.5: Differences in mean total homocysteine levels between Appropriate for
Gestational Age (AGA) and Small for Gestational Age(SGA)
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5.4 Discussion
The awareness of neural tube defect due to folate deficiency has led to give 400 ug
folic acid supplements to all pregnant women in UK, ideally before conception and
throughout pregnancy. Although the majority of the pregnancy are not well-planned,
the health-conscious population in general are likely to take folic acid and thus the
women at booking visit have usually on folic acid supplements. However, this is not
accompanied by increase in the intake of other micronutrients especially vitamin B12,
deficiency of which can result in imbalance of methionine-homocysteine cycle
because of folate trap. Consequently, the increased homocysteine levels can impair
vascular blood flow resulting in higher incidence cardiovascular and peripheral
vascular diseases and adverse pregnancy outcomes due to placental vasculopathy
including SGA (Hogeveen et al 2012; Humphrey et al 2008; Khandanpour et al 2009).
In fact, vitamin B12 deficiency in pregnancy is associated with higher risk of GDM
(Krishnaveni et al 2009). Thus, this study aimed to examine the relationship of serum
folate and vitamin B12 levels during pregnancy with other metabolic risk markers such
as homocysteine, glycaemia and SGA and the importance of their imbalance. We have
found that serum folate levels were inversely associated with serum glucose levels in
GDM with normal vitamin B12, but not B12 deficient. This relationship was also
found to be homocysteine-independent. Among vitamin B12 deficient group, there is
no association between folate and glucose denoted by folate:vitamin B12 ratio. We
have performed this analysis among vitamin B12 deficient GDM subgroup because
the interest was lowering of serum glucose levels by folate in the presence of vitamin
B12 deficiency. Moreover, in these 400ug folate supplemented GDM, serum folate did
not influence on the birth weight of babies and their centiles. Thirdly, it was found that
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vitamin B12 deficiency in GDM was significantly associated with increased BMI. This
might suggests that despite being in normal range, lowering homocysteine levels could
reduce risk of SGA. As found in type 2 diabetes population, the increased
homocysteine levels in this GDM population were strongly correlated with folate and
not vitamin B12 levels. This further strengthens the argument that folate is the strong
driver of homocysteine levels in vitamin B12 sufficient population.
5.4.1 Micronutrients and glycaemia
Although studies found that high folic acid levels in low vitamin B12 status are
associated with increased risk of insulin resistance (Krishnaveni et al 2009, Yajnik et
al 2008)), the current study did not show this as all GDM included received 400ug
folic acid compared to 5 mg folic acid in other studies. We have also found that
lowering glycaemic levels by folate in normal vitamin B12 GDM. This finding was in
consistent with systematic review on glucose lowering effects of folic acid in type 2
diabetes although the systematic review did not include vitamin B12 level (Sudchada
et al 2012). This study has also reported that this effect was due to lowering of
homocysteine levels. Likewise, one Indian study in pregnant women has reported the
association of high folate and low vitamin B12 imbalance with highest increased
homocysteine levels (Gadgil et al 2014). However, in our current study, this
relationship was found to be homocysteine-independent. This might suggest the effect
of folate on glycaemia rather than homocysteine-mediated mechanism. There is also
evidence that serum folate levels facilitate endothelial function by directly interacting
with endothelial nitric oxide synthase in type 2 diabetes (Steware te al
2011).Accordingly, this indicates that the effect of folate on glycaemia could be rather
direct, i.e, folate effects on endothelium rather than homocysteine-induced endothelial
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oxidative stress. Similarly, Selhub et al have reported that serum folate levels are
inversely associated with serum methylmalonic acid and homocysteine levels
generally, but if folate levels >20nmol/L in low B12 levels, the relationship is found
to be reverse (Selhub et al 2007). Thus, we concluded that for folates to have positive
effects on glucose levels, it is essential to have normal vitamin B12 levels in GDM.
In this study, we have given B12 injection of 1000 IU to deficient GDM soon after lab
results and have found that serum vitamin B12 levels return back to normal within a
week. Despite this, the correlation of serum folate and glucose levels at postpartum
GTT did not improve in those with formerly vitamin B12 deficient group. This might
suggest the physiological importance of vitamin B12 for cell function rather than
mechanical role. Recently, the study of vitamin B12 in adipocyte cell culture has also
reported that vitamin B12 deficiency reduced methylation potential and increased the
gene expression of cholesterol biosynthesis (Adaikalakoteswari et al 2015). This also
indicates that vitamin B12 has a priming effect on cells, i.e, needs to enter and become
incorporated into cell functional structure, in order for folate to have an effect on
lowering glucose. Moreover, it is better off using serum methylmalanoic acid levels
which is more sensitive and specific for intracellular vitamin B12 deficiency together
with serum vitamin B12 levels in follow-up replicated studies.
Although vitamin B12 status could modify the effects of folate on glucose in GDM,
there was no direct correlation of vitamin B12 and glucose levels. But, we did see the
significant negative association of vitamin B12 or folate on maternal BMI. These
findings are in line with previous indian pregnancy study where reduced HOMA-IR
and GDM risks were found across higher B12 tertiles at 5 year follow-up (Yajnik et al
2008) although they did not find any association with folate levels. Moreover, there is
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evidence that maternal vitamin B12 deficiency can increase the risks of neonatal
adiposity, HOMA-IR and dyslipidaemia (Adaikalakotewari et al 2015; Yajnik et al
2008; Stewart et al 2011). These findings might support the generational effects of
vitamin B12 that it takes considerable amount of time interval for vitamin B12 to have
a visible impact on metabolic function.
5.4.2 Micronutrients and Birth weight
At the same time, it has been reported that either low vitamin B12 or folate levels are
associated with increased risk of SGA or low birth weight (LBW) (Christian et al 2003;
Relton et al 2005; Dwarkanath et al 2013). Similar report was also done by Gadgil et
al group with imbalance of these 2 micronutrient levels in pregnancy with high folate
(5mg) intake [143]. Likewise, Dwarkanath and the group have reported low folate low
vitamin B12 intakes in 1st trimester and high folate and low vitamin B12 intakes in 2nd
trimester can increase the risk of SGA (Dwarkanath et al 2013). On the contrary, a
randomized study done by Christian et al in community setting has reported that
antenatal folate supplementation of 400ug can moderately reduce the risk of
LBW(Christian et al 2003). In this GDM study, we did not find any relationship
between serum folate, vitamin B12 and their imbalance with SGA and LBW. In our
previous study (2005-2010) (n=38), we have reported that non-significantly higher
birth weight among low vitamin B12 GDM mothers. We have seen the similar pattern
in this 2009-12 GDM group with much higher sample size but the association is not
significant(p=0.4) (Bawazeer 2011). Our GDM population were relatively folate
adequate (94.9%) with low vitamin B12 status (32.7%) in contrast to the previous 2005
GDM study with vitamin B12 and folate deficiency of 57.9% and 24.3% respectively
(Bawazeer 2011) . The discrepancies in the prevalence of vitamin B12 and folate levels
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are due to sampling differences and we collected all consecutive sample in this 2009
study. The incidences of SGA and LBW in our study are 15.3% and 7.3% respectively
which were much higher than being reported by other GDM studies. Furthermore,
there was one GDM with homocysteine levels ≥14umol/L. Despite being in normal 
range, higher serum homocysteine levels were significantly associated with increased
risk of SGA in GDM and they were negatively correlated with serum folate levels.
Therefore, it can be assumed that decreasing homocysteine levels by increased folic
acid intakes might be of benefit to bring down the incidence of SGA in GDM
Moreover, maternal homocysteine levels at mid-pregnancy could be used as a guide
for treatment modifier for target glucose adjustment for GDM with high risk of SGA
and LGA. Considering the risk of high folate in B12 deficient we would suggest that
among GDM with 400ug folic acid intakes, whether there is the effect of serum folate
and vitamin B12 levels on birth weight is still controversial. However, considering
detrimental effects of high folate in vitamin B12 deficient setting, increased folate dose
might not be a wise solution, and thus rather, we would recommend routine check of
vitamin B12 status in early pregnancy and supplementation, if deficient.
5.4.3 Strengths, Limitations and Recommendations for future studies
This study shows novel evidence of a relationship of serum folates on glucose levels
during pregnancy and at postpartum among subgroups of normal and deficient vitamin
B12 GDM with normal homocysteine levels, although only one-third of GDM women
were available for postpartum glucose data. However, this is a usual condition in
clinical practice where approximately half of GDM women attend postpartum glucose
appointment. Moreover, the availability of a wide range of variables with adequate
sample size allowed to explore the analysis deeper to provide more robustic evidence.
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Furthermore, the use of GROW centiles helped to define SGA for wider implication
and reproducible replication. The nature of population being diverse and representative
are also the strengths of this study. The limitations relate to the lack of dietary measures
and adiposity of offspring. In addition, to validate the effects of folate and vitamin B12
on birth weight in GDM, it would be required to conduct a prospective randomized
trial with vitamin B12 supplementation alongside the 400ug folic acid supplements.
Finally, examination of whether lowering down of homocysteine within normal range
by high folic acid dose in the presence of normal vitamin B12 are beneficial for birth
outcomes is worthwhile.
In summary, the study highlights high prevalence of vitamin B12 deficiency and its
importance in folate-dependent glucose reduction. It also suggests that the timing of
vitamin B12 should be adequate enough to allow physiological cell transformation.
Thus, in order for vitamin B12 to benefit during pregnancy, it is more appropriate to
implement vitamin B12 measurement and supplementation targeting at general
population.
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CHAPTER 6
ROLE OF VITAMIN B12 DEFICIENCY ON LIPID METABOLISM AND
METFORMIN ACTION IN LIVER
(STUDY 4)
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6.1 Introduction
Metformin is a well-established anti-diabetic drug, used in diabetes and because of its
role in lowering blood lipid levels, it is increasingly used for obese patients. One of its
side-effects includes decrease in serum vitamin B12 levels. It has been reported that
long-term metformin use in type 2 diabetes is associated with progressive decrease in
blood vitamin B12 levels in dose-dependent manner (de Jager et al 2010). In fact,
vitamin B12 deficiency among metformin users is 2 times higher than non-metformin
user (Reinstatler et al 2012). Thus, it is not uncommon to find vitamin B12 deficiency
among metformin-treated patients.
It has been reported that vitamin B12 deficiency is associated with impaired lipid
metabolism. There are also a number of reports from clinical studies that there is
significant association between vitamin B12 deficiency and dyslipidaemia
(Adaikalakoteswari et al 2014; Mahalle et al 2013). So far, it is suggested to occur
through altered methylation by the fact that adipocyte cultured in vitamin B12
deficient culture revealed increased intracellular cholesterol levels
(Adaikalakotewwari et al 2015). However, the role of vitamin B12 deficiency in
mitochondria is still unclear yet. It is stated that MMA accumulation due to vitamin
B12 deficiency impedes coenzyme Q biosynthesis, which is important for
mitochondrial respiratory function. Therefore, it is possible that mitochondria function
might be affected in vitamin B12 function.
Metformin primarily works by activating AMPK (adenosine monophosphate-
activated protein kinase) through raising AMP:ATP ratio by partially blocking
mitochondria complex I respiratory chain. Zang et al also reported that the lipid
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lowering effects of metformin occurs through AMPK activation(|Zang et al 2004).
AMPK is a master energy regulator of the cell. Activated AMPK in liver then
subsequently phosphorylates downstream enzymes important in lipid metabolism.
Phosphorylation at serine 79 of ACC (Acetyl-CoA Carboxylase) by AMPK could
inhibit its action on lipogenesis while favouring fatty acid oxidation(Zang et al 2004).
In addition, AMPK also inhibits SREBP (sterol regulatory element binding protein)
which is nuclear transcription factor for lipid synthesis enzymes and thereby, decreases
expression of 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR) and fatty
acid synthase (FAS), which are rate-limiting enzymes in cholesterol and triglyceride
synthesis (Li et al 2011). It is thus essential to have optimal mitochondrial function for
full efficacy of metformin on lipid metabolism.
In order to understand vitamin B12 induced dyslipidaemia and efficacy of metformin
action in vitamin12 deficient liver cells, we have chosen human hepatoma cell
(HepG2) line as a model to conduct our experiment. Liver is the storage organ of
vitamin B12 in the body and it also plays a major role in the regulation of blood lipid
levels. Moreover, the recommended culture media of HepG2 (MEM, Invitrogen) does
not contain vitamin B12. The only source of vitamin B12 in HepG2 culture media is
from the supplemented foetal bovine serum which was stated to have 120 pM levels
of vitamin B12(Oltean et al 2003). Considering the fact that these cells are replicated
successively in culture media without vitamin B12 over time, it can be assumed that
vitamin B12 in these cells are lower than the required amount for optimal cellular
function. It could therefore be postulated that long-term in-vitro culture of HepG2 can
induce vitamin B12 deficient hepatocyte model. The passage number in this
experiment started from passage 4 HepG2 as to ensure the replication of experimental
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hepatocytes in media lack of vitamin B12. We chose the vitamin B12 addition model
rather than subtraction study as it resembles much more closely to the physiological
condition.
The aim of this chapter are:
1) To examine how low vitamin B12 affects the lipid metabolism in liver cell line
and elucidate the pathway involved
2) To examine whether vitamin B12 deficiency interferes with metformin action
in liver cell line.
The molecular lab research techniques were used to understand the effects of
metformin in vitamin B12 deficient setting by using HepG2 cell culture model.
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6.2 Methods
6.2.1 Materials
Metformin (1,1-dimethylbiguanide), cyanocobalamin, 5-aza-2’-deoxycytidine (AZT),
Anti-rabbit antibodies conjugated to horseradish peroxidase and dimethyl sulphoxide
(DMSO) were purchased from Sigma. Phospho-AMPKα(Thr-172), total AMPK 
against AMPKα1 and AMPKα2, phospho-Akt (Ser-473), Akt, phospho-GSK3α/β, 
GSK3β, phospho-ACC(Ser-79), total-ACC, β-actin antibodies were purchased from 
cell signalling. Eagle’s minimum essential medium (MEM) and foetal bovine serum
were from Invitrogen. The custom taqman gene expression assays and housekeeping
gene 18s rRNA from Applied Biosystems. The gene assays with their catalogue
numbers included are: SREBF1 (Hs01088691_m1), SREBF2 (Hs01081784_m1),
FAS (Hs00236330_m1) and HMGCR (Hs00168352_m1). The gene primers and
polymerase chain reaction (PCR) test kits were from life technologies. Modified
Eagle’s Medium (MEM), foetal bovine serum, sodium pyruvate and antibiotics
(penicillin and streptomycin) were from Invitrogen.
6.2.2 HepG2 purchase, culture and freezing
HepG2 cells were kindly contributed by Dr Ming Zhan Xue, who originally purchased
them from American Type Culture Collection (ATCC). The cells were grown in MEM
supplemented with 10% foetal bovine serum (FBS), L-Glutamine (2mM), sodium
pyruvate (100mM) and penicillin-streptomycin (100 units/mL) in T-75 or T-175 flasks
(corning cell culture flask surface area 75cm2 or 175 cm2 respectively). The frozen
cells were dissolved in warm completed media and maintained as sub-confluent
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monolayer at 37°C and 5% CO2. The media was changed the next morning and then
it was changed every alternate day.
When they became 70% confluence, usually on 4th or 5th day, trypsinization and next
cell passage were done. In brief, after removal of cell culture media, cells were rinsed
3 times with warm phosphate buffer saline (PBS); treated with 2-3ml or 5 ml of 0.25%
warm trypsin-0.53mM ethylene-diamine-tetraacetic acid (EDTA) solution (Gibco,
UK) to 75cm2 or 175cm2 flask respectively and kept at 37°C until cell layer was
detached (usually 5-15 minutes). Trysin-EDTA solution was used to neutralize all
trypsin inhibitors in FBS. Then, 10/(T-75) or 15/(T-175) ml of the complete growth
media was added to halt the trypsin action and the cells were aspirated by pipetting
gently to facilitate cell separation of any clump. After cells were separated
individually, the cell mixture was put into 50ml falcon and centrifused at 1250 rpm for
5 minutes. The supernatant was then removed and the resulting cell pellet was re-
suspended in warm media and splitted into new culture flasks (1:4). Alternatively, the
cell pellet was dissolved in media containing 10%DMSO and 30%FBS and
appropriate aliquots (1:10) were added into freezer tubes and kept in -80°C freezer for
24 hours. Finally, they were submerged in liquid nitrogen for longer storage.
6.2.3 Experimental steps
6.2.3.1 Experimental treatment of HepG2 cells with different concentration of vitamin
B12
HepG2 cells were grown in MEM supplemented with 10% FBS and penicillin-
streptomycin (100 units/mL). Cells were seeded at a density of 6000cells/cm2 and
treated with different concentrations of vitaminB12 (≥98% cyanocobalamin, Sigma-
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Aldrich) (10 nM, 100 nM and 1000 nM) for 24 days (passaged on every 6th day for 4
passages) and incubated at 37°C in 5%CO2. The dose concentrations are approximated
from the previous studies of vitamin B12 regulation of methionine synthase enzyme
where 1.5uM and 3.6uM of vitamin B12 were added to HepG2 culture (Oltean et al
2003; Gulati et al 1999).The culture plates were kept in serum free medium overnight
before extraction or before any treatment. A control culture plate with respective
vitamin B12 concentration was kept alongside together with any treatment. Three
independent experiments were conducted for each treatment.
For insulin treatment, HepG2 cells on 22nd day (70% confluence) in different vitamin
B12 concentrations (0, 10, 100, 1000 nM) were treated with insulin (100nM) for 15
minutes before extraction.
For metformin treatment, metformin (2mM) was used to treat HepG2 cells on 23rd day
morning 9.00am (22-days old and left in serum free medium for overnight) (70%
confluence) in different vitamin B12 culture (0, 10, 100, 1000 nM) for 24hours before
extraction on 24th day. The dose and duration of metformin was taken from the
previous study of AMPK signalling of metformin on lipid in HepG2 cells(Zang et al
2004).
For the AZT treatment, these 22days-old HepG2 cells in vitamin B12 culture (0, 10,
1000 nM) were seeded again on 6 well plates (20% confluence) and treated with AZT
(300nM) for 3 days and then left again in respective B12 supplemented normal media
for another 2 days before extraction on day 27. The dose and duration of 5-AZT was
taken from the previous adipocyte model (Adaikalakoteswari et al 2015). AZT is a
cytosine analogue and is used in cell culture as a DNA hypo-methylation agent. It
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replaces the cystosine in DNA synthesis, forms covalent bond with DNA
methyltransferase and prevents the methylation process (Poirier S et al 2014).
6.2.3.2 Protein and RNA Extraction
At the end of each experiment, the HepG2 culture 6-well plates were washed with ice-
cold PBS for 3 times to stop metabolism and 300µl/well of prepared Radio-Immuno
Precipitation Assay (RIPA) buffer (Thermo Scientific, UK), containing a cocktail of
protease inhibitors and phosphatase inhibitors [20 mM Tris–HCl (pH 7.5), 150 mM
sodium chloride (NaCl), 1 mM EDTA, 1% NonidetP40, 0.5% deoxycholate, 0.1%
sodium dodecyl sulphate (SDS), 5 mM sodium fluoride (NaF), and 0.1mg/ml
phenylmethylsulphonyl fluoride (PMSF) protease inhibitor] was used for protein
extraction. QIAzol lysis reagent (QIAGEN, UK) of 500µl/well was added for RNA
extraction. The plates were then placed on ice tray and incubated on the shaker for 10
min and cells were scraped with cell scraper, one for each condition separately. Before
collecting into Eppendorf tubes, the cell suspensions were aspirated and well-mixed
by pipetting. The RIPA cell lysates were centrifuged at 16,000 g at 4°C for 5 minutes.
Once spun, the resultant protein-containing supernatant was then collected into new
Eppendorf tubes. Both final protein and RNA extracts were kept at -80°C before
further use.
6.2.3.3 Protein Quantification
Protein concentration in each sample was quantified using the Bio-Rad Bradford
protein assay kit (Bio-Rad Laboratories, Hercules, CA). The frozen protein samples
were left at room temperature until thawed and then vortexed for homogenous mixture.
A 5 fold concentrated Bradford reagent was diluted with deionised water to produce
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1X working concentration. A bovine serum albumin (BSA) protein standard
concentration of 1 mg/ml was also prepared. By mixing appropriate volume of BSA
and distilled water, five protein standards (0, 0.5, 1, 2, 4µg/µL) were yielded where
the dye reagent without any BSA addition was used as a blank. Three microliters of
each sample were added to 1 mL of 1X dye reagent and vortexed vigorously. Then,
they were incubated at room temperature for 5 minutes. The absorbance were
measured at a wavelength of 595 nm using a spectrophotometer (NanoQuant, Infinite
M200 PRO Tecan). Sample protein concentrations were read against a standard curve,
plotted by using absorbance values of the five BSA standards.
6.2.3.4 Western Blot Analysis of HepG2 cells
Western Blot is a chemiluminescence immunoassay method which is used to identify
and quantify target proteins. Briefly, electrophoresis is run through a gel to separate
the proteins of interest according to their size. Then, proteins are moved onto a
polyvinylidene-fluoride (PVDFTM) membrane by using electric current. The proteins
of interest, immunoblotted with specific antibodies, are illustrated by using a
colorimetric detection technique. The method is described in detail below.
6.2.3.4.1 Protein sample preparation
Protein samples were kept at room temperature until thawed. Then, equal amount (20-
40ug) of quantified protein samples were added to 1.5 ml eppendorfs containing 5uL
of 5X loading buffer to standardise the volumes (Table 6.1). After that, the samples
were denatured and linearized by heating at 95°C for 5 minutes and then cooled down
on ice for 2-5 minutes.
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Table 6.1 Quantities of reagents in loading buffer for western blotting
Reagent Quantity Final Concentration
Tri HCl (pH 6.8) 625 uL 125 mM
10% SDS 500 uL 4%
Glycerol 1000 uL 20% (w/v)
DTT 200 uL 6.5x10-3 mM (w/v)
Bromophenol Blue 125 uL 2.5x10-3 mM (w/v)
dH2O 250 uL N/A
6.2.3.4.2 Protein separation by electrophoresis
The proteins were separated using sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) according to their molecular weight. 4% stacking gel at
pH 6.8 and 7.5% or 10% resolving gel (depending on the size of target protein) at pH
8.8, were used. The amounts of reagents used in 2X 1.5mm gels preparation were
described in the following tables 6.2 and 6.3.
Table 6.2 Components of resolving gel (7.5% and 10%) for western blotting
Resolving Gel 7.5% Gel 10% Gel
Acrylamide 5.0 ml 6.6 ml
Resolving buffer 5.2 ml 5.2 ml
10% Ammonium Persulphate 100 ul 200 ul
TEMED 20 ul 20 ul
Distilled water 9.4 ml 7.8 ml
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Table 6.3 Components of stacking gel (4%) for western blotting
Stacking Gel 4% Gel
Acrylamide 1.3 ml
Stacking buffer 2.5 ml
10% Ammonium Persulphate 50 ul
TEMED 10 ul
Distilled water 6.1 ml
The glass plates were cleaned with 70% ethanol and left them to dry. The gel casting
unit was set up according to manufacturer’s instruction. The clean glass slides were
assembled in the clamp and water was poured in between to ensure no leaks. The
prepared separating gel was then poured until two-thirds of 1.5mm glass plates were
filled up. Distilled water or 100% ethanol was layered on top ensure the equal level
gel casting and kept at room temperature to allow complete polymerization. Once
resolving gel was set, the prepared 4% stacking gel was overlaid on top and wells were
created by immediately inserting a 1.5 mm thick, 10-wells comb while taking care to
minimize the bubble formation in the gel. It normally took about 1 hour at room
temperature to complete polymerization. Once set, the comb was removed gently and
gels encased in between the glass plates were secured in an electrophorator tank to
create two separate reservoirs. After that, 1L of 1X running buffer was poured into the
tank, while washing the wells of gel, until gels were completely flooded with the
buffer. The prepared samples were centrifuged and they were loaded to individual
well, with 5 ul of a rainbow molecular weight marker (14,300-220-000 Da) alongside.
The tank was then connected to the electric current using 100V voltage. It usually took
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1 or 1 and ½ hours to complete resolution of the samples in the gel which could be
monitored by dye fronts running down to the bottom of the gels.
6.2.3.4.3 Electrophoretic transfer of protein (Electroblotting)
After electrophoresis, the gels were carefully removed from the glass plates. The
stacking gels were discarded and the remaining resolving gel parts were washed in
cold transfer buffer for 10 minutes. Meanwhile, immobilon-PTM PVDF
membranes(0.45µm; Millipore, USA) was immersed in absolute methanol briefly for
membrane activation and then immediately soaked in cold transfer buffer until use. At
the same time, 2 fibre pads and 2 filter papers for each gel were soaked in cold transfer
buffer for at least 10 minutes. Firstly, a saturated fibre pad was laid on the black side
of transfer cassette, which was overlaid by a filter paper, gel, PVDF membrane, filter
paper and a fibre pad in sequential order, avoiding any bubble stacking in between
layers. Then, the enclosed cassette was then transferred into an electrotransfer tank
containing 1L of 1X transfer buffer and ice pack. Proteins on the gels were transferred
electrophoretically at 100V, 1 hour for 1.5mm thick gel. Alternatively, a constant
voltage of 25V was used for overnight transfer for high molecular weight peptide
transfer. A magnetic stirrer was also put inside the tank to reduce the heat.
6.2.3.4.3.1 Primary antibody detection
Following electroblotting, membranes were taken out from the cassette while
trimming to mark orientation and membrane number. They were then incubated with
blocking agent (0.2% I-Block in PBS-Tween 20) and placed on a shaker for 1 hr at
room temperature or overnight for ~14 hr at 4°C to prevent non-specific protein
binding and direct primary antibody binding to the membrane. After blocking, they
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were rinsed briefly in 0.1%PBS-T before incubating with primary antibody prepared
in 5ml of 0.2% i-Block in PBS-T for another 1 hour at room temperature or overnight
at 4°C on an orbital shaker. After that, membranes were washed with 0.1%PBS-T for
3 times, 10 min interval, on the shaker to remove excess primary antibody.
6.2.3.4.3.2 Secondary antibody detection
After primary antibody application, membranes were submerged again in secondary
antibody conjugated with enzyme such as horseradish peroxidase (HRP) for another 1
hour at room temperature on a shaker. Secondary antibody was made up in 0.2% i-
Block in PBS-T. Following incubation, they were washed with PBS-T for 3 times, 10
minutes apart, on the shaker. Secondary antibody is attached to primary antibody
which binds to the protein of interest.
6.2.3.4.3.3 Immunodetection
A chemiluminescent detection system, ECL/ECL+ (Amersham Pharmacia Biotech,
Little Chalfont, UK) was used to detect horseradish peroxidase conjugated secondary
antibody. In this reaction, cyclic diacylhydrazide luminol is oxidized to generate light
at 428 nm. This oxidation is catalysed by combined HRP and peroxidase, emission of
thousands of acridinium ester intermediates per minute. Peroxidase then reacts with
these intermediates to produce a high intensity chemiluminescence in slightly alkaline
conditions. The light emission can be visualised within 60 minutes by application of
HyperfilmTM (Amersham Pharmacia Biotech, Little Chalfont, UK). After secondary
antibody application and PBS washing (120 mM, pH 7.6), membranes were placed in
a clear thin film pocket with the surface of blotted protein side-up to allow
chemiluminescent reagent exposure. ECL chemiluminescent solution was prepared by
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mixture of solution A and solution B at 1:1 ratio (1 ml/membrane). The solution was
then poured onto the membranes and the membranes were incubated for 5 min at RT.
The excess ECL mixture was removed by wiping out with dry tissue papers on top of
the pocket. This plastic pocket with membranes inside was then put inside the X-ray
film cassette. In a dark room, a hyperfilmTM was then placed in the cassette on top of
membrane pocket for various duration depending on the antibody used (1-60 min) to
develop a film. Autoradiographs were finally semi-quantified using 2D densitometry
software (Imagequant, GEhealthcare, UK). The band density was then measured by
using software (Genesnap, Syngene, UK). The bands were first normalised as a
function of the loading control (protein of interest/-actin) or total expression of the
proteins (for phospho proteins), then be converted to fold change compared with
controls.
6.2.3.5 RNA extraction, isolation and quantification
Total RNA from HepG2 cell culture were isolated, extracted and quantified according
to the following steps.
A column based method (RNeasy lipid tissue kit, Qiagen, UK) was used to extract
total messenger RNA (mRNA) from samples in QIAzol according to manufacturer’s
instructions. Following mRNA columnisation, DNase digestion step was completed
by adding the mixture of 5µL DNase enzyme and 5µL reaction buffer the sample and
incubating for 15 min at RT to digest any contamination genomic DNA. Then, the
reaction was stopped by adding 5 µL of stop solution and the tubes were put on heat
block at 70°C for 10 min. Following this, total mRNA was quantified by Nanodrop
ND-1000 Spectrophotometer (LabTech, UK) at a ratio of readings at a wavelength of
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260 (mainly detected RNA) and 280 nm (detected protein, solvents, salts). This ratio
was used to measure purified RNA with the ratio of 1.8-2.0 as acceptable. Phenol
contamination was also assessed by using the absorbance at 230 and the 260/230 ratio
of 1.8-2.0 as highly purified RNA. The quantified RNA samples were finally stored at
-70°C.
6.2.3.5.1 Reverse Transcription of Isolated mRNA from HepG2 cells
Complementary DNA was synthesized from each RNA sample by the addition of
Bioscript Reverse Transcriptase (Bioline, UK), random hexamers (Bioline, UK) and
10mM dNTP mix (dATP, dGTP, dCTP and dTTP, Bioline, UK) in accordance with
manufacturer’s protocol.
An aliquot of 500 µg mRNA from each sample was used as template in cDNA
synthesis. In this reaction, Random or Oligo(dT)18 hexamer attached to its
complementary region on mRNA and cDNA was reverse transcribed using dNTP as
precursors. The steps involved in cDNA making was described in details as follows.
Firstly, each aliquot was pipetted to a sterile RNase-free microcentrifuge tube together
with 1ul each of random hexamer and dNTP mix. DEPC-treated water was then added
to standardize a final volume of 10 uL. The mixture was then incubated at 70°C for 10
min, followed by chilling on ice for 1 min. Meanwhile, the reaction premix was
prepared by mixing appropriate volumes of the required reagents described in table.
After a careful vortex, 10µL of the reaction premix were added to each sample. Then,
the samples were mixed gently by pipetting and incubated at 25°C for 10 min followed
by 42°C for 30 min. The final cDNA samples were kept at -20°C for further use.
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6.2.3.6 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Quantitative real-time PCR analysis was used to validate the mRNA expression levels
of selected genes using an ABI 7500 real-time PCR Sequence Detection system. Real-
Time PCR was done using 96 well plates, by addition of 24uL of a reaction buffer
which is a mixture of Taqman universal PCR master mix (Applera, UK), nuclease-free
water, a primer and 18s. Pre-optimized quantitative primer and probe sequences for
genes were utilized (Applera, Cheshire, UK). All reactions were multiplexed with the
housekeeping gene 18S, provided as a pre-optimized control probe (Applera), enabling
data to be expressed in relation to an internal reference to allow for differences in
relative threshold efficiency. The PCR steps started with 50°C for 2 min, 95°C for 10
min, 44 cycles of 95°C for 15 min and 60°C for 1 min. Data obtained as cycle threshold
(Ct) values according to the manufacturer’s guidelines (the cycle number at which
logarithmic PCR plots cross a calculated threshold line) were used to determine ΔCt 
values (ΔCt=Ct of 18S housekeeping gene subtracted from Ct of gene of interest). 
Measurements were carried out as triplicates for each sample. To exclude potential
bias due to averaging data which had been transformed through the equation 2-ΔΔCt, all
statistics were performed at the ΔCt stage. 
6.2.3.7 Statistics
For all analysis, data were expressed as mean±standard error of the mean (SEM) for
three independent experiments done in triplicates at least to ensure replicability. A
two-tailed unpaired Student’s t test was used to analyse the data between two groups,
using 0 nM vitaminB12 as a reference group. ‘p’ value <0.05 were considered to be
statistically significant.
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6.3 Results
6.3.1. Lipogenic genes were down-regulated by vitamin B12 supplementation
in hepatocyte cell line cultured in long-term low vitamin B12 (0nM) media
The mRNA expression levels of key enzymes of triglyceride and cholesterol
biosynthesis (FAS and HMGCR, respectively) (Figure 6.1.A and B) and their
regulatory genes (Sterol regulatory element binding factors (SREBFs)) were
measured by qRT-PCR. SREBFs are conditional transcriptional factors resided
in endoplasmic reticulum and can be stimulated when intracellular lipid levels
are low (SREBF1 mainly for triglyceride and SREBF2 mainly for cholesterol).
When activated and released by protease, nuclear SREBFs bind to the
promotor region of more than 30 target enzymes dedicated to increased
synthesis and uptake of lipids including FAS and HMGCR. We have found
that vitamin B12 supplementation significantly down-regulated the mRNA
expressions of FAS and HMGCR enzymes in 100 and 1000nM vitamin B12
conditions compared to 0nM vitamin B12 condition (Figure 6.1 A and B).
Furthermore, their transcriptional regulators such as SREBF1 and SREBF2
also showed decreased expression with increasing vitamin B12 concentrations
with the lowest in 1000nM B12 condition (Fig 6.1 C and D).
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A) Fatty Acid Synthase (FAS)
B) 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR)
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C) Sterol Regulatory Element Binding Factor -1 (SREBF1)
D) Sterol Regulatory Element Binding Factor -2 (SREBF2)
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Figure 6.1. Effects of long-term Vitamin B12 supplementation on mRNA expression
of lipogenic genes (FAS, HMGCR) and their regulatory genes (SREBF1, SREBF2) in
hepatocytes. The mRNA levels was determined by qRT-PCR (n=6). Values are
presented as mean±SEM expressed as a relative fold change to control, (0nM Vitamin
B12), which was regarded an arbitrary value of 1. p-values *p<0.05, **p<0.01 and
***p<0.001 by student’s ‘t’ test. A. Fatty acid synthase (FAS) B. 3-Hydroxy-3-
Methylglutaryl-CoA Reductase (HMGCR) C. Sterol Regulatory Element Binding
Factor-1 (SREBF1) D. Sterol Regulatory Element Binding Factor-2 (SREBF2)
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6.3.2. Vitamin B12 supplementation increased insulin signalling in
hepatocyte cell lines
Protein expression of markers in insulin signalling pathways were measured in
response to insulin (100nM for 15minutes). Once insulin receptors activated,
it acts as tyrosine kinase which subsequently activates the docking molecule -
insulin receptor substrate (IRS) and protein kinase B (PKB)/Akt. Akt is a
serine/threonine specific protein kinase which phosphorylates its downstream,
glycogen synthase kinase(GSK)3β, and inhibits its activation of glycogen 
synthase enzyme and thereby, stimulating glycogenesis. The phosphorylated
Akt and its downstream signal, GSK3α/β, were analysed using phospho-Akt 
(Ser473) and phospho- GSK3α/β (Ser21/9) antibodies. Insulin-induced 
phosphorylated signals of Akt and GSK3α/β were significantly increased in 
10, 100 and 1000 nM vitamin B12 conditions compared to low B12 (0nM)
condition. (Figure 6.2).  Protein expression of total Akt and GSK3α/β or β-
action were found to be no change.
225
A) Insulin signalling pathway
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C) Quantification of pGSK3α/β/α-GSK3β protein bands 
Figure 6.2: Effects of long-term Vitamin B12 supplementation on protein expression
levels of pAkt (Ser473) and GSK3α/β (Ser21/9) in hepatocytes, as detected by Western 
blot (n=4). Values are presented as mean±SEM expressed as a relative fold change to
control, (0nM Vitamin B12), which was regarded an arbitrary value of 1. p-values
*p<0.05, **p<0.01 and ***p<0.001 by student’s ‘t’ test. A. A representative Blot
from 3 independent experiments is shown. B and C. Quantification of bands by
densitometry.
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6.3.3. There was no change in the phosphorylation of AMPK and ACC with
vitamin B12 supplementation but the protein levels of total ACC were
down-regulated with vitamin B12 supplementation.
Western blot analyses of molecules in phosphorylated AMPK and ACC
molecules were measured in vitamin B12-treated HepG2 cells. Normally,
AMPK activation maintains cellular energy balance by stimulating catabolic
pathways such as fatty acid oxidation while preventing energy-consuming
anabolic pathways including lipogenesis through inhibiting ACC, FAS and
HMGCR enzyme activities. Once activated by phosphorylation at Thr-172 of
AMPK α subunit, it subsequently phosphorylates and inactivates, ACCα 
(Ser79), a rate-limiting enzyme for triglyceride metabolism. ACC is a
bidirectional enzyme and determine the fate of fatty acids. If phosphorylated,
it favours fatty acid towards beta-oxidation pathway whereas non-
phosphorylated form favours formation of malonyl-CoA and lipogenesis. Total
expression of AMPK protein was reprobed with AMPKα2 antibody. Total 
ACC protein was determined with ACCα/β antibody. In HepG2 cells passaged 
repeatedly in different B12 concentrations for 22 days, there were no change
in phospho-to-total AMPK, phospho-to-total ACC ratio and phospho-ACC by
total-AMPK ratios. Interestingly, there was decreased protein expression of
total ACC enzymes with vitamin B12 supplementation (Figure 6.3).
228
A) pAMPK signalling
B) Quantification of pAMPK/α-AMPKα2 protein bands 
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C) Quantification of pACC/α-AMPKα2 protein bands 
D) Quantification of pACC/total ACC protein bands
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E) Quantification of total ACC protein bands
Figure 6.3: Effects of long-term (24 days old) Vitamin B12 supplementation on protein
expression levels of pAMPK (Thr172) and pACCα (Ser79) in hepatocytes, as detected 
by Western blot (n=4). Values are presented as mean±SEM expressed as a relative fold
change to control, (0nM Vitamin B12), which was regarded an arbitrary value of 1.
p-values *p<0.05, **p<0.01 and ***p<0.001 by student’s ‘t’ test. A. Representative
Blot from 3 independent experiments is shown. B, C, D and E. Quantification of bands
by densitometry.
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6.3.4. Phosphorylation of AMPK and ACC enzymes induced by metformin was
increased in vitamin B12 supplemented culture compared to low B12 culture
(0nM)
Zhou et al have reported that metformin works by activating AMPK in liver.
Metformin partially blocks the complex I of mitochondrial oxidative respiration
thereby, altering AMP:ATP ratio which phosphorylates AMPK at threonine 172 (Zhou
et al 2001). Subsequently, the target enzymes of AMPK, such as ACC, FAS and
HMGCR, are suppressed and intracellular lipid levels are decreased. Metformin-
induced phosphorylation of AMPK is reported to be the greatest with 2mM metformin
for 24 hours treatment. We found that the protein expression levels of metformin-
stimulated phosphorylated AMPK and ACC ratios were lowest in 0nM vitamin B12
condition compared to other vitamin B12 concentrations (10, 100, 1000 nM) (Figure
6.4). Moreover, protein expression levels of total ACC enzymes were decreased with
vitamin B12 supplementation in both basal and metformin-treated conditions, with the
lowest in 1000nM vitamin B12 culture treated with metformin. There was no change
in total ACC protein expression with or without metformin treatment (Figure 6.4E).
As total ACC protein expression levels varied with vitamin B12 concentrations,
phosphorylated ACC protein levels were quantified using total AMPK as
denominator. Expectedly, phospho-ACC levels were found to be decreased in low (0
nM) B12 compared to 10, 100 and 1000 nM B12 conditions (Figure 6.4 F). Moreover,
the down-regulated mRNA levels of FAS and HMGCR together with their
transcriptional factors, SREBF1 and SREBF2 respectively, induced by vitamin B12
supplementation were significantly further decreased with metformin stimulation
significantly compared to their vitamin B12 counterparts (Figure 6.4. G, H, I and J).
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Surprisingly, among 4 vitamin B12 treated conditions, the changes of these enzymes
by metformin was highest and most significant in low (0nM) vitamin B12 condition.
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A) pAMPK phosphorylation by metformin
B) Quantification of pAMPK protein band induced by metformin
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
Ctrl 2m M 24hrM et
Fo
ld
ch
an
ge
phospho-AMPK(Thr172)
0 nM B12
10 nM B12
100 nM B12
1000 nM B12
***
***
**
234
C) pACC phosphorylation by metformin
D) Quantification of pACC protein band induced by metformin
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
Ctrl 2mM24hrMet
Fo
ld
C
ha
ng
e
pA
C
C
:t
A
C
C
phospho-ACC(Ser79)
0 nM B12
10 nM B12
100 nM B12
1000 nM B12
***
***
***
235
E) Quantification of total ACC protein band
F) Quantification of pACC/total AMPK protein band induced by metformin
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G) SREBF-2 gene expression induced by metformin
H) HMGCR gene expression induced by metformin
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I) SREBF1 gene expression induced by metformin
J) FAS gene expression induced by metformin
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Figure 6.4: Effects of metformin on protein expression levels of pAMPK (Thr172) and
pACCα (Ser79) as well as mRNA expression levels of lipogenic enzymes (FAS, 
HMGCR) and their regulatory genes (SREBF1, SREBF2) in hepatocytes. Protein
levels were detected by Western blot (n=4) and mRNA levels were determined by
qRT-PCR (n=6). Values are presented as mean±SEM expressed as a relative fold
change to control, (0nM Vitamin B12), which was regarded an arbitrary value of 1.
The levels of metformin treatment were compared against their vitamin B12
counterparts(*). p-values *p<0.05, **p<0.01 and ***p<0.001 by student’s ‘t’ test. A
and C. Representative Blot from 3 independent experiments is shown. B, D, E and F.
Quantification of bands by densitometry. G, H, I, J. mRNA expression by PCR
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6.3.5. Down-regulation of lipogenic enzymes by vitamin B12
supplementation were blocked with anti-methylating agent, 5-
azacytidine (AZT)
5-Azacytidine is a cytosine analogue, impeding DNA methylation and thereby
re-expression of hyper-methylated genes. Adipocyte culture with vitamin B12
has been reported that vitamin B12 deficiency alters the methylation potential
of the cells and induces increased expression of cholesterol biosynthetic
enzymes due to hypomethylation. To validate the role of vitamin-B12 related
methylation in the regulation of lipogenic gene expression, mRNA levels of
HMGCR and FAS were measured by qRT-PCR after differentiating the B12-
supplemented cells (10 nM, 1000 nM) vitamin B12 in media with methylation
blocker/AZT (300nM, 3 days). AZT significantly increased the expression
levels of lipogenic genes (FAS and HMGCR) down-regulated by long-term
vitamin B12 culture (Figure 6.5).
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A) FAS gene expression by AZT treatment
B) HMGCR gene expression by AZT treatment
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Figure 6.5 (A and B): Effects of Vitamin B12 on mRNA expression levels of hepatic
lipogenic genes (FAS, HMGCR) in the presence of methylation blocker (5-
azacytidine). The mRNA levels was determined by qRT-PCR (n=3). Values are
presented as mean±SEM expressed as a relative fold change to control, (0nM Vitamin
B12), which was regarded an arbitrary value of 1. The levels of AZT treatment were
compared against their vitamin B12 counterparts (*). p-values *p<0.05, **p<0.01 and
***p<0.001 by student’s ‘t’ test.
242
6.4 Discussion
The association of vitamin B12 deficiency with blood dyslipidaemia has been reported
by several clinical studies (Mahalle et al 2013; Adaikalakoteswari et al 2014;
Adaikalakoteswari et al 2015a: Adaikalakoteswari et al 2015b). The proposed
mechanistic model is that it occurs through reduced methylation potential and hypo-
methylation of lipogenic enzymes in vitamin B12 deficient condition and which has
partly elucidated by a study done on adipocyte culture (Adaikalakoteswari et al
2015a). As liver plays a central role in both uptake and transport of lipids in the
circulation, examining the changes of lipid metabolism in vitamin B12 deficient will
enable to understand how serum vitamin B12 deficiency can lead to abnormal lipid
profiles and, more importantly, whether vitamin B12 supplementation can reverse this.
Similar to the previous adipocyte study (Adaikalakoteswari et al 2015a) and in vivo
studies (Kumar et al 2013), we have found that there was increased expression of
hepatic lipogenic enzymes in low vitamin B12 condition due to impaired methylation.
The novel finding in this study is that insulin signalling and AMPK signalling
pathways can be affected by vitamin B12 deficiency. Consequently, lipid-lowering
effects of metformin are found to be impeded in low vitamin B12 cells. Finally, the
vitamin B12 supplementation culture model suggests that epigenetic changes due to
low vitamin B12 conditions can be countered by successive long-term vitamin B12
supplementation.
6.4.1. Effects of low vitamin B12 levels on lipid synthesis
Firstly, it was decided to look at the expression of enzymes important for cholesterol
and triglyceride synthesis in liver cells, which have been passaged in different vitamin
243
B12 conditions successively for several times. Enzymes for triglyceride were included
in this study because liver is central regulator of blood triglyceride levels. Moreover,
in Wister rat study done by Kumar and Frenkel groups, it was independently observed
that vitamin B12 restriction in mothers increased lipid accumulation in viscera and
altered adipose tissue composition in the offspring by increasing the activities of
hepatic FAS and ACC (Kumar et al 2013). HMGCR and FAS mRNA expression
levels were selected to be studied. FAS was chosen rather than ACC the rate-limiting
enzyme in triglyceride synthesis because of the limited resources and FAS was readily
available in our lab. Moreover, total ACC expression levels were examined with
western blotting and FAS is highly correlated with ACC and the rate of fatty acid
synthesis (Kumar et al 2013). In this study, there was down-regulation of HMGCR
and FAS mRNA levels in the liver supplemented with vitamin B12. The decreased
lipogenic enzyme levels are in coordination with their transcription factors (SREBF1
and SREBF2). The effects of maternal B12 deficiency on lipid synthesis of progeny’s
liver have been studied in animals over time and they have consistently reported that
maternal vitamin B12 deficiency increased liver lipid content, triglyceride, total
cholesterol, cholesterol ester and free cholesterol, in their offspring(Moore et al 1962;
Armstead et al 1971; Icayan et al 1962). Furthermore, an adipocyte cell culture model
indicated that the cholesterol levels were found to be increased in no or low vitamin
B12 conditions (Adaikalakoteswari et al 2015a). Accordingly, the possible findings of
intracellular lipids in our study could be decreased with vitamin B12 supplementation.
At the same time, as vitamin B12 is essential for normal metabolic function in the
cells, another possibility is that vitamin B12 supplementation might return the cellular
metabolism to normal and the decreased expression of the rate-limiting enzymes in
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our study might suggest that the allosteric inhibition of the enzymes by the end
products, cholesterol and triglyceride levels. Thus, we would suggest to include the
measurements of intracellular lipid content in the future studies.
6.4.2. Impaired methylation due to low vitamin B12 levels implicates the changes in
lipigenic gene expression
Next, in order to explore the possible mechanism behind vitamin B12-induced
decrease in expression of lipid synthetic enzymes, the effects of vitamin B12
supplementation to the expression levels of these enzymes were studied by adding the
methylation blocker, AZT to our HepG2 model with long-term vitamin B12 culture.
An increase in expressions of HMGCR and FAS enzymes by AZT was seen in
comparison to their basal vitamin B12 counterparts. The change by AZT was higher
than low (0nM) vitamin B12 condition, suggesting that the amount of vitamin B12
(120pM) in FBS was high enough to methylate the lipogenic gene expression to
considerable extent. Studies of Vitamin B12 as an cofactor for methionine
synthase(MS)/methyltransferase in epigenetics have also reported that vitamin B12
helps the stability of MS by translational up-regulation (Oletean et al 2003; Gulati et
al 1999; Kamely et al et al 1973). As MS is vital for one carbon change in methylation
which is important for normal DNA package, it is presumable that intracellular low
B12 levels can induce hypomethylation. Based on this evidence and our findings of
AZT treatment, we have postulated that in vitamin B12 deficiency, the DNA sequences
are loosely packed because of reduced methylation and this might result in increased
gene expression.
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6.4.3. Vitamin B12 supplementation improves insulin sensitivity
In addition to the association of dyslipidaemia with vitamin B12 deficiency, there are
a number of reports from clinical studies that vitamin B12 deficiency can increase
insulin resistance done by HOMA-IR(Yajnik et al 2008; Krishnaveni et al 2014), for
which intracellular mechanism has not yet been confirmed. Thus, we decided to look
at the insulin signaling pathway. We have found that HepG2 differentiated in vitamin
B12 supplemented culture for prolonged period can increase phosphorylation of Akt,
an upstream insulin signal. This effect is followed by increased phosphorylation of
GSK enzyme which subsequently inhibits glycogen synthase enzyme and thereby
glycogenesis in the presence of insulin. Thus, this might indicate that vitamin B12
supplementation to HepG2 culture improves insulin signaling. In other words, this
might also suggest that long-term low vitamin B12 culture induces insulin resistance
in HepG2 cells. As previously described in (Chapter 1.4.2), the primary role of liver
in lipid metabolism is by regulating synthesis of ApoB100 lipoprotein in the balance
of insulin and fatty acid entry. It is stated that in liver with normal insulin sensitivity,
there is inhibition of ApoB100 synthesis and thereby suppression of very low density
lipoprotein (VLDL) production which represents major endogenous triglyceride
compartments in the blood. Although the causal relationship between lipid
dysregulation and insulin resistance in vitamin B12 deficient state has not yet been
examined extensively, Saravanan and his group suggested that insulin resistance was
preceded by intracellular impeded lipid metabolism in vitamin B12 deficiency
(Saravanan et al 2010). Based on our findings in this chapter, the postulated
mechanism of how low vitamin B12 condition leads to dyslipidaemia has been
developed. Firstly, in vitamin B12 deficient liver with normal insulin sensitivity, there
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might be impaired mobilization of intracellular lipids due to increased biosynthesis
and suppression of ApoB100 production at the same time, possibly resulting in liver
steatosis. This is supported by a clinical study which observed the significant
association of vitamin B12 deficient population with higher risk of non-alcoholic fatty
liver disease (NAFLD)(Koplay et al 2011). Subsequently after that, large amount of
lipid accumulation later induces metabolic stress inside the cell and eventually the cell
becomes insulin resistant.
6.4.4. Lipid-lowering effects of metformin in vitamin B12 deficient hepatocytes
At the basal condition without metformin treatment, there was no change in
phosphorylated AMPK (Thr172) levels among HepG2 culture with vitamin B12
addition. When metformin was given, the increased phosphorylation of AMPK was
observed in all HepG2 cells with additive vitamin B12 culture. This might indicate
that metformin-induced AMPK phosphorylation was impeded in low B12 conditions
and cells with vitamin B12 supplementation could improve the situation. There are
some suggestions on how vitamin B12 deficiency might interfere with metformin
action on activation of AMPK. Then, we have looked at metformin effect on the
phosphorylation of ACC at Ser79, the downstream signal of AMPK. In line with
AMPK phosphorylation, there was no difference in ACC phosphorylation. Similarly,
once AMPK activated by metformin, the ACC phosphorylation was found to be
increased positively with vitaminB12 concentrations. Previous in-vivo studies have
reported that increased levels of total ACC mRNA expression with vitamin B12
deficiency (Khaire et al 2015). As the phosphorylation capacity of AMPK on ACC
also depends on total ACC availability, we also examined the levels of total ACC-1
protein expression. We chose ACC-1 because it is highly expressed in the liver. There
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was decrease in ACC total protein expression with vitamin B12 supplementation. Even
in semi-quantitative like Western Blot, the effect was quite apparent. We also
determined the ratio of ACC phosphorylation levels by dividing with either total ACC
protein levels or total AMPK levels and there was increased phospho:total-ACC or
phospho-ACC:total-AMPK with increasing B12 conditions. This might suggest that
vitamin B12 supplementation could improve the mitochondrial function of hepatocyte
which is the primary site of metformin action. Theoretically, in vitamin B12
deficiency, MMA is accumulated and impedes Coenzyme Q biosynthesis. Thus, it is
possible that vitamin B12 sufficient culture helps relieve these MMA and thereby
enhancing mitochondrial respiration. This work should be further confirmed by future
study with vitamin B12 on mitochondrial respiration. It should also be noted that as
phosphorylated ACC is the inhibitory form of ACC enzyme which converts acetyl
CoA to malonyl CoA, a precursor for triglyceride synthesis. The increased fatty acid
oxidation can be explained by the fact that reduced MMA accumulation due to vitamin
B12 can improve cytosolic fatty acyl transfer into mitochondria which was previously
inhibited at carnityl parmitoyl transferase-1 (CPT-1) by vitamin B12 deficiency. Thus,
we would conclude that vitamin B12 supplementation helps improve lipid lowering
effects of metformin, possibly by improving energy metabolism within the cells.
We also examined other important downstream enzyme expression of AMPK,
important for lipogenesis, FAS and HMGCR together with their transcriptional factors
SREBF 1 and 2. AMPK activation by metformin or other drugs/metabolites are
reported to reduce the expression of these enzymes with their transcriptional factors in
liver (Lee et al 2008). Likewise, when metformin was given, we have observed that
HMGCR and FAS expression levels were further reduced by metformin treatment and
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this was accompanied by reduction of their transcriptional factors. The levels are in
accordance with increasing concentrations of vitamin B12. Thus, it is likely that in
vitamin B12 deficient cells, metformin-induced lipid lowering effects of metformin
can be enhanced by adding vitamin B12.
6.4.5. Strengths and Limitation
The strength of the study is that this is the first study to support that cells with
supplemented vitaminB12 can improve the efficacy of metformin on AMPK activation
and improve lipid profiles. Moreover, the use of liver cell culture could help
extrapolation of the mechanism to clinical studies. Furthermore, the causal relationship
of up-regulation of hepatic lipid synthetic enzymes with vitamin B12 deficiency was
confirmed by AZT study. In addition, the inclusion of 4 different vitamin B12
concentrations will help for future successive studies. However, these data are
supported by long-term vitamin B12 supplementation and thus, the metformin effect
on liver cell with shorter duration of treatment would be of advantage before
implementing the supplementation of vitamin B12 to vitamin B12 deficient patients at
metformin initiation. Although we have reported the AMPK signalling pathway of
metformin affected by vitamin B12 concentrations, the findings should be confirmed
by inhibitor studies using blockers or transfection of AMPK. Moreover, the finding
should be confirmed in animal model of vitamin B12 supplementation with metformin
treatment before future implication.
6.4.6. Suggestions for future study
The future study should be expanded by looking at other key enzymes in lipid
metabolism such as ACC, HMGCS and LDLR together with intracellular lipid content.
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Then, we need to explore the other factors contributing to elevated VLDL outputs such
as increased fatty acid influx, mainly from lipolysis of adipocytes. Amstead and his
group have predicted that the enzyme for conversion of free to esterified cholesterol
might be impaired in vitamin B12 deficiency (Armstead et al 1971), possibly
suggesting involvement of lipid esterification enzyme, whereas Khaire et al has
reported that the lipid fractions in the liver are affected by vitamin B12 (Khaire et al
2015). Thus, we suggest that the individual fatty acid fractions of increased lipid
content(such as total cholesterol and triglyceride levels) due to vitamin B12 addition
should be included. In addition, a recent study of vitamin B12 supplementation to
wistar rats during pregnancy has suggested that there is increased plasma triglyceride
levels in offspring of vitamin B12 supplemented rats with decreased hepatic
eicosapentaenoic acid (EPA) accumulation which regulates triglyceride metabolism
(Khaire et al 2015). Thus, the relationship between omega3 fatty acid with vitamin
B12 on lipid metabolism should be further explored. Furthermore, the role of vitamin
B12 in mitochondrial dysfunction and metabolic dysregulation need to be fully
established. In addition, as the lipid composition of the tissues and the circulation can
be differed by gender (Icayan et al 1962), it is of importance to report findings from
the clinical studies looking at the lipid profile in B12 deficiency by gender.
6.4.7. Clinical implications
Vitamin B12 is vital for normal lipid homeostasis. However, because of high storage
in liver and low prevalence of vegetarian population, its significance is usually
ignored. On the other hand, having aware of importance of folic acid in neuronal
development, folic acid fortification is everywhere from elderly diet to antenatal care.
It should be noted that B12 deficiency is quite common in pregnancy due to high
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demand. In fact, one prospective study has reported that the intakes of low B12 high
folate diet in pregnant mothers have high risk of small-for-gestational-age
(Dwarkanath et al 2013). The possible mechanism could be that the associated
dyslipidaemia and high homocysteine levels in vitamin B12 deficient mothers disturb
with placenta blood flow, thereby, altering the size of intrauterine baby (Hogeveen et
al 2012; Adaikalakoteswari et al 2015b). Although adequate vitamin B12 levels can
help improve these outcomes by providing enough methyl groups for normal foetal
programming, there is limited data to support that vitamin B12 supplementation are
beneficial. Thus, considering the importance of vitamin B12 in pregnancy,
epidemiological and mechanistic studies looking at vitamin B12 deficiency and
supplementation are highly demanded before implementation of vitamin B12 at
population levels.
In conclusion, vitamin B12 deficiency can impede methylation of lipid synthesis
enzymes as well as the efficacy of metformin, particularly its lipid lowering effects,
can be impaired in vitamin B12 deficiency. Thus, before metformin is given, it should
be considered to check vitamin B12 levels.
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CHAPTER 7
THESIS SUMMARY AND CONCLUSIONS
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7.1 Overview
Since 1954 when the term GDM has been first developed, the optimal GDM care has
not been agreed upon internationally. With different diagnostic criteria and
prevalences worldwide ranging from 5-25%, GDM is in the upward trend
successively. The target of GDM management is to keep the pregnancy safe from
adverse effects of hyperglycemia. Diet and lifestyle intervention is the first strategy to
achieve the target glycemic levels and if required, insulin is the universally acceptable
medication to add on. For the past few years, metformin role in pregnancy is found to
be beneficial in many aspects of GDM management. However, because of placental
drug transfer and its long-term concerns, it is not widely used in pregnancy yet.
Moreover, the use of metformin is also associated with reduction in serum vitamin
B12 and folate levels which are critical micronutrients for foetal development during
pregnancy. Folate being part of antenatal program, the deficiency is not common
during pregnancy but vitamin B12 deficiency is. It is also well-known that high folate
levels can have detrimental effects on health in patients with vitamin B12 deficiency.
Thus, it is important to understand how metformin, vitamin B12 and folate interact
with each other to ensure the delivery of metformin in GDM effectively and safely.
This thesis aimed to improve the overall management of GDM by evaluating the
current evidence of metformin in GDM, examining the inter-relationship of vitamin
B12 and folate on pregnancy outcomes in UK GDM population and finally, study the
efficacy of metformin in vitamin B12 deficiency condition.
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7.2 Systematic review of metformin in GDM
The role of metformin in GDM is increasing over the last few decades. Evidence from
a number of recent meta-anlayses have suggested that metformin could be better
medication than insulin for GDM. However, all of them included only randomized
controlled trials, most of which are of poor quality. The addition of non-randomized
trials data in GDM might help to increase the sample sizes and allow sensitivity
analysis to generate more precise outcome estimates.
In line with previous reviews, metformin could be better than glibenclamide and
insulin in GDM management. Our meta-analyses was complete and included 9 RCTs
and 6 NRCTs which revealed that metformin in GDM can benefit less maternal weight
gain, pregnancy-induced hypertension, neonatal hypoglycaemia and NICU admission
rates in comparison with insulin. Moreover, the NRCTs meta-analyses have suggested
possible reduction of LGA, SGA and macrosomia whereas the sensitivity analysis of
RCTs suggested reduced neonatal jaundice and decreased birth weight and
macrosomia. Most of the limitations of NRCT findings are that the recruitment of
moderate hyperglycemic group as well as exclusion of metformin-treated GDM with
additional insulin and GDM women with <10% foetal abdominal circumference in
metformin arm. This might favour the better improvement of pregnancy outcomes in
metformin-treated arm. Out of 15 studies included, only 2 RCTs are of high quality.
Thus, future randomized controlled trials should be focused on GDM with moderate
hyperglycemia with adequate power to detect the outcomes suggested by NRCTs. It
should be noted that sensitivity analysis of RCTs effect estimate suggests increased
risk of prematurity with metformin than insulin. Furthermore, the toddler follow-up
metformin data from 2 RCTs suggest comparable outcomes with insulin. There is also
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a need of follow-up RCTs with complete measurement of adiposity in these children.
At the same time, 3 RCTs with glibenclamide have indicated the increased neonatal
hypoglycemic risk with glibenclamide. So far, metformin seems to be the best oral
antihyperglycemic agent in GDM.
Moreover, we have systematically collected the data on characters of GDM women
who are likely to need additional insulin (metformin failure) in later pregnancy. It is
suggested that risk factors of GDM like older age, higher BMI and higher glucose
levels can be predictors of metformin failure and metformin failure might also relate
to certain ethnic groups. Understanding the factors contributing to metformin failure
helped to develop a predictive model to identify subgroup of GDM with potential
metformin faiure. Thus, using the retrospective clinical data of metformin users in
GDM, we have established the predictive tool in our chapter 4.
Based on current available data, metformin is safe to use in GDM and it also can
benefit GDM in many aspects such as increased patients’ compliance, saved healthcare
budgets and better reallocation of healthcare resources.
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7.3 Predictors of metformin failure in GDM
Being a drug with less maternal weight gain, metformin could be a very convincing
candidate in GDM to reduce the prevalence of childhood obesity and related risks.
However, a significant proportion of metformin-treated GDM required additional
insulin for optimal glycaemic control. Some of the studies revealed that the doses of
insulin needed after metformin failure are higher than those with insulin initiation after
dietary failure. This might suggest poor glycaemic control among metformin-failed
GDM which in turn increases foetal insulin stimulation. Thus, if a treatment strategy
with metformin in GDM is developed, these high-risk mothers could manage with
options other than metformin in order to avoid unnecessary risk.
In our systematic review, it have been reported that some of the maternal baseline
characters such as age, BMI, fasting glucose at OGTT and high risk ethnicity are
associated with higher risks of insulin resistance could predict metformin failure. Our
retrospective study of metformin in GDM (Chapter 4) have also shown that older age,
higher fasting glucose at OGTT, higher HbA1c at OGTT and earlier gestational age at
dietary failure can be determinants of metformin failure. We have also established a
diagnostic algorithm that fasting glucose >4.8mmol/L or fasting glucose ≤4.8mmol/L 
and GA at OGTT ≤27+5 weeks can detect almost 90% of women who are at risk of
metformin failure. Moreover, there are almost 4 in 5 chance of metformin failure
among women who have been diagnosed GDM either by IADPSG fasting or NICE
2015 fasting criteria. Finally, women with metformin failure are associated with 2
times higher risk of having premature babies.
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Thus, we have concluded that metformin can be an effective or even better alternative
to insulin in GDM with certain characteristics. However, GDM with very high fasting
glucose levels at OGTT are at high chance of needing supplementary insulin if they
are initiated with metformin as first-line medication. This could be avoided by limiting
metformin to GDM with moderate hyperglycemia. Moreover, the prospectus GDM
diagnosed by IADPSG or NICE 2015 fasting glycemia, insulin or other treatment
option other than metformin should be given in order to ensure adequate glycaemic
control throughout GDM. Since different criteria of metformin failure were presented
with readily available information, this might help healthcare personals in rural areas
for confident use of metformin in GDM and identify GDM who might need insulin for
tertiary referral. This consequently allow better allocation of resources efficiently.
Furthermore, the finding that metformin-failed GDM mothers are likely to deliver
premature babies should be replicated by future prospective studies with larger sample
sizes as this is an observational data and the confidence interval for the association is
very large. In addition, in order to exclude GI side-effects of metformin as a trigger
factor for prematurity, future studies with extended-release metformin are required.
Finally, as these findings are based on retrospective data, the results should be
validated with randomized controlled studies before implementing in policy.
In the absence of such data, it can be concluded that metformin might work better for
GDM women with postprandial hyperglycaemia or those with moderate severity.
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7.4. Role of vitamin B12 and folates in GDM
Micronutrients, important for cellular differentiation, are essential for normal foetal
development. During pregnancy, both vitamin B12 and folate levels are necessary to
be sufficient to ensure the optimal one-carbon transfer cycle which is critical for proper
methylation and normal foetal programming. Folates being part of antenatal program
as 400ug to 5 mg supplementation, it is common to encounter pregnancy with high or
normal folate levels in their late trimester. On the other hand, despite high prevalence
of vitamin B12 deficiency during pregnancy, it is not given routinely to pregnant
women yet. Thus, pregnancies with high/normal folates among low vitamin B12 status
can be seen in every antenatal clinic. In fact, vitamin B12 deficiency and GDM are
highly associated almost half of GDM women have low vitamin B12 levels. There are
a number of reports in pregnancy that high folate supplementation (5mg) in vitamin
B12 deficient state can have negative impact on pregnancy outcomes including SGA
and diabesity. However, the effect of normal folates among vitamin B12 deficient
mothers are yet to be examined.
In contrast to the effects of folic acid supplementation on blood glucose levels in type
2 diabetes, we have found that serum folate levels are inversely associated with OGTT
and postpartum fasting glucose levels in vitamin B12 deficient GDM women with
antenatal 400ug folic acid intake in Chapter 5. There was no association of serum
vitamin B12 and folates with neonatal birth sizes in GDM. This might suggest that it
is relatively safe to give folic acid of 400ug supplements to GDM women and this
should be accompanied with adequate vitamin B12 levels. Moreover, the
homocysteine independent effects of folates on fasting glucose levels might also
advocate the direct vascular involvement of folates on vitamin B12 sufficient
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endothelial cell rather than homocysteine-related vasculopathy, indicating the role of
folic acid supplementation in glycemic control among GDM with normal vitamin B12
levels. Furthermore, here was high correlation between folate levels and homocysteine
levels but not vitamin B12. At the same time, high homocysteine levels in GDM can
increase the prevalence of SGA among GDM which was around 15% in our study.
Thus, it is likely that increased doses of folic acid have a possibility to reduce high
rates of SGA among GDM. However, considering the adverse risk of high folates
among low vitamin B12 GDM population, this should not be the next preferable
option. Instead, studies looking at the impact of 400ug folate intakes in low and normal
B12 vitamin GDM on pregnancy outcomes should be examined first. Then, only after
replication of this observation of increased prevalence of SGA among normal B12 and
folate GDM population, increased folate dose should be another step to bring down
the SGA prevalences. This is the first study of impact of normal folate levels in low
vitamin B12 state and this should be followed by studying the interaction of normal
folate-low vitamin B12 effects in different settings including type 2 diabetes. Overall,
this chapter highlights the importance of normal vitamin B12 levels for folates to play
its role at full potential.
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7.5 Vitamin B12 deficiency on Lipid metabolism and Metformin action in Liver
Metformin is a powerful insulin sensitizing agent and it have a capacity to lower down
the blood lipid levels. However, one of its drawbacks includes decreasing serum
vitamin B12 levels. As vitamin B12 deficiency in diabetes mellitus is not uncommon
association, low vitamin B12 state can be worsened by metformin indication. Being
an increasingly popular drug in GDM where vitamin B12 sufficiency is important not
only for mothers but also for intrauterine babies, it is important to understand how
metformin might work in vitamin B12 sufficient state.
In chapter 7, we have proved that by affecting the genes involved in lipid metabolism
through abnormal methylation and reduced AMPK phosphorylation, vitamin B12
deficiency can reduce the potency of lipid-lowering effects of metformin in
hepatocytes. Moreover, repeated cultivation of these cells in vitamin B12
supplemented state can reverse these effects. This might indicate that for metformin to
have full potential on cellular metabolism, it is important to ensure the cells have
grown in normal vitaminB12 levels. For women who would receive metformin during
pregnancy, they should have normal vitamin B12 levels before metformin start and
throughout the metformin exposure. This could be achieved by supplementing vitamin
B12 at multifaceted levels, firstly targeting general population to ensure the normal
vitamin B12 levels among reproductive women and then additional supplements to
those who are in pregnancy.
Although it is found that vitamin B12 supplementation can improve the efficacy of
metformin, the duration and timing of supplementation still needs to be established.
As most of vitamin B12 deficient GDM could be detected just before metformin
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initiation, the question of whether vitamin B12 supplements together with metformin
can have similar efficacy to those on metformin with normal vitamin B12 levels are
not yet examined. This should be done by conducting randomized controlled trials
among GDM with metformin commencement with or without vitamin B12
supplements. Meanwhile, liver having high capacity for vitamin B12 storage and there
is no clinical reports of vitamin B12 toxicity due to supplementation, it might be safe
enough to give vitamin B12 supplements to those who are sufficient. Thus, it is better
to check vitamin B12 levels of all GDM who are going to be offered metformin and
vitamin B12 should be supplemented accordingly to enable metformin to act at full
efficiency.
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7.6 Overall Conclusions
In conclusion, the studies conducted in this thesis presented the new insights for the
use of metformin in GDM women and highlighted the importance of normal vitamin
B12 levels for overall improvement in GDM management. Evidence is based on
contemporary comprehensive systematic review of metformin in GDM, establishment
of different strategies to identify GDM sub-group who could potentially have high risk
of metformin failure, understanding the inter-relational effects of folate in normal
range in the context of vitamin B12 deficiency on pregnancy outcomes and finally,
elucidating the mechanism how metformin works in vitamin B12 deficient cell. It is
hoped that the findings from these studies will inform the health policy makers in
implementing metformin as first-line in GDM guidelines and will facilitate diabetes
specialists to provide the best GDM care as possible with metformin.
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9.1 Systematic Review
9.1.1. Search strategy
MedLine (23/5/15)
1. gestational diabetes.mp. or exp *Diabetes, Gestational/
2. pregnancy$ diabetes.mp. or exp *Diabetes, Gestational
3. (impair* adj5 glucose).mp.
4. (impair* adj5 sugar).mp.
5. (abnormal adj5 glucose).mp.
6. (abnormal adj5 sugar).mp.
7. (glucose adj5 intolerance).mp.
8. hyperglycemia.mp. or exp *Hyperglycemia/
9. (high adj5 glucose).mp.
10. (high adj5 sugar).mp.
11. insulin resistan$.mp.
12. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13. metformin.mp. or exp *Metformin/
14. glucophage.mp. or exp *Metformin/
15. exp *Metformin/ or diabex.mp.
16. exp *Methylguanidine/ or dimethylguanidine.mp.
17. exp *Biguanides/ or exp *Metformin/ or dimethylbiguanid$.mp.
18. glumetza.mp. or exp *Metformin/
19. diaformin.mp.
20. diformin.mp.
21. 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
22. 11 and 21
23. limit 22 to pregnancy
24. exp *Pregnancy/ or exp *Pregnancy Trimester, Third/ or late pregnancy.mp.
25. second trimester.mp. or exp *Pregnancy Trimester, Second/
26. third trimester.mp. or exp *Pregnancy Trimester, Third/
27. 24 or 25 or 26
28. 22 and 27
29. 23 or 28
[mp=title, abstract, original title, name of substance word, subject heading
word, protocol supplementary concept, rare disease supplementary concept,
unique identifier]
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Embase(23/5/15)
1. gestational diabetes.mp. or exp *pregnancy diabetes mellitus/
2. (impair$ adj2 glucose).mp.
3. (impair$ adj2 sugar).mp.
4. (abnormal adj2 sugar).mp.
5. (abnormal adj2 glucose).mp.
6. (high adj2 glucose).mp.
7. (high adj2 sugar).mp.
8. exp *insulin resistance/ or insulin resistan$.mp.
9. hyperglycemia.mp. or exp *hyperglycemia/
10. (glucose adj2 intolerance).mp.
11. pregnancy$ diabetes.mp. or exp *pregnancy diabetes mellitus/
12. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13. exp *third trimester pregnancy/ or pregnancy.mp. or exp *second
trimester pregnancy/ or exp *pregnancy/ or exp *"pregnancy disorders of
endocrine origin"/ or exp *pregnancy diabetes mellitus/
14. late pregnancy.mp. or exp *third trimester pregnancy/
15. second trimester.mp. or exp *second trimester pregnancy/
16. third trimester.mp. or exp *third trimester pregnancy/
17. 13 or 14 or 15 or 16
18. 12 and 17
19. exp *metformin embonate/ or exp *metformin/ or metformin.mp. or exp
*metformin 4 chlorophenoxyacetate/ or exp *metformin glycinate/
20. glucophage.mp. or exp *metformin/
21. diabex.mp. or exp *metformin/
22. glafornil.mp. or exp *metformin/
23. glisulin.mp.
24. exp *metformin/ or risidon.mp.
25. exp *metformin/ or dianben.mp.
26. dimethylbiguanid$.mp. or exp *biguanide derivative/
27. exp *biguanide/ or dimethylguanylguanidine.mp. or exp *metformin/
28. glumetza.mp. or exp *metformin/
29. fortamet.mp. or exp *metformin/
30. glycomet.mp. or exp *metformin/
31. diaformin.mp. or exp *metformin/
32. diformin.mp. or exp *metformin/
33. bolamyn.mp.
34. riomet.mp. or exp *metformin/
35. 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31
or 32 or 33 or 34
36. 18 and 35
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[mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword]
The Cochrane Library(23/5/15)
1. "gestational diabetes"
2. "pregnancy* diabetes"
3. impair* Near/2 glucose
4. impair* near/2 sugar
5. abnormal near/2 glucose
6. abnormal near/2 sugar
7. "insulin resistan*"
8. glucose near/2 intolerance
9. hyperglycemia
10. high near/2 glucose
11. high near/2 sugar
12. (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR
#11)
13. pregnancy
14. (late pregnancy)
15. second trimester
16. third trimester
17. (#13 OR #14 OR #15 OR #16)
18. (#12 AND #17)
19. metformin
20. glucophage
21. diabex
22. gliphage
23. glafornil
24. merckfomin
25. risidon
26. dianben
27. dimethylbiguanid*
28. dimethylguanylguanidine
29. glumetza
30. fortamet
31. glycomet
32. diaformin
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33. diformin
34. bolamyn
35. riomet
36. (#19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR
#28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35)
37. (#18 AND #36)
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CINAHL(23/5/15)
1. (gestational diabetes)
2. (pregnancy$ diabetes)
3. impair$ NEAR2 glucose
4. impair$ NEAR2 sugar
5. abnormal NEAR2 glucose
6. abnormal NEAR2 sugar
7. high NEAR2 glucose
8. high NEAR2 sugar
9. (insulin resistan$)
10. hyperglycemia
11. glucose NEAR2 intolerance
12. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11
13. pregnancy
14. (late pregnancy)
15. (second trimester)
16. (third trimester)
17. 13 OR 14 OR 15 OR 16
18. 12 AND 17
19. metformin
20. glucophage
21. diabex
22. gliphage
23. glafornil
24. merckfomin
25. risidon
26. dianben
27. dimethylguanid*
28. dimethylguaniguanidine
29. glumetza
30. fortamet
31. glycomet
32. diaformin
33. diformin
34. bolamyn
35. riomet
36. metformin
37. 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29
OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36
38. 18 AND 37
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Web of science(23/5/15)
1. Topic=("gestational diabetes") OR Topic=("pregnancy* diabetes") OR
Topic=(impair* NEAR/2 glucose) OR Topic=(impair* NEAR/2 sugar)
OR Topic=(abnormal NEAR/2 glucose) OR Topic=(abnormal NEAR/2
sugar) OR Topic=(high NEAR/2 glucose) OR Topic=(high NEAR/2
sugar) OR Topic=("insulin reistan*") OR Topic=(hyperglycemia) OR
Topic=(glucose NEAR/2 intolerance)
2. Topic=(pregnancy) OR Topic=("late pregnancy") OR Topic=("second
trimester") OR Topic=("third trimester")
3. 2 AND 1
4. Topic=(metformin) OR Topic=(glucophage) OR Topic=(diabex) OR
Topic=(gliphage) OR Topic=(glafornil) OR Topic=(merckfomin) OR
Topic=(risidon) OR Topic=(diaben) OR Topic=(dimethylbiguanid*) OR
Topic=(dimethylguanylguanid*) OR Topic=(glumetza) OR
Topic=(fortamet) OR Topic=(glycomet) OR Topic=(diaformin) OR
Topic=(diformin) OR Topic=(bolamyn) OR Topic=(riomet)
5. 4 AND 3
271
9.1.2. Data proforma sheet (systematic review)
Evaluation of Metformin in Gestational Diabetes
Data Extraction Proforma
1. Source
Study ID
Report ID
Country
Language
Date of study
Authors,
Contact details
Citation
2. Eligibility
Population
Intervention
Study Design
Outcomes
considered
Reason for
exclusion
3. Methods
Duration
Setting
Sample size
Total number of participants
at baseline
Total number of participants
during analysis
Intention-to-treat analysis?
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The reason of missing
Participants
Inclusion and exclusion criteria
Screening method
Diagnostic criteria
Lifestyle intervention
The level at which drug treatment
was started
Characteristics of Participants
Character Intervention
1
Intervention
2
Intervention
3
Dif Note
Age(yr)
Early pregnancy
weight
Weight at entry
Weight gain
during study
GA at entry
GA at OGTT
Ethnicity
Glucose level at
OGTT
Glucose level at
entry
Glucose control
throughout
pregnany
Smoking n(%)
Parity/Gravidity
n(%)
Nullip n(%)
History of chronic
hypertension
BP at enrolment
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Previous history
of n(%)
GDM
PE
GHT
Macrosomia
CS
<37 wks
Infant with
congenital
anomaly
Bad obstetric
history
No of pregnancy
Family h/o of
diabetes
Hypertension
preeclampsia
Foetal abdo
circumference %
Education
Intervention
Specific intervention Intervention 1(n) Intervention 2(n)
i.duration
ii.dose
iii.particular
drug used
iv.Maximum dose
v.if fail to achieve
target, insulin
added/replaced?insulin
used(type and dose)?
vi.proportion of GDM
failed to achieve target
with specific intervtn,
n(%)
Integrity of
intervention
Target glucose level
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Design
For randomized study,
Sequence generation
Allocation sequence
concealment
Blinding(participants, personnel
and
Outcome assessors)
Other bias
Type of analysis
For observational study,
Was there a comparison?
Were groups created by?
Baseline demographic factors
comparability
Statistical methods to control
confounding
Design
Analysis
Outcomes
Outcome Intvtn
1
Intvtn
2
Intvtn 3 p RR Diff Note
Foetal BWt in g
Macrosomia
LGA
SGA
BWt centile
MOD(%)
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Secondary
Baby
Outcome Intervention 1 Intervention
2
Intervention
3
p RR Note
APGAR score
Arthropometric
Hypoglycemia
Cord blood C-
peptide/insulin
SCBU admission
Rate & duration
Perinatal
mortality
GA at birth
Major or minor
abnormality
Shoulder dystocia
Birth trauma
Nerve palsy
fractures
Cephalhaematoma
Respiratory
distress
Cord artery pH
Neonatal
Jaundice(n)
Additional note
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Mother
Any subgroup analysis
Any sensitivity analysis
4. Others
Ethical approval
Funding
Conflict of
interest
5. Conclusion
Study conclusion
Reviewer conclusion
Comment
GRADE quality
Level of evidence
Outcome Ivt 1 Ivt 2 Ivt 3 p RR Note
HCP
Induction of labour
Antepartum complication
Intrapartum complication
Postpartum complication
Postnatal GTT
Postnatal psychological changes
Hypoglycemic event
Change in HbA1c
Cost
Additional note
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User guide for data extraction proforma
Basically, try to collect the data as specific and comprehensive as possible using
short terms. For the information that needs for justification of the quality of the
study, collect direct quotation with "--".
If you intend to justify the item, use appropriate term for your justification with the
referring page number and line numbers where you get such information. E.g. some
study may give dietary management in details and if you justify it is appropriate ,
note down your justification with reference to the text.
Source
Study ID – Last name of the first author, publication year
Report ID – date/mth/year
Country – where the study was conducted
Language –
Date of study – as specific as possible
Authors – maximum 3 authors. Last name with initials of first and middle name
Contact details – contact author full name, address with email(preferable).
Citation –
Eligibility
i)Population –
how was gestational diabetes diagnosed(75 g/100g OGTT)?(name only)
Gestational period during which the test was assumed to be performed.
Proportion of gestational diabetes if the population was mixed with other
types of diabetes
ii)Intervention – Is there a separate arm for metformin? Code Y – Yes, N – No.
Which interventions were compared to metformin?(name only)
iii)Design – randomized or observational?(name only)
iv)Outcomes considered – refer to objectives of the study and primary outcomes
considered in the method section(if any).
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Methods
Duration – in months(mth)
Setting – where the study was conducted(describe all hospitals & clinics involved).
Sample size – Is there any sample size calculation before the study was started?
                         If yes, describe α value, β value, outcome of interest,  
the estimated difference of the outcome considered and the number
needed.
Number of participants at the start – collect the number in separate group. ‘At the
start’ refers to the number of participants in each group after randomization in
randomized trial where as in non-randomised study, it refers to the numbers of whose
the researcher collected for baseline data.
Total number of participants at the end – collect the number in separate group. ‘At
the end’ refers to the number of participants included during analysis.
Intention-to-treat analysis - (Y – yes, N- No)
The reason of missing – e.g. loss of data
Participants
Inclusion and exclusion criteria - all the criteria the participants must be fulfilled so
that she would be eligible for screening
Screening(methods and details) – refers to risk factor based or oral glucose challenge
test based screening to identify pregnant women to offer diagnostic oral glucose
test(OGTT).
Diagnostic criteria –
The level at which was considered to be impaired glucose level and start lifestyle
intervention.
Describe the type of OGTT and number & type of blood glucose level needed to be
considered impaired.
Lifestyle intervention –
Describe the dietary advice in details(who gave the advice and what was it?).
How the blood glucose was monitored(timing, frequency, device used, duration) with
comparable care pathway or not.
The level at which drug treatment was started –
Describe the values of impaired glucose control in details(type, number, etc).
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Characteristics of participants table
Row : character
Column : add specific drug name in the intervention box with number of participants
on which the analysis of the characters are based;
p : p<0.05 – statistically significant difference;
note : describe the number of participants in each group if they differed with baseline
numbers, the specific definition of character term(e.g. self-reported in ethnicity
row) and other specific consideration for each term.
Definition of the character terms(entry/enrollment = the time at which drug treatment
was commenced, n= number)
Age –
Early pregnancy BMI, weight – All BMI or weight value taken before OGTT was
given(when the OGTT was done).
BMI at entry – BMI when they were given drug treatment.
Weight change – the increase or decrease of weight from the start of the drug
treatment to the late trimester(36/37 weeks gestation)
GA at the start – all gestational age apart from that at enrollment
GA at entry – gestational age(GA) at which drug treatment was started
Ethnicity –
Glucose level at the start – blood glucose level apart from that at enrollment
Glucose level at entry – blood glucose level at which drug treatment was started
(Fasting-FBS, Postprandial- PP, Hb A1c)
Glucose control throughout pregnancy – from the start of the drug treatment to the
end of gestation or from diagnosis of OGTT to the end of gestation
(Fasting-FBS, Postprandial- PP, Hb A1c)
Blood pressure(BP) at enrollment
Past history of chronic hypertension
Smoking
Parity/Gravidity – number of previous pregnancy
Nullip – number of woman who never bore a baby
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Previous obstetric history of gestational diabetes(GDM), preeclampsia(PE),
gestational hypertension(GHT), Macrosomia, Caesarean section(CS), premature
baby, infant with congenital anomaly, Bad obstetric history(e.g.recurrent
miscarriage(≥3 termination ofpregnancy)), baby with birth defect 
Number of pregnancy – number of baby in current pregnancy(single/multiple)
Family history of – diabetes, hypertension, preeclampsia
Foetal abdominal circumference
Education
Intervention
Duration – the time during which the intervention was taken
Dose – average or total dose of the intervention
Particular drug used – brand name, start dose, method of increment over a period
Target glucose level – describe if it was different from the level at which drug
treatment was started
Maximum dose – beyond which was considered to be treatment failure for oral
hypoglycemic agents
If fail to achieve target, insulin added/replaced? Describe type, dose and duration if
any.
Proportion of treatment failure –
Integrity of intervention –
It includes number of participants in each group who stopped taking the treatment
before the end of pregnancy apart from those with treatment failure. Describe the
number and reasons and what was done(stop treatment or reduce the dose).
Design
Use the table according to the study design(randomized/observational).
For randomized study, record the direct quote from the paper as much as possible. If
it is not possible for direct quotation, describe the relevant key information in short
term with relevant reference.
For observational study,
Was there a comparison? – respond Y- yes or N-no, number of comparison,
Were groups created by?- describe how each group was formed and if there was any
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difference between group formation- time, location, patient preference, etc)
Baseline demographic factors comparability – Any other different character between
the 2 groups apart from that was listed in characteristics of participants table
Statistical methods done to control confounding –
Design – matching, stratification, exclusion
Analysis – regression model, sensitivity analysis, stratification
Outcomes
Describe each outcome in definition(how the outcome was assessed) if any in note
box and each intervention with number analysed . If the outcomes was not
considered or described, put “-“ in the box.Add number analysed for particular
outcome if it was different.
Primary
Foetal birthweight/Macrosomia/Large for gestational age(LGA)/Small for gestational
age(SGA)/BWt centile
Mode of delivery(MOD) – vaginal/normal spontaneous delivery/ instrumental/
assisted/ caesarean section(CS)
Hypoglycemia according to definition given,
Cord blood C peptide/insulin
SCBU admission – SCBU(special care baby unit)/NICU(neonatal intensive care
unit)admission rate &/or duration
Perinatal mortality – the number of baby which was not born alive(still birth,
miscarriage/abortion, perinatal death)
GA at birth – the value that indicates how mature the baby born(preterm, term, full-
term)
Major or minor abnormality – all congenital anomaly
Shoulder dystocia
Birth trauma
Nerve palsy
Fractures
Cephalhaematoma
Respiratory distress
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Cord artery pH
Neonatal Jaundice according to the definition (those needing phototherapy or those
with hyperbilirubinaemia)
Additional note
Secondary
APGAR score according to the text given(in number with APGAR 7, or specific
APGAR score)
Arthropometric measure(at birth)
Mother
Hypertensive complication of pregnancy(HCP)- the increased blood pressure that
was first developed during preganancy, gestational hypertension(GHT),
preeclampsia(PE), Eclampsia
Induction of labour
Antepartum complication(Polyhydramnios, APH, Abruption, Antepartum infection)
Intrapartum complication(obstructed labour, prolonged labour, instrumental delivery,
3rd degree tear)
Postpartum complication(postpartum/peripartum haemorrhage, postpartum infection)
Postnatal GTT – oral glucose test result (number or any glucose valuethat was taken
after the delivery of baby)
Postnatal psychological changes
Hypoglycemic event
Change in Hb A1c
Cost -
Additional note
Subgroup analysis, e.g. Metformin alone vs metformin failure
Sensitivity analysis, e.g. the results of the outcomes after confounders were being
controlled.
Others
Ethical approval –
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Funding body
Conflict of interest
284
9.1.3. Risk of bias tools
9.3.1 Risk of bias tool(RCT)
Items (page,
lines)
Justification Code
1.Randomization
2.Allocation concealment
3. Double Blinding
4.Same Care Pathway
5.Blinding of outcome
assessors
6.Prior sample size
7.Intention to treat
analysis
8.Acceptable attrition rate
9.Comprehensive
outcome report
10. Free from other risk
of bias
11.Population
12.Intervention
13. Comparator
14.Explicit reported
outcomes
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User guide for risk of bias tool for randomized studies
Coding instruction
‘+ ‘means ‘yes’ to the question item that the item is stated in the report; information given is
adequate enough to justify that there is low risk of bias.
‘- ‘ means ‘no’ to the question item that information given is adequate enough to justify
high risk of bias or the item is not stated in the report
‘?’ means‘unclear’ to the question item that the item is stated but information given is not
adequate to justify the risk of bias.
General items
1. Randomization
Did the study describe proper randomization method?+, -, ?
At the start of the study, the researcher needs to ensure that the chance of all participants to
be involved in each intervention group must be equal. The justification was based on the
method used to allocate participants to each treatment group, taking account of the fact that it
is truly random. E.g of adequate randomization includes using a computer random number
generator, referring to a random number table. E.g. of inadequate randomization includes
sequence generated by odd or even date of birth, some rule based on hospital or clinic record
number.
2. Allocation concealment
Did the study adequately prevent assignment of participants to people involved in the
research?+,-,?
The sequence of the enrolling participant assigned to the intervention group must be
adequately concealed, i.e, participants, investigators and caregivers could not foresee who
was assigned to which group. E.g. of appropriate concealment includes sequentially
numbered, opaque, sealed envelopes; central allocation. E.g. of inappropriate concealment
includes alternation; open random allocation schedule.
3. Double blinding
Did the study adequately blind who received which treatment from participants and
researchers?
The double blinding of the study allows unbiased attention and care of the participants
independent of treatment type. It should be noted that if the routes of intervention are
different (subcutaneous injection route in insulin and oral route in metformin), it is difficult
to blind the participants from the intervention. If the study claimed to be double-blinded in
this case, the details on how double-blinding was performed should be described.
4. Same carepathway
Did every included participants get enough and equal attention and care regardless of the
intervention? +/-/?
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For a prospective study, both subjects in 2 intervention arms should be managed by the same
care pathway, same team at the same setting over the same follow-up frequency and period.
5. Blinding of outcome assessors (including those involved in data analysis) +,- , ?
Were the outcome assessors adequately blinded to the intervention the participants assigned?
In trials comparing different routes of administration or different sizes of drugs where it
might be difficult to be properly blinded to the caregivers and participants, it is crucial to
ensure the adequate blinding of outcome assessors. The justification for this item is “No” if
either outcome assessor or data analyst is not properly blinded or information is not given.
6. Prior sample size
Did the study describe proper sample size calculation? +, -, ?
Before any study is conducted, the number of participants required in each group to detect
the difference in outcome of interest should be adequately calculated and the study should
recruit enough number of participants to minimize the play of chance.
7. Intention to treat analysis
Were outcomes of all participants randomized measured and included in the analysis as
initially randomized group? +,-
A response of “Yes” to each part of the above question is justified to be low risk of bias.
Alternative is true to high risk of bias.
8. Acceptable attrition rate +, -
If there is missing data, were they equal in terms of number and reason in each arm?
Was the attrition rate not enough to have impact on the effects of intervention?
The attrition rate of <20% is considered to be acceptable if the missing data were equal in
terms of number and reasons.
To have a record of “+”, the response to both question items must be YES.
9. Comprehensive outcome report
Was the study free from selective outcome reporting at study-level judgement?
In practice, it is difficult to assess the selective outcome reporting. But, it is suggested that at
least all outcomes that the researcher mentioned in the method section needed to be reported
in results. If the study failed to report the outcomes reported by most of the studies, it could
be suspicious that the study might be intentionally omit the outcomes. Moreover, if the study
did not report the related outcomes together(large for gestational age and low for gestational
age), risk of selective reporting bias should be suspected. Furthermore, if the study failed to
report any of important clinical outcomes considered in this review, “-“ sign should be noted.
10. Other risks of bias
Was the study free from other potential risks of bias? State them.
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Other quality assessment items which could introduce bias to the quality of the study
includes early stopping, baseline imbalance, blocked randomization in unblinded trials and
interim results. In unblinded study, block randomization could introduce selection bias as it
is probable that the next allocated intervention could be predicted. The level of type I error
increases with the number of interim analyses(“if the investigator looks at the accumulating
data at α=0.05 at every interim, then the actual overall α level rises with the number of 
challenges – eg, overall α=0.08 after 2 challenges, α=0.11 after three and α=0.19 after 
ten.[250]”)
11. Population
Did the study clearly describe the eligible subjects, those included and excluded?+/-/?
12. Intervention
Did the study clearly report explicit intervention used?+/-/?
The study should report the details of the intervention(start dose, frequency, maximum dose,
how to increase or decrease the dose, time awaited to justify inadequate intervention). It is
important either for generalizability of the study or the reasons of difference in proportion of
participants who suffered from treatment side-effects.
13. Comparator
Did the study clearly report explicit comparator(e.g.insulin) used?+/-/?
The study should report the details of the intervention(start dose, type, frequency, maximum
dose, how to increase or decrease the dose, time awaited to justify inadequate intervention).
It is important either for generalizability of the study or the reasons of difference in
proportion of participants who suffered from treatment side-effects.
14. Explicit outcome +/-/?
Were the reported outcomes clearly defined?
Some clinical outcomes(respiratory distress, neonatal hyperbilirubinaemia or neonatal
jaundice, neonatal hypoglycemia) were necessary to be clearly defined in order to ensure the
comparability across studies and generalizability.
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Specific items
9.3.2 Risk of bias tool (NRCT)
Items (page,
lines)
Justification Code
1.Consecutive sample
2. Unbiased Selection
criteria
3.Baseline
comparability
4.Same care pathway
5.Favours group
6.Blinding of outcome
assessors
7.Prior sample size
8.Intention-to-treat
analysis
9.Complete outcome
report
10. Confounders
controlled
11.Population
12.Intervention
13. Comparator
14.Explicit outcomes
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User guide for risk of bias tool for observational studies
General Coding instruction
‘+ ‘means ‘yes’ to the question item that the item is stated in the report; information given is
adequate enough to justify that there is low risk of bias
‘- ‘ means ‘no’ to the question item that information given is adequate enough to justify
high risk of bias or the item is not stated in the report
‘?’ means‘unclear’ to the question item that the item is stated but information given is not
adequate to justify the risk of bias
General items
1. Consecutive sample
Were the participants recruited as a consecutive sample?+/-/?
In observational study, it is difficult to assess the selection bias. In order to avoid bias in
selection of patients, one might ensure that all the participants who are eligible and
accessible to the study should be recruited and included in data analysis. Accordingly, all
potentially eligible subjects for the study should be clearly defined in terms of place and time
period as well as selection criteria for those selected for intervention arm and comparator
arm. If there is any reason to leave out a particular group of patients, the reason must have
been recorded. For example, if the study is intended to recruit all GDM in between 2009-
2010 at a particular hospital, data from all GDM mothers who bore her baby during that
period are considered to be eligible population.
2. Unbiased selection criteria
How the group was formed?
This item aims to assess whether the health care professionals or the personnels who are
responsible to patients recruitment could foresee and could determine the patients’
allocation.
If patients are allocated according to site in a prospective cohort study, it is justified that the
responsible person for patients’ recruitment could foresee the outcomes or might have some
biases in his decision and there is probable high risk of bias. If the allocation depends on
patients’ choice, it is justifiable that it is unlikely to foresee the outcome and there might be
low risk of biases.
3. Baseline comparability
Were there any significant difference(clinical or statistical) in between group?
What are they?
4. Same carepathway
Did every included participants get enough and equal attention and care regardless of the
intervention? +/-/?
For a prospective study, both subjects in 2 intervention arms should be managed by the same
care pathway, same team at the same setting over the same follow-up frequency and period.
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5. Favours group
Which intervention group have less glycaemic risk factors at baseline?
The box should be filled in with abbreviation of intervention(D=Diet, M=Metformin,
I=Insulin, G=Glibenclamide, MF=Metformin failure)
The favourable group in this item means the group with less insulin resistance states (e.g.
younger age, lower BMI, lower baseline glucose, etc).
6. Blinding of outcome assessors (including those involved in data analysis) +,- , ?
Were the outcome assessors adequately blinded to the intervention the participants assigned?
Although blinding is not a common practice in observational studies, in trials comparing
different routes of administration or different sizes of drugs where it might be difficult to be
properly blinded to the caregivers and participants, it is crucial to ensure the adequate
blinding of outcome assessors. The justification for this item is “No” if either outcome
assessor or data analyst is not properly blinded or information is not given.
7. Prior sample size
Did the study describe proper sample size calculation? +, -, ?
Before any study is conducted, the number of participants required in each group to detect
the difference in outcome of interest should be adequately calculated and the study should
recruit enough number of participants to minimize the play of chance.
8. Intention-to-treat analysis
Was the study justified that the attrition rate is not biased enough to have an impact on the
outcome? -/ ?/ +/ ++
All the consecutive population should be included in the analysis section. If there is missing
data, the data should be balanced between 2 intervention arms(+) and the attrition rate is not
more than 20%(+). If the information is not clear enough to justify the consecutive
population, the sign”?” should be noted.
9. Complete outcome report
Was the study free from selective outcome reporting at study-level judgement?
In practice, it is difficult to assess the selective outcome reporting. But, it is suggested that at
least all outcomes that the researcher mentioned in the method section needed to be reported
in results. If the study failed to report the outcomes reported by most of the studies, it could
be suspicious that the study might be intentionally omit the outcomes. Moreover, if the study
did not report the related outcomes together(large for gestational age and low for gestational
age), risk of selective reporting bias should be suspected. Furthermore, if the study failed to
report any of important clinical outcomes considered in this review, “-“ sign should be noted.
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10. Confounders controlled
Did the investigator consider justify enough confounders in design and analysis sections.
Tips : list and compare confounders in all studies.
The major confounders considered for this review included age, parity, prepregnancy BMI,
weight gain during pregnancy, blood glucose at OGTT, hypertension history, Bad obstetric
history(hypertensive complications of pregnancy, LGA, Stillbirth, cesarean section).
Please refer to the confounder table. (Appendix 9.1.5)
(-) the investigator did not consider any confounder or did not attempt to control any
confounder in design and analysis section.
(+) the investigator considered some major confounders to the primary outcome and tried to
control them.
(++) the investigator considered all major confounders to the primary outcome and tried to
control all of them.
(+++) the investigator considered and controlled enough major confounders and we are
confident that the primary outcome result could not be influenced by confounders.
11. Population
Did the study clearly describe the eligible subjects, those included and excluded?
12. Intervention
Did the study clearly report explicit intervention used?
The study should report the details of the intervention(start dose, frequency, maximum dose,
how to increase or decrease the dose, time awaited to justify inadequate intervention). It is
important either for generalizability of the study or the reasons of difference in proportion of
participants who suffered from treatment side-effects.
13. Comparator
Did the study clearly report explicit comparator(e.g.insulin) used?+/-/?
The study should report the details of the intervention(start dose, type, frequency, maximum
dose, how to increase or decrease the dose, time awaited to justify inadequate intervention).
It is important either for generalizability of the study or the reasons of difference in
proportion of participants who suffered from treatment side-effects
14. Explicit outcomes +/-/?
Were outcomes clearly defined?
Some clinical outcomes(respiratory distress, neonatal hyperbilirubinaemia or neonatal
jaundice, neonatal hypoglycemia) were necessary to be clearly defined in order to ensure the
comparability across studies and generalizability.
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9.1.4. Description of potentially relevant conference proceedings and ongoing trials for systematic review
Table 9.1. Description of RCTs studies (Metformin vs Insulin)
Study ID Design Participants Intervention Outcomes
Rnnemaa
2010[251]
Prospective
cohort study of
ongoing
randomized
trial
150 GDM pregnancies; FBS > 7 mmol/L or PP > 11
mmol/L were not included in this trial.
75 in metformin vs 75 in insulin group
Mean maternal age (31.8 vs 32.2 years), pre-
gestational BMI (29.3 vs 39.5 wks), glucose values
in pre-treatment OGTT or gestational weeks at
delivery (39.3 vs 39.5) did not differ between the two
treatment groups.
Metformin
insulin
Criteria for impaired
glucose control or when
to add additional insulin :
FBS >5.5mmol/l and/or
PP >7.8mmol/L
Outcomes compared: Metformin vs insulin in GDM
mothers stratified by pre-gestational BMI 30 kg/m2
into obese and non-obese.
Perinatal outcomes
1. Birth weight(g, mean)- higher in pre-gestationally
obese compared with non-obese mothers(3658g vs
3556 g, p=0.19)
- Similar in metformin vs insulin group irrespective
of maternal pre-gestational BMI.
2. Macrosomia (low in all study group)
3. Metformin failure rate (20%)
Martinez
2010[252]
Randomized
prospective
trial
100 first GDM patients(final number 278) requiring
pharmacological therapy
Maternal demographic or obstetric data did not differ
between the groups
Metformin
Insulin
Metformin vs insulin group
Perinatal outcomes: No significant difference in
neonatal hypoglycaemia or birth weight percentile,
NICU transmission, 5 min APGAR scores and
umbilical artery pH.
Significant differences (p<0.05) were found in
neonatal breathing problem (more in insulin group)
and vacuum assisted deliveries (more in insulin
group).
Metformin failure rate (20%)
Bell2010[253] Cohort study
Setting : five
maternity units
in north-east
England
116 GDM delivered between April 2008 – June 2009
screened by blood glucose measurement at booking
and 28 weeks but data were available for 103
women(52% obese; 16% non-white ethnicity; 30%
family history of diabetes; 12% previous GDM
history; 24% no risk factors defined by national
guidance; 20% diagnosed before 24 weeks).
34% GDM dietary advice
only;
38% insulin alone;
6% metformin alone;
13% both metformin and
insulin during pregnancy
Infant outcomes: 105 births (one stillbirth, three
major congenital anomaly, two > 4500g birth weight.
Maternal outcomes: 49(48%) delivered by caesarean
section; 14% at ≥ 39 weeks gestation; 59% had 
postnatal OGTT and further 13% had fasting glucose
only – two diabetes women and six (10%) impaired
glucose tolerance.
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Table 9.1. Description of RCTs studies (Metformin vs Insulin)
Study ID Design Participants Intervention Outcomes
Hayden
2010[254]
Retrospective
case note
review(audit)
Setting :
Heartlands
hospital
17 GDM women treated with metformin Metformin vs
standards(insulin) for
pregnancy outcomes
set by NICE
guidelines 2008
Perinatal outcomes :
1. Foetal macrosomia (n=1, 7%)
2.NICU admission (n=1)
3.No neonatal hypoglycaemia
4.gestational age at birth( 64.2% of neonates were born
between 38 and 39 weeks gestation, 1 neonate was born
under 38 weeks(37+0), 4 born over 39 weeks)
Maternal outcomes :
1. Emergency caesarean rate (15.4%) but did not exceed
the background population (15.5%) (Both due to failure
to progress following induction between 38 - 39 weeks).
2. optimal glucose control in 80% of the GDM
Hashmi
2012[255]
A retrospective
cohort study
Setting:
Pakistan
(Jan 2009 to
June 2010)
110 GDM(53 metformin-treated and 56 insulin-
treated)
Metformin vs insulin -Similar birth weight(2.9 kg in metformin(M) group vs
2.88 kg in insulin(I) group)
-comparable SGA; 5.7%(M) vs 9.3%(I)
-higher gestational hypertension in insulin group;
13.7%(M) vs 22.2%(I), p=0.31
-one neonate with respiratory distress syndrome vs none
in insulin group
- similar NICU admission rate; 7.8%(M) vs 3.6%(I),
p=0.42
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9.2. Characteristics of relevant conference proceedings (Metformin vs Glibenclamide)
Study ID Design Participants Intervention Outcomes
Bertini 2011[256] RCT
July 2008 to
September 2010
200 GDM women who required
adjunctive (metformin) therapy to diet
and insulin therapy.
104 GDM women in metformin group vs
96 GDM women in glibenclamide group
No difference was found(p>0.05) in the
groups regarding maternal age,
gestational age at inclusion, body mass
index, glucose levels in 75g OGTT and
glycemic control.
However, higher numbers of previous
pregnancies in Metformin group(2.84 vs
2.47, p=0.04)
less weight gain during pregnancy in
Metformin group (7.78 vs 9.84 p=0.04)
Metformin
Glibenclamide
Both drugs were replaced by
insulin when they reached the
maximum dose without glycemic
control.
Metformin(M) vsGlibenclamide(G) group
(assessed outcomes : weight and neonatal blood
glucose)
Perinatal outcomes: No differences (p>0.05) in
caesarean delivery, gestational age at delivery,
number of LGA newborns, neonatal
hypoglycaemia, admission to intensive care unit
and perinatal death.
Differences were found in
1. Birth weight(g): 3193 g(M)vs 3387 g(G),
p=0.01
2. Ponderal index: 2.87(M) vs 2.96(G),
p=0.05
Neonatal blood glucose levels in 1st (59.78(M) vs
54.08(G), p=0.01) and 3rd hour (61.53(M) vs
55.89(G), p=0.01)
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Table 9.3. Characteristics of relevant conference proceedings (Metformin vs Diet)
Study ID Design Participants Intervention Outcomes
Gururaj
2010[257]
Retrospective study
(?)
46 GDM (January 2008 to June 2009) form
pregnancy database; 46 GDM identified of
which 28 were treated with metformin. Age,
BMI and parity were similar.
(28)Metformin vs (18) Diet only Glucose tolerance test values at diagnosis were
higher in metformin compared to diet (4.91±0.6 vs
4.63±0.3). Significant reduction in 2hr post GTT
values at 6 weeks postpartum in both groups
(metformin: 5.76±1.7, p<0.0002 and diet:
4.78±0.9, p<0.002 from baseline) and fasting
glucose level fall by -0.14% in metformin and rose
by 0.43% in diet group.
Table 9.4. Characteristics of relevant conference proceedings (Metformin monotherapy vs Metformin Failure)
Study ID Design Participants Intervention Outcomes
Siddaramaiah
2011[258]
Retrospective
audit
66 GDM women with
singleton pregnancies
Booking BMI : 31.3(7.8)
kg/m2, 49.1% of women had
BMI ≥ 30 kg/m2 
Metformin: Mean duration
8.3(6.9) weeks; six (9.2%)
had intolerance with three
switch to insulin; 36.4%
required additional insulin
Neonatal outcomes: 7 premature babies (10.7%), mean birth weight (3.44 kg,
0.6%), 16.9% were over 97 percentile, 7(10.7%) NICU admission due to
prematurity or hypoglycaemia, 4(6.1%) transiently APGAR < 7 at 1 min, 23%
hypoglycaemia(<2.6% mmol/l) ,46 % of whose mothers received insulin, no
perinatal death
Maternal outcomes : mean weight gain 9.24 kg (from booking to GDM
diagnosis) and 1.44 kg ( from GDM diagnosis to term); 1.5% pregnancy related
complications(PIH, eclampsia, hyper emesis and miscarriage); 3% PET, Ante
partum haemorrhage, polyhydramnios,
Bertini
2011[259]
Retrospective
study of RCT
104 GDM women who
required adjunctive
(metformin) therapy to diet
and physical activity.
82 GDM women in success
group vs 22 GDM women in
failure group
Criteria for metformin
failure or when to add
insulin : absence of
glycemic control obtained
or foetal abdominal
circumference ≥90% 
Epidemiological characteristics of the two groups were compared.
Maternal age (32.42 vs 32.38, p=0.96), parity (2.73 vs 3.19, p=0.13), weight
gain during pregnancy (7.30 vs 5.38, p= 0.13), 2hr OGTT (164.15 vs 167.15,
p=0.56) were comparable between the two groups (p>0.05).
However, later gestational age at inclusion (27.57 vs 24.33, p=0.04), lower
baseline BMI (27.64 vs 31.62, p<0.01) and lower FBS in OGTT l (91.56 vs
108.09, p<0.01) were found in metformin success group.
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Table 9.5. Characteristics of ongoing trials
1. JacekBrazert 2008
Study name Metformin in gestational diabetes mellitus
Methods Prospective randomized open labelled trial
Participants 18 years of minimum age, inclusion : diabetes diagnosed during pregnancy,
single pregnancy, ineffective diet therapy,
Exclusion : pre-gestational diabetes, foetal malformation, multiple pregnancy,
contraindication to metformin therapy(liver or kidney disease)
Setting : Poland
Intervention Metformin vs human recombined insulin
Outcomes Primary : newborn weight(1hour of life)
Secondary : parameters of metabolic control in mother and newborns : insulin
resistance, inflammatory reaction, oxidative stress, foetal growth, during
pregnancy and up to 12 hours after delivery
Starting date May 2008
Contact
information
Hanna Mitkowska Wozniak,
ph : +48 601 88 60 00
hanna.mitkowska@onet.eu
2. Ware Branch 2011
Study name
Methods Prospective randomized, double-blind placebo controlled trial
Participants 100 samples for pilot study
Inclusion : Women delivered > 37 weeks gestation baby within last 18 months
with history of GDM in immediately prior pregnancy, previous infant > 4000
gms, BMI > 30 6mths postpartum, Hb A1c>6.1% 6 months postpartum, family
history of type 2 diabetes,
Exclusion : >1 miscarriage or foetal demise, No contraindication to metformin,
Hypertension(>135/85), No other endocrine, metabolic, renal or autoimmune
medical disorders, history of preterm delivery, neonatal palsy, shoulder dystocia,
uterine malformations, illicit drug or alcohol abuse during current pregnancy,
multifoetal pregnancy including first trimester embryonic demise of one or more,
intent to deliver elsewhere, non-availability for prospective data
Setting : Intermountain Healthcare Urban Central region, Utah, United States
Intervention Metformin vs placebo
Outcomes Primary - incidence of GDM (pre-conception to delivery)(at 8-week interval)
Secondary - maternal and foetal pregnancy outcomes (pre-conception to
discharge) (4-week interval)
Starting date April 2010
Contact
information
Camille Broadwater-Hollified,
ph : 801-507-7864
camille.hollifield@imail.org
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3. Maslovitz 2012
Aim/Hypothesis To assess whether the addition of metformin to insulin treated pregnant
women would improve glucose control and lower insulin requirements
Methods Retrospective cohort
Participants 64 pregnant women with diabetes requiring > 100 units of insulin.
Unbalanced glucose levels requiring further treatment were divided into
(40) group A (increasing insulin doses alone) vs (24) Group B (addition of
metformin 850 mg bd along with insulin).
Two groups were similar in terms of maternal age, body mass index, uterine
scar and percentage of pre-gestational diabetes.
Intervention Metformin vs Insulin
Outcomes Mean daily insulin : 1352.3 units(A) vs 1053.6 units(B)(p≤0.05) 
Optimal glycemic control: 8.31.2 days vs 10.11.2 days (p≤0.05); achieved 
earlier with combined treatment.
Maternal satisfaction score: 4.3 vs 3.6(p≤0.05); better tolerated with 
combined treatment.
Similar birth weight(4385212 g vs 3387138 g), NICU admission rates,
neonatal hypoglycemia and macrosomia
Reason for exclusion Conference abstract, Unclear GDM population
Contact
information
S.Maslovitz
Department of obstetrics and gynaecology,
Lis Maternity Hospital, Isreal.
maslovitz@gmail.com
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Table Proforma: Assessment of confounders in NRCT
Study ID
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Age
Early pregnancy
BMI
BMI at entry
Weight change
during study
GA at entry
GA at OGTT
Ethnicity
BS at OGTT
BS at entry
Glucose control
throughout
pregnancy
Smoking
Parity
Nullip
History of chronic
hypertension
BP at enrollment
History of diabetes
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NA – No analysis found although the confounder was reported.
? – there is no statistically significant difference in the confounder reported but the reviewer identify the difference as clinical significance
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Previous history
-GDM
-PE
-GHT
-Macrosomia
-CS
-Prematurity
-infant with
congenital anomaly
-bad obstetric
history
No of pregnancy
Family history
-diabetes
-hypertension
-preeclampsia
Foetal abdominal
circumference
Tertiary education
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9.2.Clinical Studies
9.2.1 Manual Data proforma sheet for data collection
1. Patient Identification
2. Any (+)ve Social History
Smoking details
Alcohol
Drug
3. PMH
Hypertension
Gestational Diabetes
PIH
Any +ve
Family
Partner family
4. Folic acid
Start date and Dose
5. P/E (gestational wks included)
Wt/BMI at booking
Wt/BMI at OGTT
Wt near term
Hospital no
Ethnic
Ethnic of parter
Religion
Employment (pt)
Employment(parter)
Parter age
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6. Currently taking drugs (apart from anti-diabetics)
Type Dose
7. Past obstetric h/o
1st Baby Alive/SB
Sex
BWt
GA
MOD
Any C’
DOB
2nd Baby Alive/SB
Sex
BWt
GA
MOD
Any C’
DOB
3rd Baby Alive/SB
Sex
BWt
GA
MOD
Any C’
DOB
misscarriage 12/40
8. Current pregnancy
LMP
EDD based on dating scan
G, P
BP at booking
Gestation at booking
No of antenatal visit
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9. MOD
Type
Any indication
PIH/PE/E
Any antenatal C’
Any intrapartum C’
Any postpartum C’
Type of Perineal tear
10. Baby
Alive/SB
Gest Maturity(wks)
Sex
BWt
Head Circum(cm)
APGAR
Cord pH(At)
Cord pH(V)
NICU admission
(duration, indication)
Respiratory distress
Phototherapy/Bilirubin
DOB
Glucose after delivery
11. Glycemic control
Start date
End date
>7.8 PP
> 6 FBS
<3 any time
Forget
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9.3.Laboratory Study
9.3.1. Solutions and Buffers
General Cell Culture Solution
1. Lysis Buffer
Ammonium Chloride (NH4Cl)
Potassium Bicarbonate (KHCO3)
2. Completed MEM media
MEM media (21430-020, Gibco) 500mL
Foetal Bovine Serum 50mL
Pen/Strep 5mL
Pyruvate 5mL
Medium was kept at 4 °C
Western Blotting Solution
1. Sodium Dodecyl Sulphate (SDS) (4%)
SDS 4g
H2O 100mL
2. Loading Buffer
125 mMTris-HCl (pH 6.8) 625µL
4%SDS 500µL
Glycerol 1mL
Dithiothreitol (DTT) 200µL
Bromophenol Blue 125 µL
Distilled H2O 250 µL
3. Phosphate Buffer Saline (PBS) (pH 7.6)
Na2HPO4 1.44g
KH2PO4 0.24g
NaCl 8g
KCl 0.2g
Distilled H2O 1L
4. PBS-T
PBS 1L
Tween 20 1mL
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5. Blocking solution (20%)
i-Block powder 0.2g
PBS-T 100mL
Solutions used for RT-PCR
1. DNase Treatment
DNase I Reaction Buffer Stop Solution
1 U/µL in
50% Glycerol
10mM Tris-HCl (pH 7.5)
10mM CaCl2
10mM MgCl2
200mM Tris-HCl (pH 8.3)
20mM MgCl2
50mM EDTA
2. Reverse Transcription Buffer
100 mM Tris-HCl (pH 9.0 at 25 °C)
500 mM KCl
1% Triton® X-100
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